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FOXC1 encodes a mesenchymal transcription factor that is not normally expressed in 
haematopoietic cells. However, recent studies from this and another laboratory 
demonstrated that FOXC1 is inappropriately de-repressed in Acute Myeloid Leukaemia 
(AML). Through epigenomic profiling of primary AML samples, we showed that FOXC1 
was specifically upregulated in the aggressive FLT3-ITD subtype of AMLs, in parallel 
with the activation of FOX:E-box composite cis-regulatory elements. Furthermore, 
complementary studies from the Somervaille laboratory demonstrated that FoxC1 
expression in AML was leukaemogenic by establishment of a monocyte differentiation 
block and enhancement of clonogenic potential. 
Collectively, these data indicated that FoxC1 plays a critical role in leukaemogenesis, but 
the target genes and mechanisms by which this occurred were not known. To address 
this, we performed an integrative genome-wide analysis of FoxC1 binding, chromatin 
accessibility and gene expression in primary AML samples, in vivo models and cell lines. 
These studies revealed that FoxC1 acts to block normal myeloid differentiation by 
contributing to the widespread repression of differentiation-specific target genes. 
Critically, we identify Meis2, a proto-oncogene which collaborates with Hoxa9, as a 
putative direct target of FoxC1, providing compelling indications of a potential FoxC1-
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Chapter 1: Introduction 
 
1.1 Chromatin structure and function 
The first recorded description of chromatin was made by the cytologist Walter Flemming 
in the late 1800s, who observed “stainable material” in the nuclei of cells treated with a 
basophilic dye. Indeed, the word ‘chromatin’ is derived from the Greek word for ‘colour’, 
‘khroma’1. However, it was not until many years later that the diverse functions of 
chromatin became apparent. 
Firstly, chromatin contains the entire nuclear genome, which is approximately 3 billion 
bases of DNA in humans. The genome exists in chromatin as part of a complex 
macromolecular structure containing RNA, histone and non-histone proteins. The tight 
association of the genome with chromatin proteins is what enables sufficient compaction 
to accommodate ~2 m of linear DNA sequence into a nucleus less than 10 μm in 
diameter2. 
Secondly, it emerged that chromatin is highly dynamic and intrinsically connected to 
essential processes throughout the cell cycle. For example, during metaphase, 
chromatin reaches maximal compaction as discrete chromosomes to ensure complete 
transmission of genetic material onto daughter cells during mitosis. Furthermore, during 
interphase, chromatin structure and organisation is intimately involved in the regulation of 
gene transcription, DNA replication and DNA repair3. 
1.1.1 The nucleosome 
The lowest level of chromatin structure is the simplest repeating unit of DNA and 
histones, known as the nucleosome. Although it was known for some time that chromatin 
contained both DNA and proteins, it was not until X-ray diffraction studies by Kornberg in 
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the 1970s revealed that chromatin was at its simplest level comprised of DNA associated 
with a complex of histone proteins, termed the nucleosome4. Subsequent advances in 
nucleosome research culminated in high resolution crystal structures of the core 
nucleosome particle some 20 years later5,6. Based on these structures and other 
biochemical data, we now have a very detailed understanding of what constitutes the 
core nucleosome particle and how they are assembled.  
 
Figure 1:1 Assembly of histone proteins into nucleosome particles. 
A schematic depiction of core histone assembly, where two H3-H4 dimers first associate to form a 




Nucleosomes are comprised of an octameric complex of the core histones H2A/B, H3 
and H4, which all feature a conserved structural helix-loop-helix domain termed the 
‘histone fold’ (Figure 1:1). Two histone folds on discrete proteins form ‘handshake motifs’ 
which mediate head-to-tail heterodimerisation of histones H2A with H2B, and H3 with 
H46. Two H3-H4 heterodimers form a tetramer which is bound above and below by H2A-
H2B heterodimers to form the core histone octamer. Basic, arginine-rich grooves of 
individual histone monomers are presented on the outer surface of the octamer, forming 
a gyre-shaped channel which associates with the minor groove of DNA by electrostatic 
interations. In all, 147 bp of DNA is wound around the histone octamer ~1.65 times for a 
single core nucleosome particle5.  
1.1.2 Chromatin fibres  
Multiple nucleosomes spontaneously assemble in vitro into long arrays separated by 
~20-80 bp of intervening DNA to form chromatin fibres. These structures were originally 
visualised under salt-free conditions using electron microscopy and described as 10 nm 
‘beads on a string’ arrays7. However, in vitro studies using physiological salt conditions 
demonstrated that nucleosome arrays condense further into 30 nm fibres, suggesting 
that the popular textbook images of 10 nm arrays very rarely exist in vivo, if at all8. 
Furthermore, experiments in living cells demonstrated that even the least condensed 
domains of chromatin existed as 30 nm fibres9.  
In native chromatin, two processes promote the compaction of nucleosomes into 30 nm 
fibres. Firstly, an additional linker protein, usually histone H1, associates with DNA 
entering nucleosomes to form larger particles incorporating an additional ~20 bp of DNA 
called chromatosomes10. Furthermore, recruitment of linker histones seems to increase 
the steric compliance of DNA, allowing tighter compaction of chromatin11. It was originally 
thought thought that these 30 nm fibres were organised into a simple solenoid, but it is 
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now generally assumed that chromatin assembles as an interdigitated zig-zag like 
structure12,13.  
 
Figure 1:2 Models of chromatin fibres. 
In vitro studies demonstrate nucleosomes spontaneously form regularly-spaced nucleosome arrays. 
However, in vivo, nucleosome arrays rarely exist, and are generally bound by linker histones to form 
more compact 10 nm chromatosomes. It is generally accepted that the next step in compaction is to 
form 30 nm chromatin fibres, however the precise structure acquired remains unclear. Both solenoid 
and zig-zag models of chromatin fibres have been proposed12,13. 
 
1.1.3 Chromatin domains  
30 nm chromatin fibres containing several kilobases of DNA condense further into a 
hierarchy of discrete independently regulated chromatin domains. Genome-wide 
chromosome interaction studies revealed that the mammalian genome is organised into 
megabase-scale regions called ‘topologically associated domains’ (TADs). TADs are 
characterised by high chromatin interaction frequencies within the domain, but few 
interactions across different TADs14,15. The boundaries defining TADs are highly 
conserved, both across cell types in a given species and across evolution. However, 
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these TADs are differentially arranged in the nucleus according to cell-type specific gene 
activity14. Thus, changes in gene expression across different cell types arise not from 
changes in TAD boundaries, but rather the spatial repositioning of TADs between active 
and inactive chromosome compartments. 
The boundaries of TADs are important sites for regulation of genome architecture, and 
are frequently bound by domain-organising proteins. These include CTCF, a DNA-
binding transcription factor which in this context helps to bring linearly-separated 
segments of DNA into close proximity by looping, and functions at insulators to isolate 
gene activity within one TAD from another14. 
Finally, it is important to remember that the nuclear genome in eukaryotes does not exist 
as one continuous linear sequence of DNA in chromatin, but instead is composed of 
discrete chromosomes. These structures are most clearly visualised during mitosis, 
when chromatin reaches its most condensed state in metaphase, allowing individual 
chromosomes to be defined with microscopy16. Chromosomes and their domains both sit 
above the level of TADs in the hierarchy of genome organisation, and are also arranged 
according to gene activity. 
1.1.4 Chromosomes occupy distinct territories within the nucleus 
During interphase, chromosomes preferentially occupy discrete nuclear spaces called 
chromosome territories17. Chromatin domain localisation also correlates with 
transcription activity and gene density. Chromosomes are organised radially, with 
transcriptionally active chromatin domains preferentially localising to the centre of the 
nucleus, or into the inter-chromosomal spaces, while inactive chromatin domains tend to 
lie closer to the periphery (Figure 1:3). An illustrative example of this phenomenon in 
human cells is the gene-rich chromosome 19, which tends to be found closer to the 
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centre of the nucleus. By contrast, the gene-poor and inactive chromosome 18 is usually 
found nearer to the nuclear membrane18. 
 
Figure 1:3 Gemome organisation at the intra and inter-chromosomal level. 
TADs demarcate megabase level regions of chromosomes and are partitioned into chromosome 
domains in a tissue-specific manner, according to the activity of genes they contain. Furthermore, 
entire chromosomes are broadly organised within the nucleus according to their overall transcriptional 
activity19. The nuclear spaces preferentially occupied by particular chromosomes are referred to as 
chromosome territories. Chromosome domains that preferentially associate with the nuclear lamina 
are termed lamina-associated domains (LADs). 
 
1.1.5 Chromatin is partitioned according to gene activity 
Long before the identification of TADs in the late 2000s, it was already known that 
interphase chromatin exists in one of two general phases that broadly correlates with 
gene activity. The first such observations were made by Emil Heitz in 1928 when 
visualising moss nuclei under the microscope. He found that certain regions of 
chromosomes stained more intensely when treated with basophilic dyes and did not 
undergo decompaction after mitosis. These stably condensed regions were termed 
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‘heterochromatin’ and those that de-condensed following mitosis ‘euchromatin’20. Since 
then, it is now known that these cytologically discrete states of chromatin are also 
functionally distinct: fluorescence in situ hybridisation (FISH), chromosome interaction 
assays and other approaches have all demonstrated that active chromosome domains 
are euchromatic in contrast to inactive domains, which exist as heterochromatin14,21,22.  
Several functional consequences arise from the partitioning of active and inactive 
chromatin domains. Firstly, the centre of the nucleus is enriched for active RNA 
polymerase and transcription factors, allowing robust expression of genes located in this 
space19. Secondly, the localisation of inactive heterochromatin domains to the periphery 
permits interaction of these domains with structural proteins of the nuclear lamina. These 
lamina-associated domains (LADs) contribute not only to the gross organisation of 
chromosomes in the nucleus by providing anchoring points, but are also associated with 
the stable repression of genes23. 
The spatial positioning of chromatin domains within the nucleus is not static, but is in fact 
a highly dynamic process intimately connected to shifts in gene expression patterns 
across cell types and developmental pathways. Domains containing inactive genes 
which become activated are repositioned from the nuclear periphery to the centre. 
Conversely, gene domains transitioning to a state of repression often move towards the 
outside of the nucleus. A prime example of these processes occurs at the HoxB cluster 
during mouse ES cell differentiation, where the induction of genes within the domain 
coincided with its repositioning towards the centre of the nucleus24. 
1.1.6 Chromatin is an intrinsic barrier to gene transcription 
For gene transcription to occur, the underlying DNA sequence needs to be accessible to 
the basal transcriptional machinery to permit the recruitment and passage of RNA 
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polymerases. However, because of its highly condensed nature, chromatin is inherently 
repressive to transcription, as DNA sequences are not readily accessible to the 
transcriptional machinery. A critical step in gene activation is the localised de-compaction 
of chromatin at target genes and their associated cis-regulatory elements. Increased 
accessibility allows recognition of target sequences by transcription factors which, 
through various mechanisms discussed in 1.3.4, lead to gene activation2. 
1.1.7 Active chromatin is distinguished by increased nuclease sensitivity  
A milestone in our understanding of active chromatin was made in the 1970s and 1980s 
by Weintraub and colleagues, who demonstrated that active genes resided in broad 
nuclease-sensitive domains25,26. In fact, active domains were found to be at least twice 
as sensitive to digestion by DNase I enzyme as inactive domains, with later studies 
suggesting nuclease sensitivity was perhaps an order of magnitude higher at specific 
loci27. In parallel studies, the nuclease sensitivity of particular chromatin domains was 
observed to be cell type-specific, and correlated with changes in local gene activity28,29. 
The heightened nuclease sensitivity of active loci is now accepted to arise from localised 
increases in chromatin accessibility which are necessary to allow recognition of target 
DNA sequences by transcription factors for gene activation2. Establishment of active 
chromatin also involves the deposition of covalent histone modifications and nucleosome 
remodelling, processes discussed in the next section. Collectively, these processes 
disrupt the interactions between histone H1 and linker DNA and the stable ordering of 
nucleosomes, causing localised de-compaction of chromatin. This exposes tracts of 
naked DNA for preferential binding by transcription factors in vivo, or digestion by 
nucleases in vitro. In addition to general de-compaction of active chromatin domains, 
there are also specific nucleosome-free genomic regions known as DNase I 
Hypersensitive Sites (DHSs) which exist at cis-regulatory elements (Figure 1:4). More 
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recently, genome-wide adaptations of chromatin analysis methods such as DNase-seq 
and ATAC-seq were developed and are used to map the entire complement of 
accessible chromatin features in specific cell types or conditions30,31.  
 
Figure 1:4 Structure of DNase I-hypersensitive sites. 
Regions of accessible chromatin that generally correspond to active cis-regulatory elements feature 
exposed tracts of naked DNA which are preferentially sensitive to cleavage by DNase I and other 
nucleases (red arrows), in contrast to condensed chromatin to which DNase I enzyme cannot 
efficiently cleave. 
 
Now that the general roles of chromatin in genome architecture and compaction have 
been introduced, the specific features of chromatin relating to gene activation shall be 
introduced. 
1.2 Features of active and inactive chromatin 
1.2.1 DNA methylation 
The existence of methylated cytosine residues, or 5-methylcytosine (5mC), was first 
described in 1925, although a role for 5mC in gene activity only became clear some 50 
years later32,33. DNA methyltransferases (DNMTs) catalyse the addition of methyl groups 
to cytosine, most commonly at CG dinucleotides to form 5mC. In mammals, symmetric 
methylation of both DNA strands is predominant, although asymmetric methylation also 
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occurs more rarely, particularly during germ-cell development34,35. DNA methylation 
occurs either as a replication-coupled process, preserving parental DNA methylation 
patterns on daughter strands, or in a replication-independent manner for de novo 
deposition36. DNA methylation dynamics begin to influence chromatin architecture and 
gene regulation almost immediately following fertilisation during embryogenesis37. 
Generally, 5mC deposition near a given gene is associated with its repression. Extensive 
5mC deposition is also a feature of transcriptionally silenced pericentromeric and 
telomeric sequences, and during X-chromosome inactivation in female mammals36. The 
mechanisms of repression are not yet fully understood, but 5mC residues are generally 
thought to be targeted by methyl-CG binding proteins (MBPs) from the methyl-CG 
binding domain (MBD) or BTB/POZ families. MBPs directly impede the binding of gene-
activating factors and recruit additional factors that establish stable gene repression38,39.  
In contrast to its deposition, removal of 5mC occurs by passive as well as active means. 
Passive demethylation most commonly arises from an absence of DNMT1 expression 
during DNA replication, leading to a two-fold dilution of methylated bases in cells with 
each division. The best example of passive methylation is during early embryogenesis, 
where low DNMT1 expression permits gradual removal of parental DNA methylation 
patterns, followed by de novo methylation catalysed by DNMT3A/B35,40. Active 
demethylation of 5mC is generally considered to be thermodynamically unfavourable, but 
it does occur as a by-product of single-stranded DNA repair processes36.  
Another, more recently described DNA modification is 5-hydroxymethylcytosine (5hmC), 
the product of 5mC oxidation by the ten-eleven translocation (Tet) family of 
oxygenases41. In contrast to 5mC, 5hmC enrichment at gene loci positively correlates 
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with their expression. Diverse roles for 5hmC both in normal development and disease 
are becoming apparent in this emerging field of intense study42. 
1.2.2 Covalent modification of histones and the histone code hypothesis 
The earliest connection between histone modifications and gene regulation was made in 
the 1960s, when it was shown that histone acetylation increased gene transcription, and 
suggested that histone acetylation might exert locus-specific effects on gene regulation43. 
Since then, well over 100 different post-translational histone modifications - alone and in 
combination - have been catalogued and associated with a multitude of nuclear 
processes including gene regulation44. Furthermore, it has emerged that for many 
histone modifications, the genome-wide distributions are largely cell-type specific45. The 
histone code hypothesis, put forward by Allis and others in the early 2000s, postulates 
that key regulatory information relating to gene expression is embedded in locus-specific 
patterns of histone modificationss46,47.  
It is widely accepted that these reversible histone modifications play an important role in 
both chromatin organisation and gene expression, but the causal contribution they make 
to lineage-specific gene regulation is a topic of intense debate2. The view taken here is 
that many - but not all - histone modifications are a product of signal integration in 
chromatin by transcription factors and other proteins to increase the robustness of gene 
regulation, rather than intrinsic effectors of regulation themselves. Nevertheless, the 
mapping of histone modifications is a useful tool to identify the complement of cis-
regulatory elements active in a given cell type. The most significant players in the 




Table 1:1 A summary of the principal histone modifications involved in the regulation of gene 
transcription.  
Modification Associated with Target histone residues 
Acetylation Activation H3 K9, K14, K18, K56 
H4 K5, K8, K12, K16 
H2B K6, K7, K16, K17 
Methylation Activation H3 K4me2, K4me3 
H3 K36me3, K79me2 
Methylation Repression H3 K9me3, K27me3 
H4 K20me3 
 
1.2.3 Histone acetylation correlates with gene activation 
Following the connection between histone acetylation and gene activation being made by 
Allfrey in the 1960s, subsequent studies of the active chicken ß-globin locus 
demonstrated that histones in accessible regions were hyperacetylated48. In fact, of all 
the known histone modifications, acetylation exerts the most profound impact on 
chromatin accessibility. Acetylation of histone lysine residues disrupts the higher-order 
folding of the histone octamer, diminishing the electrostatic attractions between basic 
residues on histones and the phosphodiester backbone of DNA within nucleosomes, and 
also abrogating inter-nucleosomal interactions required for condensation into chromatin 
fibres. The resultant increase in chromatin accessibility enhances the recognition of 
underlying DNA sequences by transcription factors involved in gene regulation2. Of all 
the acetylation marks described, the two most relevant to gene activation are acetylation 
of histone H3 lysine 27 (H3K27ac) and H4 lysine 16 (H4K16ac).  
Site-specific acetylation of histone lysine residues is catalysed by histone 
acetyltransferases (HATs), enzymes first shown to be directly involved in gene activation 
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in yeast49. Several mammalian orthologues have subsequently been identified50. 
Conversely, histone deacetylation is achieved by histone deacetylases (HDACs), 
causing localised re-compaction of chromatin and gene repression51. The best-
characterised HATs in mammals are the p300/CBP and MOF proteins. Furthermore, 
lysine acetylation is also able to directly promote the recruitment of transcriptional 
activators that contain bromodomains that recognise various acetylated lysines on 
histones and other proteins52. 
p300 and CBP are closely related ubiquitously expressed co-activators with intrinsic HAT 
activity and a broad range of target histone lysine specificity53, including H3K27. 
H3K27ac is usually enriched on nucleosomes flanking promoters and enhancers, and 
positively correlates with gene activity54. Mouse knockout studies have underlined the 
importance of these enzymes, where heterozygous deletion of either p300 or CBP led to 
severe viable phenotypes or embryonic lethality55. In addition to enhanced chromatin 
accessibility resulting from H3K27ac deposition, p300 and CBP are also thought to 
further promote gene activation by directly antagonising deposition of the repressive 
modification H3K27me356. 
Finally, MOF catalyses deposition of H4K16ac, which has a particular significance in the 
establishment and maintenance of active chromatin. In vitro experiments have 
demonstrated that H4K16ac efficiently inhibits the condensation of nucleosome arrays 
into 30 nm fibres, and also disrupts the interactions between chromatin fibres that allow 
further compaction57,58. In vivo, H4K16ac is enriched throughout the bodies of active 
genes in human cells. In Drosophila, H4K16ac mediates gene-dosage compensation, a 
process leading to a global two-fold upregulation of gene expression59,60.  
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1.2.4 The diverse effects of histone lysine methylation on gene activity 
Histone lysine methylation was first reported in Drosophila to result from the activity of 
Su(var)3-9, and was associated with inactive heterochromatin61. Subsequent studies 
identified the human orthologue, SU(VAR)3-9, and the target residue as histone 3 lysine 
9 (H3K9)62,63. H3K9 can be methylated up to three times to generate H3K9me1/2/3. Each 
methyl group provides a structural moiety that is recognised by repressive factors 
including heterochromatin protein 1 (HP1) which directly impairs nucleosome 
accessibility to inhibit transcription64. In fact, SU(VAR)3-9 belongs to a much broader 
class of enzymes, termed histone lysine methyltransferases (KMTs). A major subclass of 
KMTs comprising ~50 enzymes feature a common SET methyltransferase domain, with 
each enzyme targeting distinct lysine residues65.  
Of the multitude of other lysine methylation marks known, two further modifications of 
crucial relevance in gene regulation are H3 lysine 4 methylation (H3K4me) and H3K27 
trimethylation (H3K27me3). In contrast to H3K9me, H3K4me is associated with 
transcriptional activation. Like H3K9me, KMT enzymes catalysing H3K4me1/2/3 also 
contain conserved SET domains66. Of all the H3K4 KMTs in mammals, the MLL proteins 
are the best characterised and have been shown in knockout studies to be essential 
genes. Mll1 or Mll2 heterozygous-null mice featured severe defects at birth, owing to 
comprehensive deregulation of homeotic genes involved in body patterning, while 
homozygous-null mice were embryonic lethal67,68. MLL proteins can catalyse the mono-, 
di- or tri-methylation of H3K4 to give H3K4me1/2/3, respectively69. 
H3K4me3 is an activating mark enriched at promoters, gene bodies and enhancer 
elements of active genes. At promoters, H3K4me3 is often maximally enriched most 
proximal to the transcription start site (TSS) compared to H3K4me1 and H3K4me2, 
typically at -300 bp and +100 bp70. Furthermore, at certain genes including tumour 
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suppressors, H3K4me3 enrichment exists as broad domains extending well into the gene 
body and is associated with increased transcriptional elongation. In the same study, 
broad domains of H3K4me3 were also reported at highly active enhancer elements71. 
Conversely, shortening of these broad H3K4me3 domains was indicative of diminishing 
transcription. H3K4me3 promotes gene activation via recruitment of the SWI/SNF 
chromatin remodelling complex. SWI/SNF promote lysine acetylation and nucleosome 
eviction, increasing accessibility to positively regulate transcription72,73. Although the 
above evidence would suggest that H3K4me3 is simply an activating mark, one study 
found that 59% of inactive gene promoters were also enriched for H3K4me370. Partly 
accounting for conflicting reports regarding H3K4me3, studies by the Lander laboratory 
identified a distinctive pattern of chromatin at promoters of silent or lowly expressed 
genes featuring co-association of H3K4me3 with the repressive H3 lysine 27 
trimethylation (H3K27me3) mark. They termed these promoters ‘bivalent’74. 
H3K4me1 and H3K4me2 enrichment occurs at active enhancer elements in many tissue-
specific contexts, and typically co-occurs with the activating H3K27ac mark75. 
Furthermore, H3K4me1 is a target for further activating proteins. For example, in the 
context of estrogen receptor alpha (ERα) signalling, ERα promotes the recruitment of the 
TIP60 histone remodelling enzyme to H3K4me1. TIP60 deposits an additional activating 
mark, H2A lysine 5 acetylation (H2AK5ac), at ERα target loci, further stimulating gene 
activation76. H3K4me1 is also elevated in the promoter regions of active genes together 
with H3K4me2/370. 
In contrast to H3K4me1, the relationship between H3K4me2 and gene activation is more 
nuanced. Like H3K4me1, H3K4me2 is often enriched at active gene promoters, but is 
maximally enriched more proximal to the TSS than H3K4me170. However, H3K4me2 
enrichment also occurs at silent gene promoters in the absence of H3K4me3 
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(H3K4me2+/me3-). In one study of haematopoietic cells, silent genes in multipotent 
progenitors featuring H3K4me2+/me3- were rapidly activated when these cells 
differentiated, with an accompanying deposition of H3K4me377. These and similar 
observations in other systems have led to the definition of H3K4me2+/me3- as a marker 
of transcriptional ‘poising’. Further underlying its special role in gene regulation, 
H3K4me2 at tissue-specific enhancer regions is required for the recruitment of the 
pioneer factor FoxA178, which promotes target gene activation through mechanisms 
discussed in more detail in 1.3.6. 
1.2.5 Bivalent chromatin marks genes for later activation or repression 
Bivalent chromatin domains were identified from ChIP-Chip studies of H3K4me3 and 
H3K27me3, which found the individual patterns overlapped at a substantial number of 
silent promoters of genes in mouse embryonic stem (ES) cells. While H3K4me3 was 
mostly found proximal to the silent TSS, H3K27me3 marked broader domains across the 
TSS. Furthermore, re-ChIP experiments confirmed that nucleosomes were often co-
occupied by these modifications74.  
The significance of bivalent promoters was realised when it was observed that they often 
regulated critical developmental transcription factor genes. An elegant example of this is 
the neural-specific regulator Olig1, which has a bivalent promoter in mouse ES cells. 
Upon differentiation into neural progenitor cells (NPCs), Olig1 was strongly upregulated 
and the repressive H3K27me3 mark was lost, whilst the activating H3K4me3 was 
maintained74. By contrast, the non-neural Gata6 locus is bivalently marked and lowly 
expressed in ES cells, and differentiation into NPCs silenced Gata6 and led to loss of 
H3K4me3. However, Gata6 expression is upregulated in macrophage development, and 




H3K27me3 deposition is catalysed by multi-subunit Polycomb 2 (PRC2) complexes, 
which are thought to be recruited to target promoters by several features including 
lncRNA transcription and high levels of DNA methylation80,81. PRC2 contains a catalytic 
subunit, EZH2, with a conserved SET domain responsible for H3K27 KMT activity. 
Another PRC2 co-factor, Jarid2, aids in targeting the complex to chromatin and induces 
an allosteric change in EZH2 to promote H3K27me3 depostion, leading to localised 
nucleosome condensation80. In vitro studies have shown a single PRC2 complex 
compacts about three nucleosomes via interaction with the histone core82. This is a 
silencing mechanism distinct from H3K9me marking discussed in 1.2.4, which promotes 
recruitment of repressive HP1 complexes63. 
Finally, PRC2 occupancy competes with SWI/SNF binding at bivalent chromatin83,84. This 
is just one example of a tightly-regulated functional antagonism between activating and 
repressive factors at bivalent chromatin. Subtle shifts in the balance between these 
factors, for example in response to developmental stimuli, can lead to targeted tissue-
specific gene expression. Critically, perturbation of this antagonistic relationship is a 
recurring feature of oncogenic transformation85.  
1.2.6 Histone variants 
In addition to post-translational modifications of canonical histones, several histone 
variants with alternative amino acid sequences also exist86. Histone variants often play 
even more dynamic roles than their canonical counterparts. For example, although 
canonical histones are almost exclusively synthesised during S-phase of the cell cycle 
and are incorporated into nucleosomes in a replication-dependent manner, histone 
variants are expressed and incorporated throughout the cell cycle. Histone variants are 
recruited to target nucleosomes by a complement of histone chaperone proteins which 
mediate histone exchange86.  
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The divergent amino acid sequences of histone variants affects their tertiary structure, 
impacting both nucleosome stability and the strength of DNA:histone interactions, 
leading to localised changes in chromatin compaction. Of particular relevance to gene 
activation are the variants H2A.Z and H3.3, which are enriched in accessible 
chromatin87. For example, nucleosomes containing H3.3 are more sensitive to disruption 
than those with canonical H3 alone, whereas nucleosomes containing H2A.Z do not 
efficiently recruit linker histones for further chromatin compaction88. By contrast, the 
macroH2A variant stabilises nucleosomal structure and has a repressive effect on 
transcription89. MacroH2A is often localised at silenced genes and on portions of the 
inactivated X chromosome in mammals90. 
1.2.7 ATP-dependent chromatin remodellers 
In addition to specific enrichment of histone modifications and histone variants, active 
regions of the genome also feature highly dynamic nucleosome positioning. Re-
positioning of nucleosomes is an ATP-dependent process driven by large multi-subunit 
complexes of chromatin remodelling factors. The best characterised chromatin 
remodellers belong to the SWI/SNF, IWSI and SWR1 families, which are grouped 
according to the distinct ways in which they alter nucleosome conformation91. For 
example, SWI/SNF complexes directly evict nucleosomes, while IWSI complexes slide 
nucleosomes along the DNA spooled around it. In gene activation, the consequence of 
both SWI/SNF and IWSI family members is the creation of nucleosome-free regions that 
expose target DNA sequences for binding by transcription factors2,91. SWI/SNF 
recruitment to target genes can be a transcription factor-dependent process, or it can be 
via intrinsic bromodomain-mediated recognition of acetylated histones92.  
ISWI can also repress gene activation by sliding nucleosomes over TSS of genes, 
occluding their core promoter elements for recognition by trans-acting factors. SWR1 
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families catalyse the substitution of canonical H2A-H2B histone dimers for those 
containing the H2A.Z variant. Nucleosomes containing H2A.Z are often enriched at 
active gene promoters and the intron-exon boundaries of actively transcribed genes93. 
1.3 Regulation of Gene Expression 
A unifying theme of all the processes discussed so far is the transition of chromatin 
between a condensed, inactive state and a more relaxed, accessible structure which 
favours gene transcription. Now that these properties have been introduced, the 
mechanisms by which genes are precisely regulated shall be explored. 
1.3.1 Mechanisms of gene transcription by RNA polymerase II 
Transcription of protein-coding genes in eukaryotes is co-ordinated chiefly by a large 
RNA polymerase II (RNAPII) complex. The RBP1 subunit of RNAPII features a C-
terminal domain (CTD) containing 52 tandem repeats (in humans) of the consensus 
sequence Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7, which are extensively regulated by 
phosphorylation throughout the course of transcription. RNAPII works in concert with 
several other proteins including general transcription factors (GTFs), activators and co-
activators94.  
During the first phase of transcription, termed ‘initiation’, RNAPII is recruited to the DNA. 
This begins with the co-operative assembly of GTFs on to the nucleosome-free core 
promoter sequence, usually starting with TFIID. This complement of factors is known as 
the pre-initiation complex (PIC) which permits recruitment of RNAPII and other cofactors 
immediately upstream of the TSS95. In the presence of ATP, the core DNA sequence 
bound by the PIC is melted to produce a ‘transcription bubble’ and the open promoter 
complex94 (Figure 1:5). Formation of the open promoter complex brings the template 
strand of DNA into close proximity with the RNAPII active site, which begins nascent 




Figure 1:5 Initiation of transcription at the promoter proximal region 
1: Assembly of the pre-initiation complex at the TSS; 2: Recruitment of RNAPII to the core promoter; 
3: Initial burst of transcription; 4: The presence of the +1 nucleosome and binding of the pausing 
factors DSIF and NELF to RNAPII lead to pausing of polymerase complexes prior to the elongation 
phase of transcription.  
Adapted from Chen et al. (2015). 
 
 
Following recruitment to the core promoter during initiation, RNAPII enters the elongation 
phase of transcription. After an initial burst of 20 to 60 nucleotides of RNA synthesis over 
the TSS, RNAPII frequently pauses. Precise mechanisms for pausing have yet to be 
determined, but it is thought that the +1 nucleosome immediately downstream of the TSS 
presents a physical barrier hindering RNAPII elongation97. Furthermore, the presence of 
pausing factors including PIC subunits and others including negative elongation factor 
(NELF) seem to tether RNAPII, and are displaced during ‘escape’ of RNAPII from the 
promoter-proximal region98. At highly-inducible genes, it was originally thought that 
multiple paused RNAPII complexes accumulate at the promoter-proximal region99. 
However, a recent high resolution footprinting study of RNAPII binding dynamics in 
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single cells proposed an alternative pausing mechanism featuring rapid RNAPII turnover 
at the promoter-proximal regions of active or inducible genes100.  
Escape of RNAPII from the promoter-proximal region is dependent upon phosphorylation 
of the paused RNAPII CTD, a process mediated mainly by BRD4 and the P-TEFb 
complex. In actively cycling cells with abundant gene transcription, up to 90% of P-TEFb 
is inactivated by its association with HEXIM, 7SK small nuclear RNA and other 
components. However, recruitment of BRD4 to promoters during gene activation 
outcompetes binding of these inhibitory factors to P-TEFb, activating the CDK9 kinase 
domain of P-TEFb101. Activated P-TEFb phosphorylates Ser5 of the RNAPII CTD, evicts 
the pausing factor NELF, and phosphorylates a target residue of another pausing factor, 
DSIF, which becomes permissive to elongation. The elongation phase begins with 
RNAPII Ser2 phosphorylation and the eviction of PAF1 from RNAPII, presenting binding 
surfaces on the polymerase complex that promote assembly of the super elongation 
complex (SEC)102. Assembly of the SEC aids in the transition to productive elongation by 
recruiting chaperones and the FACT complex, causing eviction of H2A-H2B dimers from 
downstream nucleosomes. This allows RNAPII to efficiently transcribe from DNA without 
displacement of remaining core histones in the nucleosome. Complete histone octamers 
rapidly reform following RNAPII procession, owing to a localised pool of free H2A-H2B 
dimers and the activity of histone chaperones103,104. Productive elongation by RNAPII is 
initially quite inefficient, with a transcription rate of ~0.5 kb/min. This rises to 2-5 kb/min 
after ~15 kb, as RNAPII accumulates Tyr1 and Ser2 phosphorylation and pausing factors 
across the gene body are removed105.  
Finally, as RNAPII approaches the 3’ end of a gene and the polyadenylation (Poly(A)) 
site, Tyr1 residues in the RNAPII CTD are rapidly dephosphorylated, prompting 
recruitment of cleavage and polyadenylation specificity factor (CPSF) complex. CPSF 
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simultaneously interacts with RNAPII and the Poly(A) site to stall elongation and induce 
pausing, leading to the generation of R-loops forming between the nascent transcript and 
the genome. R-loop structures are resolved by SETX which permits access of the 
exoribonuclease XRN2 to degrade the 3’ end of the nascent transcript, which is thought 
to eject RNAPII from the 3’ end of the gene, terminating transcription106,107. The CPSF 
complex cleaves the pre-mRNA, permitting its release for subsequent processing and 
maturation. 
1.3.2 The transcriptional machinery persists at active genes 
At sporadically or lowly expressed genes, transcriptional termination is followed by the 
gradual reacquisition of an ordered nucleosome array across the gene, re-compaction of 
chromatin and release of the transcriptional machinery108. In contrast, active genes 
feature conformational differences that prime continued transcription. Firstly, ‘scaffold 
PICs’ persist at the promoter-proximal region even after an RNAPII complex escapes to 
begin productive elongation. Scaffold PICs promote high levels of gene expression by 
facilitating multiple successive rounds of RNAPII recruitment and transcription109,110. 
Finally, multiple actively-transcribed genes co-localise, appearing as visible foci using 
microscopy. These regions, distinguished by a concentrated pool of active RNAPII and 
associated factors, were termed ‘transcription factories’111 (Figure 1:6). Furthermore, 
genes localised to a given transcription factory are often regulated by similar 
combinations of sequence-specific transcription factors. In contrast to other models of 
transcription, it is thought that RNAPII complexes in transcription factories are spatially 
fixed, with the template DNA being fed through the transcribing RNAPII by other 
mechanisms112. Finally, genes can be moved in and out of transcription factories, 




Figure 1:6 Transcription factories. (Left) Highly active regions of chromosomes co-localise within 
nuclear spaces enriched for active RNAPII complexes and activating co-factors, called transcription 
factories. (Right) These regions can be visualised under microscopy as distinct foci in the nucleus, 
using a combination of DNA FISH (green) and immunofluorescence targeting active RNAPII (red). 
Image on right from Bender et al. (2012). 
 
1.3.3 Tissue-specific gene regulation is driven by transcription factors which 
shape the epigenetic landscapes of different cell types 
An inherent characteristic of multicellular eukaryotes is the vast range of different cell 
types that make up the body, yet almost all of these cells share a common genome. To 
generate this functional diversity, genes need to be transcribed at the right level, in the 
right place and at the right time. Waddington was the first to define epigenetics as the 
study of processes “by which the genes of the genotype bring about phenotypic effects”, 
underlining longstanding observations that the specialised functions of different cell types 
in complex organisms could not be explained by Mendelian genetics alone114. He later 
proposed that the phenotypic diversity of differentiated cells arise not from alterations in 
genetic inheritance, but instead from changes in the “epigenetic landscape” during 




Figure 1:7 Waddington’s epigenetic landscape. This classical model depicts a cell as a ball at the 
top of a hill, with the potential to follow one of multiple paths according to subsequent fate restriction 
events (depicted as branches/valleys in the hill). However, once the cell has passed a certain point, its 
fate is determined, and it cannot travel back up the hierarchy to a more ‘potent’ state114,115. 
 
Shortly after Waddington’s epigenetic landscape model was proposed, Jacob and Monod 
found empirical evidence of the relationship between environment and gene expression 
as being central to changes in phenotype. In pioneering studies, they observed that 
genes could be induced or repressed via “functionally specialised genetic determinants” 
in response to “specific metabolites”116. Today, we know of these “genetic determinants” 
by another name: lineage-specific transcription factors (TFs), distinct from the GTFs 
which are involved in the transcription of all genes. 
TFs work in concert at cis-regulatory elements of target genes to promote, maintain or 
repress the active chromatin structure required for gene transcription. Individual TFs form 
nodes in highly interconnected regulatory networks, with ‘master regulator’ TFs exerting 
the most influence in these expression control circuits. The first master regulators to be 
identified were the ‘bithorax’ genes, which emerged in the 1960s and 1970s from mutant 
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studies in Drosophila as essential for correct morphogenesis and segmentation in larval 
development. Disruption of any of these genes leads to a range of abnormal body plan 
phenotypes117. Bithorax genes were found to be part of a much broader class of 
‘homeotic’ TF genes, and orthologues were subsequently identified in vertebrates. As in 
Drosophila, disruption to these genes, particularly those in the HOX gene family, result in 
severe developmental defects in both mice and humans118,119.  
The potential of master regulator TFs to fully specify developmental pathways is also 
elegantly illustrated by cellular reprogramming studies, where cell lineages can be 
switched from one type to another by the forced expression of just one or a select few TF 
genes. For example, over-expression of the myogenic master regulator MyoD is 
sufficient to reprogram adult fibroblast cells into muscle cells120. Furthermore, Shinya 
Yamanaka demonstrated that the expression of four TF genes alone could convert fully 
differentiated somatic cells into induced pluripotent stem cells (iPSCs) with reasonable 
efficiency121. 
1.3.4 Generalised roles and properties of transcription factors 
The primary roles of all TFs, including the GTFs introduced in 1.3.1, are to control the 
rate of gene transcription. Distinct from GTFs, TFs integrate changes in cellular signalling 
and metabolism to elicit targeted regulation of specific genes. For this reason, TF 
proteins feature regulatory sites that are post-translationally modified by signalling 
proteins, or domains which bind metabolic co-factors, nuclear hormones or other TFs. 
TFs often belong to large families related by a common DNA-binding domain, for 
example the Forkhead (Fox) family122. Consequently, different members of such TF 
families may target similar DNA sequences, but have diverse effects on transcription due 
to differences in functional domains or interacting partners. 
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The broadest distinction between TFs was made based on their observed effect of 
increasing (activator TFs) or decreasing (repressor TFs) transcription. However, all TFs 
and co-factors alter transcription by the following principle mechanisms: 
1. Interaction with target gene promoters to affect the assembly of the PIC and 
RNAPII recruitment at the promoter-proximal region123. 
2. Modulation of the activity of the general transcriptional machinery by 
catalysing post-translational modifications, conformational changes or 
recruitment/eviction of interacting partners124,125. 
3. Activation or repression of the activity of chromatin remodellers to open, 
maintain or close chromatin at target loci126. 
4. Promoting the physical interaction of distal cis-regulatory elements with the 
promoters of target genes to to stimulate activation, or to partition other genes 
into inactive chromatin domains127,128.  
The majority of TFs bind directly with target DNA sequences via specialised DNA-binding 
domains. The primary amino acid sequence and tertiary structure of these domains 
largely determine the specific DNA sequences, or binding motifs, which are recognised 
by particular TFs. Furthermore, many TFs feature interaction domains which allow 
binding to DNA motifs as multimeric complexes. One such example is the ‘basic region 
leucine zipper’ (bZIP) family of TFs. bZIP monomers dimerise with their leucine zipper 
domains prior to interacting with DNA via positively charged arginine and lysine residues 
in the basic region. In many cases, the monomers comprising a functional TF complex 
can be the same protein (homotypic) or different (heterotypic), creating functional 
diversity that either increases specificity of DNA binding or provide redundancy for robust 
regulation of critical genes129. 
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Co-activators and co-repressors are distinct from TFs in that they do not directly bind 
DNA, but instead modulate the activity of DNA-binding TFs by other means. One class 
can co-operatively promote the PIC assembly at promoters, as is the case of the TBP 
associating factors (TAFs). TAFs recruit subunits of the basal transcriptional machinery 
to sequence-specific TFs bound at promoters via several interaction domains130. Another 
class of co-factors affect transcription through their intrinsic histone modifying activity. 
For example, the HAT enzymes CBP and p300, previously discussed in 1.2.7, are often 
recruited by TFs bound at target loci whereupon they acetylate adjacent histones to 
stimulate gene activity131. 
1.3.5 Transcription factors co-operate to disrupt nucleosomes at target loci 
Despite their evident roles in gene regulation, the overwhelming majority of TFs cannot 
efficiently recognise binding sites on DNA if they reside on nucleosomes in chromatin. 
However, there is considerable evidence to show that TFs co-operate to bind target 
sequences which are otherwise occluded by their association with nucleosomes132,133. 
This mechanism was elegantly demonstrated in pioneering in vitro studies by the 
Workman laboratory. They found that three factors - GAL4, USF and NF-κB – individually 
bind inefficiently to intra-nucleosomal target sites located 46 bp from the nucleosome 
boundary. However, if these target sites were located within 20 bp of the nucleosome 
boundary, individual binding was significantly more efficient for all of these TFs. The +20 
bp site is more efficiently bound by individual TFs because the association between DNA 
and histones is much weaker at nucleosome boundaries than at intranucleosomal 
sequences. Furthermore, the binding of any of these factors at the +20 bp site greatly 
increased the ability of TFs to consequently bind to the +46 bp nucleosomal site, by as 
much as 2 orders of magnitude. This was significant because USF and NF-κB could both 
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subsequently bind to intranucleosomal sequences, demonstrating an intrinsic 
cooperativity of binding.  
 
Figure 1:8 Transcription factors co-operate to bind to nucleosomal sites. A generalised model 
from Cockerill (2011), in which the binding of factor A to a partially exposed binding site at the 
nucleosome boundary sufficiently dissociates adjacent nucleosomal DNA for a second factor to 
subsequently bind. 
 
The early in vitro studies which established the above model of TF binding have been 
supported more recently by genome-wide and live cell approaches, which confirm co-
operative binding as a broader mechanism of TF recruitment to cis-regulatory 
elements134,135. A generalised model of co-operative binding is depicted in Figure 1:8, 
where the initial binding of factor A to a site at the nucleosome boundary disrupts weak 
DNA:histone interactions, partially ‘unzipping’ DNA from the nucleosome and allowing 
subsequent recognition of sites by factors B and then C. In this manner, individual TFs 
with little or no nucleosome binding properties can co-operate to progressively 
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destabilise nucleosomes and activate target cis-regulatory elements2. Critically, the vast 
majority of these TFs can still not recognise target binding motifs as they exist in 
condensed chromatin. In this context, DNA sequences that are not wrapped around the 
core nucleosome are either occluded by association with histone H1/H5 or neighbouring 
nucleosomes in chromatin fibres, preventing the initial binding event for co-operative 
binding to occur136. Prior events that increase chromatin accessibility – particularly the 
eviction of histone H1, which disrupts higher order nucleosome folding – are still 
essential pre-requisites for the overwhelming majority of TFs to recognise binding 
sequences and for co-operative binding to follow137. 
1.3.6 The specialised properties of pioneer factors in gene regulation 
Pioneer factors are distinguished from all other TFs by their unique ability to efficiently 
bind target sites in condensed chromatin fibres de novo, without prior de-compaction by 
other processes. Pioneer factors such as the Forkhead domain (FOX) TFs gain entry into 
chromatin fibres by outcompeting binding of linker histones H1 or H5 via specialised 
protein domains, increasing local chromatin accessibility for other factors to recognise 
and bind their binding sequences. As a result, pioneer factors promote gene activation by 
conferring ‘transcriptional competence’ at target loci. 
Establishment of transcriptional competence by pioneer factors can be either an active or 
a passive process (Figure 1:9). In the active role, pioneer factors target sites on 
compacted chromatin and rapidly increase local accessibility, exposing other sequences 
for recognition by conventional TFs137. Conversely, passive regulation involves stable 
pioneer factor occupancy at accessible chromatin to prime cis-elements for rapid 
induction by promoting the subsequent assembly of other factors. Excellent examples of 
passive pioneering are observed during androgen and estrogen receptor activation, 
which are often recruited to cis-elements ‘bookmarked’ by the pioneer factor FoxA1138,139. 
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Finally, pioneer factors can persist at target sites throughout the cell cycle, ensuring rapid 
re-induction of crucial genes following mitosis140.  
 
Figure 1:9 Pioneer factors can behave in a passive or active manner to prime gene activation. In 
the passive context (left), the pioneer factor remains stably bound at inactive enhancer regions, 
priming these elements for subsequent activation in the presence of additional non-pioneer TFs, 
perhaps by maintaining an accessible chromatin structure. Conversely, in the active context (right), 
pioneer factors gain direct entry into compacted chromatin fibres, allowing other TFs to recognise 
target binding sites in the accessible region created. 
 
Our current knowledge of how pioneer factors work is largely due to landmark studies 
from the Zaret laboratory on the prototypical pioneer factor FoxA1. They first identified 
FoxA1 as a liver-specific TF that could efficiently bind a target site in the Albumin gene 
enhancer, even though this sequence was located on the nucleosomal surface and not 
be easily recognised by conventional TFs141. Subsequently, they demonstrated that 
FoxA1 could bind target sites on nucleosomes more stably than on free DNA, in stark 
contrast to most other TFs142. Structural characterisation of FoxA1 identified the ‘winged-
helix’ DNA-binding domain responsible for this specialised activity143. The winged-helix 
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domain closely resembles histone H1/H5, allowing FoxA1 to efficiently recognise target 
sites in compacted chromatin by directly outcompeting linker histone binding to DNA144. 
Point mutations to the winged-helix domain demonstrated that FoxA1 actually recognises 
sites in chromatin via both nonspecific nucleosome binding and sequence-specific DNA 
binding activities140. The unusual ability of FoxA1 to bind nucleosomes in a nonspecific 
manner greatly slows its nuclear mobility compared to conventional TFs, allowing it to 
‘scan’ chromatin for target sequences145 (Figure 1:10). 
FoxA1 belongs to the Forkhead (Fox) family of TFs, comprising 50 family members in 
humans which all share the conserved winged-helix domain122,146. Because all Fox 
proteins contain this key structural feature, it is not surprising that other family members 
in addition to FoxA1, including FoxO1 and FoxE1, have since been characterised as 
pioneer factors147,148. 
Finally, in addition to the Fox family of pioneer factors, a selected number of other TFs 
have been shown to have comparatively modest pioneer activity. For example, three of 
the four Yamanaka factors used to generate iPSCs – Oct4, Sox2 and Klf4 (OSK) - can 
also recognise partial binding motifs as they exist on nucleosomes149. These properties 
are almost certainly necessary to reprogram differentiated cells with deeply-embedded 
chromatin profiles into a pluripotent state. The final Yamanaka factor, Myc, binds co-
operatively as a conventional TF following prior binding to targets by one or more of 
OSK. However, despite the emergence of new pioneer factors, their ability to recognise 





Figure 1:10 Slow nuclear mobility is a defining feature of the pioneer factor FoxA1. Non-specific 
interactions between FoxA1 and histones, via the winged-helix DNA binding domain, give it a greatly 
reduced nuclear mobility compared to conventional TFs. This is elegantly illustrated in fluorescence 
recovery after photobleaching (FRAP) experiments using GFP-tagged proteins.  
A: While c-Myc, a conventional TF, can return to bleached areas of nuclei in an order of seconds, 
several minutes pass before a fluorescent signal is observed from FoxA1 returning to bleached 
areas145. (Left) The change in average fluorescence intensities over time are shown for photobleached 
(blue lines) and unbleached areas (red lines) are plotted, demonstrating a much slower recovery of 
unbleached FoxA1 molecules to previously bleached areas of nuclei. (Right) Fluorescence microscopy 
images of a live cell nuclei taken before and after photobleaching demonstrate substantial movement 
of unbleached c-Myc molecules into bleached regions of nuclei in less than a minute, in contrast to the 
much slower mobility of unbleached FoxA1 molecules.  
B: Schematic model of compacted chromatin scanning by pioneer factors, which is thought to explain 






Figure 1:11 The Forkhead DNA-binding domain is conserved across the FOX protein family.  
As this schematic diagram adapted from Lam et al. (2013) demonstrates, different FOX proteins 
exhibit considerable diversity in the complement of different domains they contain. However, the 
presence of the winged-helix forkhead DNA binding domain (FHD) that in FoxA1 and FoxO1 confer 
pioneer activity is a unifying feature across the FOX protein family. 
ID = inhibitory domain; LZ = leucine zipper domain; NES = nuclear export signal; NLS = nuclear localisation 
signal; TAD = trans-activation domain; TRD = transcriptional repressor domain. 
 
1.3.7 Non-coding cis-regulatory elements and their roles in gene regulation 
Just ~1.5% of the human genome sequence encodes protein-coding genes. However, if 
the remaining DNA did not serve a biological purpose, it is generally considered that it 
should have been eliminated across generations through evolution, as replication of 
unnecessary tracts of genome comes at a cost to an organism’s biological fitness. 
Precisely how much of the remaining non-coding DNA has a biological function is an 
area of intense debate. Differing accounts ascribe 8 to 80% of the human genome as 
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functional, depending on the definition and methodology used151,152. Disputes 
notwithstanding, it is widely accepted that a significant portion of the non-coding genome 
is involved in the regulation of genes through cis-regulatory elements. Most genes have 
several cis-regulatory elements, which may be found proximal to the coding sequence, in 
intragenic regions, or at long distance from the gene they control153. Such long-range 
distal elements can be separated by a few kb to as far as a mega-base (Mb) of 
intervening DNA sequence, which may contain other genes. The primary roles of cis-
regulatory elements are to control the timing and levels of target gene expression with 
TFs in a highly tissue-specific manner. The different classes of these cis-regulatory 
elements shall now be discussed. 
1.3.8 Promoters  
As previously introduced, promoters are cis-regulatory elements that define the TSS of a 
gene and permit recruitment of the PIC, basal transcriptional machinery and RNA 
polymerases during gene activation94. Despite the commonly accepted functional 
definition of the core promoter as the minimum DNA sequence required for accurate 
transcriptional initiation, there is no universal sequence unifying all core promoter 
elements154. For example, the TATA binding element, first identified in archaea and then 
eukaryotes, was considered for many years to be a ubiquitous promoter element, yet it is 
only present in 10-20% of human core promoters155. The most common sequence 
feature of many promoters are initiator sequences (Inr) that span the TSSs of both TATA 
and TATA-less promoters156,157. Both TATA box and downstream promoter elements 
interact with TFIID to promote recruitment of the PIC during transcriptional activation158. 
TATA-less promoters are distinguished by other sequence features, including the GC-
box, CCAAT-box and CG islands154,159. Unlike TATA-box elements, these elements 
generally operate independently of sequence orientation and distance relative to the 
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TSS159. Firstly, GC-boxes may contain one or more of the consensus sequence 5’-
GGGCGG-3’, which are recognised by Sp1 family TFs160. The first GC-box promoter was 
described in the SV40 virus early gene promoter, which is regulated by the ubiquitously-
expressed TF, Sp1. GC-box promoters are typically involved in the regulation of 
housekeeping or ubiquitous genes161,162. Secondly, CCAAT-box elements are typically 
positioned 60-100 bp upstream of the TSS and recognised by NFYA as part of a trimeric 
complex. The first such elements were identified at the human beta-globin gene 
promoter163. Finally, CG islands are long tracts of typically ~0.5-2 kb of (G+C)-rich 
sequences that span the TSSs in over 70% of human promoters. Although CG motifs are 
the normal targets of 5mC deposition by DNMT enzymes, which leads to stable gene 
repression36,164, these motifs are predominantly unmethylated in CG islands at 
constitutive promoters active in most cells. 
The organisation of elements at a given gene promoter lies along a continuum between 
focussed and dispersed154. Consistent with their name, focussed promoters have a 
dense hub of sequence features involved in their regulation, and often appear at tissue-
specific genes. In contrast, dispersed promoters have broader domains of elements - CG 
islands being one example - with most constitutive genes falling under the control of this 
type of promoter. 
1.3.9 Enhancers 
Enhancers are the “logic gates” for activation of gene expression, and can greatly amplify 
the transcriptional activity of the promoters they regulate. Enhancer elements operate in 
a highly context-specific manner, and therefore play a critical role in establishing tissue-
specific gene expression. They are typically ~200-400 bp in size and found distal to their 
target promoter, most commonly from 1 kb to 1 Mb away. Enhancers feature an 
increased density of binding motifs for TFs, which bind to increase gene transcription 
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under the appropriate conditions165,166. The first enhancers were described in the early 
1980s and included an “upstream modulator” of the sea urchin histone H2A gene, the 
SV40 virus enhancer and the mammalian immunoglobulin gene enhancers167–172. 
Highly regulated genes are typically under the control of multiple enhancers, which either 
act independently of each other to activate transcription in response to different stimuli or 
tissue-specific TFs, or synergistically to achieve even greater target gene 
expression173,174. This phenomenon was first demonstrated in elegant studies of the 
human beta globin locus, which identified five individual elements working in concert as a 
‘locus control region’ (LCR) to direct tissue-specific expression. It was also shown that 
these elements had enhancer activity independently of their relative position to the target 
gene175. 
While inactive enhancers are normally occupied by nucleosomes, active enhancers 
acquire increased TF occupancy and an accessible, nucleosome-free chromatin 
structure detectable as DHS peaks in DNase-seq analyses2. Other general features of 
active enhancers are DNA hypomethylation, enrichment of the histone variants H2A.Z 
and H3.3, and H3K4me1/2 and H3K27ac modifications.  
Finally, enhancers can activate target gene promoters by bringing the two linearly-
separated DNA sequences into close physical proximity by DNA looping (Figure 1:12). 
Such long-range interactions are driven by the enhancer TF-dependent recruitment of 
the Mediator super-complex, which directly stimulates PIC formation on the target 
promoter. The assembly of cohesin further stabilises enhancer-promoter 
interactions176,177. Finally, in keeping with physical proximity to the promoter, active 
enhancers feature bidirectional transcription of enhancer RNAs (eRNAs), perhaps by 




Figure 1:12 Long-range interactions between distal enhancers and promoter elements. Three-
dimensional chromatin looping interactions are now widely accepted to occur at a substantial 
proportion of genes during activation. This process is thought to be promoted by TF-dependent 
recruitment of chromatin architecture proteins, including mediator, which help to bring two sequences 
that may be separated by megabases of linear genomic distance into close proximity of each other. 
Such looping interactions are thought to be stabilised by cohesin complexes, allowing enhancer-
dependent activation of promoter by currently unclear mechanisms but is thought to involve direct 
stimulation of the PIC at target gene promoters. Figure from Allen and Taatjes (2015). 
 
1.3.10 Super enhancers 
Super enhancers are somewhat arbitrarily distinguished from LCRs as particularly broad 
domains of individual enhancers that have an especially strong effect on gene activation. 
They are often described as being an order of magnitude larger in size than LCRs, 
featuring greater levels of H3K27ac enrichment and Mediator binding, and correlate 
more strongly with target gene expression than LCRs. Super enhancers commonly 
regulate critical lineage-determining genes or ‘master regulators’179. More recently, it has 
been proposed that super enhancers can also participate in higher order DNA loop 
structures involving three interacting sequences at key developmental TF genes, such as 
 
38 
the Sox2 locus in ES cells180,181. Collectively, these features are thought to increase the 
general robustness of target gene activation under the appropriate conditions. 
1.3.11 Priming enhancers 
Despite large numbers of cis-regulatory elements being defined as enhancers according 
to descriptive features such as enrichment for H3K27ac and DNase I hypersensitivity, up 
to 80% of these elements lack an ability to directly stimulate gene transcription when 
directly tested for enhancer function182,183. Furthermore, studies from this laboratory 
identified ~3,000 such elements in T cells that do not typically activate transcription per 
se, but instead maintain an accessible chromatin structure at target genes, priming them 
for rapidly inducible gene expression184. These elements were termed priming enhancers 
or priming DHSs (pDHSs).  
A model example of priming enhancer function is evident at the human IL3 locus, which 
is under the control of at least four pDHSs at -1.5 kb, -4.1 kb, -34 kb and -41 kb. These 
pDHSs did not induce a luciferase reporter driven by the IL3 promoter in enhancer 
assays, neither individually nor in combination, in contrast to another classical enhancer 
at -37 kb which did strongly induce the luciferase reporter184. However, CRISPR deletion 
of the -34 kb pDHS in Jurkat T cells resulted in a diminution of IL3 accessibility as 
measured by DNase I hypersensitivity, and a delayed induction of IL3 expression. In light 
of this and other evidence, it is likely that a significant portion of cis-elements previously 
defined as classical enhancers will be re-classified in the near future. 
1.3.12 Silencers 
Opposing the function of the broad class of enhancers, silencers are elements that 
negatively regulate gene expression. They were originally identified in the 5’ UTR of 
genes, but have since also been found elsewhere. Silencers are the least understood 
class of cis-regulatory element, and are generally thought to work by one of two 
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mechanisms. Firstly, silencers can act to disrupt assembly of the PIC at the promoter-
proximal region of genes, perhaps by recruitment of HDACs, PRC2 complexes, H3K9 
methyl transferases or DNMTs that remove histone acetylation and subsequently deposit 
repressive H3K27me3, H3K4me2/3 or 5mC, respectively. In contrast, silencing elements 
operating further away from the promoter may contain sites recognised by repressive 
TFs which disrupt the binding of activating TFs at nearby enhancers185. 
1.3.13 Insulators 
Insulators are the final major category of cis-regulatory elements, and primarily act to 
increase the target gene specificity of enhancers. Insulation of gene activity is an 
important function, since it has been demonstrated that insulator disruption can lead to 
off-target promoter-enhancer interactions, both experimentally and in cancer186. 
Furthermore, insulator elements can also act as barriers to prevent the inappropriate 
spreading of repressive heterochromatin into nearby genes187.  
Active mammalian insulator elements are bound by the protein CTCF 188. CTCF interacts 
with Cohesin and these complexes mediate between insulator elements to bring linearly-
separated DNA sequences into close physical proximity via DNA looping, establishing 
segregated functional domains189 referred to as ‘insulated neighbourhoods’ . Such 
interactions can be short range, partitioning the activity of one gene from another a few 





Figure 1:13 Insulated neighbourhoods partition active genes from silent ones. 
A: Further detail of the organisational hierarchy of chromosomes: the TADs previously described in 
1.1.3 are partitioned further into insulated neighbourhoods.  
B: stereotyped example of an insulated neighbourhood, where a gene and its cognate enhancers are 
physically partitioned by cohesin and CTCF to prevent the activation of other nearby genes.  
C: deletion or disruption of CTCF sites that participate in gene insulation can lead to the ectopic 
reactivation of other local genes.  
Adapted from Hnisz et al. (2016). 
 
Further increasing the specificity of insulator function, these CTCF sites must be oriented 
towards each other for dimerisation and loop formation to occur190. The partitioning of the 
genome into insulated neighbourhoods was demonstrated to be functionally significant in 
human ES cells, where over 90% of all detected promoter-enhancer interactions 
occurred within the boundaries of insulated neighbourhoods191. Insulated 
neighbourhoods are also referred to as sub-TADs, a constituent of the TADs described in 
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1.1.3, and are generally constitutive across different cell types191. In some instances, 
insulators have also been defined as silencers due to their enhancer-blocking activity. In 
the case of the lysozyme gene, activation of non-coding transcription from an enhancer 
was sufficient to suppress a silencer by removing CTCF from its binding site192,193. 
Finally, CTCF binding at some specific sites is highly sensitive to DNA methylation, and 
cancers with aberrant DNA methylation function often feature abnormal insulator or TAD 
patterns resulting from disrupted CTCF binding. Insulator dysfunction can also lead to 
the ectopic activation of oncogenes194. 
1.4 Haematopoiesis and the haematopoietic stem cell 
Haematopoiesis is the process by which all blood cell types are produced. Despite their 
vast functional diversity, mature blood cells arise from a common stem cell with the 
potential to propagate all lineages. The existence of such cells was first postulated in 
cytological studies by Maxinow in the 1900s, who observed a “ubiquitous, non-
differentiated” cell type in foetal blood that could “produce a variety of differentiation 
products”195. 
However, it was not until the 1960s that a functional understanding of haematopoiesis 
began to emerge with the work of Till and McCulloch, who demonstrated that rare cells 
from the bone marrow could clonally repopulate in vivo, forming macroscopic colonies on 
recipient mice spleens196,197. 
With the development of fluorescence-activated cell sorting (FACS), it became possible 
to separate cells by their immunophenotype, leading to the isolation of what we know 
today as haematopoietic stem cells (HSCs) by Weissman and colleagues at Stanford198. 
These HSCs were operationally defined by their ability to fully reconstitute the 
haematopoietic system in lethally irradiated recipient mice199. HSCs have an innate 
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capacity to self-renew, ensuring the production of comparatively short-lived mature blood 
cells is sustained throughout life. Thanks to sustained intense research, the 
haematopoietic system is perhaps the best understood adult developmental pathway in 
the body and HSCs have become a paradigm for the general study of stem cell biology 
in other tissues.  
1.4.1 Discovery of the haematopoietic stem cell niche 
It was known for many years from work by Till and McCulloch that adult HSCs reside in 
the bone marrow, and that this environment was somehow critical to their function196. 
However, HSCs are extremely rare, accounting for ~0.003% of all cells in the bone 
marrow200. HSCs occupy one of two microenvironments in the bone marrow, called the 
endosteal and perivascular niches. These anatomically distinct niches also have 
functional implications for the HSCs embedded within, and an understanding of their 
highly complex nature only recently started to become clear.  
The endosteal niche is located towards the outer edge of the bone marrow, is hypoxic, 
and is enriched for quiescent long term HSCs (LT-HSCs). It is not fully clear why LT-
HSCs preferentially localise to this niche, but paracrine signalling from nearby 
osteoblasts is thought to help maintain LT-HSC quiescence201. Hypoxia is also likely to 
promote the long-term potential of LT-HSCs by enforcing metabolic dormancy and 
minimising mutations arising from oxidative stress202,203.  
By contrast, the perivascular niche at the core of the bone marrow is distinguished by 
extensive sinusoidal vasculature, is highly oxygenated, and occupied by actively cycling 
short term HSCs (ST-HSCs). Perivascular mesenchymal stem cells (MSCs) secrete 
cytokines critical to the maintenance of ST-HSCs, including CXCL2 and stem cell factor 
(SCF)204. There is evidence from mice that vascular endothelial cells also support ST-
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HSCs via VEGFR2 signalling205. Furthermore, ST-HSC mobilisation to peripheral blood 
appears to be subject to circadian regulation by sympathetic nerve fibres acting on 
perivascular cells206,207. With appropriate stimuli, ST-HSCs divide asymmetrically to give 
rise to the progenitors that go on to populate all differentiated cell types of blood via 
haematopoiesis. 
1.4.2 The classical model of haematopoiesis 
In the years following the isolation of HSCs in 1986, further work pioneered by the 
Weissman laboratory characterised phenotypically discrete subsets of precursor cells, 
suggesting that adult haematopoiesis is a hierarchical process198,199,208,209. At the apex of 
this hierarchy are multipotent, self-renewing HSCs which have the capacity to give rise to 
all mature blood cell types via ordered fate restriction events involving progressively less 
potent progenitor cells210 (Figure 1:14). 
The HSC compartment is divided into two subsets of cells according to their capacity for 
self-renewal. The more ‘primitive’ LT-HSCs are the most quiescent and capable of self-
renewal throughout adult life. By contrast, ST-HSCs retain multipotency but are more 
actively cycling than their long-term counterparts and have a comparatively lower self-
renewal capacity211. 
By the time cells enter the multipotent progenitor (MPP) compartment, self-renewal is 
lost entirely in favour of greater cell proliferation. Crucially, although these cells retain 
sufficient potency to differentiate into any mature lineage, MPPs are already 
developmentally committed and cannot re-enter the HSC compartment209. 
The first lineage bifurcation in this model occurs following the MPP stage, where cells 
become committed to either lymphoid or myeloid/erythroid lineages. These are termed 
the common lymphoid progenitor (CLP) and common myeloid progenitor (CMP) 
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compartments, respectively. CLPs give rise to all lymphoid cells, including B cells, T 
cells, NK cells and others comprising the adaptive immune system. Lymphoid 
development occurs in the bone marrow until immature lymphocytes emerge, which 
enter the circulation to mature at distal sites including the thymus (T cells) and germinal 
centres (B cells)212,213. 
In contrast to CLPs, CMPs in this model retain potency to generate either myeloid or 
erythroid cells following progression into one of two more specified compartments: the 
megakaryocyte/erythroid progenitors (MEPs) and granulocyte/monocyte progenitors 
(GMPs)208. GMPs ultimately give rise to all mature myeloid lineages in this model. 
 
Figure 1:14 The classical Weismann model of haematopoiesis. 
In the Weismann model, an HSC undergoes defined step-wise transitions during haematopoiesis. The 
defining lineage commitment step in this model occurs at the MPP state, where cells are thought to 
commit strictly to either the myeloid/erythroid or lymphoid lineages, via a CMP or CLP progenitor state 
respectively. Adapted from Adolfsson et al. (2005). 
LT-HSC = Long-term haematopoietic stem cell; ST-HSC = short-term haematopoietic stem cell; MPP = 
multipotent progenitor; CMP = common myeloid progenitor; CLP = common lymphoid progenitor; GMP = 




1.4.3 Updated models of haematopoiesis 
Since this classical model of haematopoiesis was proposed, more recent observations 
from the Jacobsen laboratory have prompted revision of key aspects of the model. 
Firstly, an additional compartment of progenitors was identified, featuring the expression 
of lymphoid marker genes and FMS-like tyrosine kinase (Flt3). These cells could 
generate both lymphoid and myeloid cells, but not erythroid lineages, and thus were 
named lymphoid-primed multipotent progenitors (LMPPs)214. Secondly, it was observed 
that some MEPs were derived directly from MPPs without passing through an 
intermediate CMP state, suggesting that the strict lymphoid or myeloid partitioning is not 
the earliest lineage restriction step215. Taken together, the accumulated evidence support 
a revised model of haematopoiesis featuring a greater degree of plasticity in fate 
restriction events, which are perhaps determined in a probabilistic manner by 
heterogeneity within the ST-HSC and MPP compartments brought about by both 
intrinstic and extrinsic factors (Figure 1:15). 
Despite greatly expanding our understanding of how blood cells are produced, two main 
limitations of historic approaches to studying haematopoiesis have become apparent. 
Firstly, the model was largely built up from studies of cell populations purified using 
subjectively-defined FACS sorting gates and immunophenotypes. Bulk analyses of 
sorted populations are reliant on average molecular profiles, masking functionally 
significant heterogeneity between individual cells. Furthermore, although single-cell 
analyses on these populations may reveal underlying patterns of sub-population 





Figure 1:15 The updated Jacobsen model of haematopoiesis. 
In contrast to the Weissman model, the Jacobsen model proposes that some lineage restriction takes 
place before the ‘MPP’ state, in the ST-HSC compartment. ST-HSCs may directly commit to the 
erythroid/megakaryocyte lineages at this stage, or instead develop into lymphoid-primed multipotent 
progenitors (LMPPs) that can generate myeloid and lymphoid, but not erythroid lineages. Adapted 
from Adolfsson et al. (2011). 
 
Secondly, there is longstanding concern over the reliance on colony forming assays and 
transplantation as a reliable proxy for the in vivo, homeostatic haematopoietic 
environment. This issue is underlined by renewed debate over where lineage bifurcations 
occur, partly arising from the FACS marker and experimental assay used215,217. 
Significantly, the emergence of methods to profile chromatin and gene expression in 
single cells is prompting a complete reconsideration of the classical model of 
haematopoiesis. Compelling data from recent studies suggest that lineage commitment 
in fact starts at a much earlier stage than previously thought: in the phenotypic HSC 
(CD150+CD34-Flt3-KSL) compartment. Traceable barcoded cells from this population 
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have been shown to directly give rise to unipotent progenitors without need for an 
oligopotent intermediate218,219, consistent with earlier reports from the Jacobsen 
laboratory regarding the origin of MEPs215. 
A more recent investigation using index-sorted single cell HSPCs, with parallel 
measurement of immunophenotype and either transcriptome or functional output in the 
same cell, suggested that previously defined compartments such as MPPs and LMPPs 
are not discrete cell types per se, but rather transitory states that exist along a continuum 
of “cloud-HSPCs”, with a higher probability for a single lineage commitment220. These 
results also suggested that in adult haematopoiesis, oligopotent lineage priming is a 
comparatively rare event, with the overwhelming majority of cells being either multipotent 
or already committed to a single lineage. These findings corroborate fate-mapping 
experiments of endogenously-labelled HSCs in mice, where immunophenotypically-
equivalent stem cells were found to have diverse enhancer DNA methylation patterns 
priming distinct lineage outputs221. 
The most recent model of haematopoiesis considers the latest insights into lineage 
commitment as shown in (Figure 1:16). As the power and robustness of single cell 
approaches continue to develop at pace, it is likely that our understanding of 




Figure 1:16 The cloud-HSPC model of haematopoiesis. 
The most recently proposed model of haematopoiesis postulates there are no clearly-defined MPP or 
LMPP compartments. Instead, HSCs have at least some degree of predetermined lineage bias, which 
may be overcome in response to the balance of external cues. Considerable epigenetic heterogeneity 
within the HSC compartment is partly thought to underpin this model. Figure from Velten et al. (2017). 
 
1.4.4 Transcription factors regulate myelopoiesis 
Lineage specification of HSPCs into mature blood cells is associated with a loss of self-
renewal and the parallel acquisition of mature cell characteristics. These outcomes result 
from dramatic shifts in gene expression; the repression of self-renewal genes and 
concurrent activation of differentiation-specific genes. Genes involved in these processes 
exist as nodes in highly-connected networks, where individual genes may antagonise or 
synergise with one another following the tightly-regulated activities of lineage-specific 
TFs. Of all the pathways involved in haematopoiesis, the instrumental roles of TFs are 




Figure 1:17 Defined roles for transcription factors in myelopoiesis. 
The most critical regulators of myelopoiesis are PU.1 and C/EBPα, which function in a highly dose-
dependent manner to regulate lineage commitment from the GMP stage to either granulopoietic (G) or 
monopoietic (M) progenitors. These factors operate in gene regulatory networks with other TFs 
characterised by more restricted expression patterns to promote terminal differentiation. 
 
Atop the regulatory hierarchy in myelopoiesis is the transcription factor RUNX1. RUNX1 
contains a conserved ‘Runt’ DNA-binding domain which recognises 5’-YGYGGTY-3’ 
sequences to regulate the expression of target genes222. RUNX1 is actually a master 
regulator throughout haematopoiesis, required for the emergence of definitive 
haematopoietic cells from haemogenic endothelium during embryogenesis and 
expressed across adult haematopoiesis223–225. In myelopoiesis, RUNX1 promotes the 
expression of key myeloid genes including IL-3, CSF1R and - critically – the myeloid TF 
genes SPI1 and CEBPA226,227. 
The first stage of myelopoiesis occurs when MPPs/LMPPs commit to the myeloid 
pathway via the CMP state instead of entering the lymphoid pathway. Two key features 
of this event are the continued expression of PU.1 (SPI1), a member of the ETS family of 
TFs, and the parallel downregulation of GATA1. The role of PU.1 in myelopoiesis was 
first illustrated using reverse genetic approaches: Spi1-/- mice are embryonic lethal, likely 
due to impaired erythroid differentiation, but also lack myeloid differentiation228. More 
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recent, conditional knockout studies showed that Spi1-/- HSPCs failed to fully 
reconstitute the haematopoietic system, including defects again at the CMP and CLP 
level229. In the normal context, PU.1 activates myeloid-specific target genes230. 
A requirement for downregulation of GATA1 during CMP lineage commitment was 
demonstrated in vitro, where forced expression of GATA1 blocked myelopoiesis and 
expanded the erythroid compartment231,232. The antagonistic relationship between 
GATA1 and PU.1 emerged with co-immunoprecipitation assays showing that GATA1 
binds to the PU.1 DNA binding domain, inhibiting its ability to activate pro-myeloid 
genes233. Further chromatin immunoprecipitation experiments showed that GATA1 and 
GATA2 bind to SPI1 regulatory elements and act sequentially to repress its 
expression234. The assumption that PU.1 and GATA1 expression levels determine 
myeloid lineage commitment was recently disputed. Continuous analyses of protein 
expression levels for these TFs in single cells suggested that early myeloid restriction is 
not determined simply by relative levels of PU.1 and GATA1. Moreover, the role of these 
TFs is to reinforce fate decisions determined by other mechanisms235. 
The next fate restriction occurs at the CMP/GMP transition. After this step, cells are 
capable of generating myeloid lineage cells only. Progression to the GMP compartment 
requires the expression of C/EBPα, a TF containing a common bZIP DNA-binding 
domain shared with all six human C/EBP family members236,237. This requirement was 
demonstrated in Cebpa-/- mice, which lack GMPs and granulocytic lineages, but not 
monocytes238. However, this seems to be a stage-specific requirement, as conditional 
deletion of C/EBPa in mouse GMPs was not found to disrupt in vitro granulopoiesis239. 
Like PU.1, C/EBPα is known to activate myeloid-specific genes, including M-CSF240. 
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Following the GMP stage, myeloid precursors commit to either the monocyte or 
granulocyte lineages. The balance between PU.1 and C/EBPα expression levels is an 
important feature of this process. In GMPs, moderate levels of PU.1 regulate a bipotent 
network of genes involved in both monocyte and granulocyte development. However, 
increasing levels of PU.1 shifts the GMP gene expression programme towards the 
monocyte/macrophage lineage fate, in a regulatory circuit involving IRF8 and the AP-1 
family of TFs241. IRF8 co-operates with PU.1 to activate expression of NF1, a feature of 
differentiating monocytes242. AP-1 proteins, including c-Jun and c-Fos, work alone and 
with other TFs to reinforce the monopoietic expression programme. For example, 
PU.1:c-Jun complexes induce the expression of Interleukin-1β and other 
monocyte/macrophage-restricted genes greater than PU.1 alone243. In contrast, C/EBPα 
and c-Jun can interact via their leucine zipper domains, inhibiting the ability of C/EBPα to 
bind to DNA and activate granulocytic target genes244. Taken as a whole, the effects of 
this subset of TFs re-inforce the monocyte/macrophage lineage commitment. 
Conversely, granulocyte lineage commitment involves the upregulation of CEBPA and 
granulopoietic factors, including the transcriptional repressor GFI1245. GFI1 participates 
in a feed-forward mechanism in granulopoiesis by repressing PU.1-dependent activation 
of monopoietic genes246. The final specification of granulocytes into terminally 
differentiated neutrophils and eosinophils requires the continued activity of GFI1 to 
reinforce repression of immature target genes, and the upregulation of C/EBPε which 
activates more mature target genes247. 
1.5 Acute Myeloid Leukaemia 
Acute Myeloid Leukaemia (AML) is a clonal haematological malignancy characterised by 
the rapid, uncontrolled expansion of abnormal myeloblast cells. If these blasts exceed 
20% of bone marrow cellularity, a clinical diagnosis of AML is made. The incidence of 
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AML is most common in adults, and accounts for 25% of all adult leukaemias. The rapid 
expansion of abnormal blasts interferes with normal haematopoiesis and leads to 
leukaemic cell infiltration of peripheral organs including the spleen, liver, lungs and brain. 
Without treatment, AML generally progresses rapidly, causing bone marrow failure, 
infection and fatality in a matter of weeks248. 
AMLs are classified into several subtypes according to one of two commonly used 
systems; the French-American-British (FAB) system or the World Health Organisation 
(WHO) system. The FAB system classifies AMLs on the basis of cell morphology and the 
level of leukaemic cell differentiation, while the more recently introduced WHO system 
adopts more specific criteria including cytogenetic risk and specific genetic 
aberrations249. 
1.5.1 Mutations co-operate to drive clonal transformation in AML 
AML, like many neoplasms, has long been considered to be a clonal malignancy arising 
from a single cell of origin250. In this model, the accumulation of oncogenic mutations in 
‘founder’ cells permit the expansion of multiple clones which compete with one another 
for finite resources according to Darwinian selection251. Eventually, a clone with 
advantageous mutations emerges as the dominant population detected in bulk AML 
samples at presentation. Gilliland and Griffin first proposed that two classes of mutations 
are necessary for AML to develop in their so-called ‘two-hit’ model252. Mutations were 
categorised into two classes according to their functional consequences, but at least one 
from each class is required for leukaemogenesis. Class I mutations confer enhanced 
proliferation, whereas class II mutations suppress normal myeloid differentiation. 
Consistent with the property of increasing cell proliferation, class I mutations most 
commonly affect mitogenic signalling molecules. A good example of a class I mutation is 
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the internal tandem duplication (ITD) of FLT3. The wild-type FLT3 gene encodes a 
receptor tyrosine kinase which is activated upon extracellular binding of FLT3 ligand 
(FL)253. In normal cells, FLT3 signalling stimulates proliferation of ST-HSCs and, to a 
lesser extent, early B cell progenitors254,255. This process is tightly regulated, not only by 
control of FL secretion, but also via the juxtamembrane (JM) domain of FLT3 itself, which 
mediates auto-repression of signalling after activation by FL. However, FLT3-ITD 
mutations generate in-frame insertions within the JM domain from 3 to over 400 bp in 
size, nullifying this auto-repressive activity256. The result is constitutive ligand-
independent activation of FLT3-ITD signalling and ectopic activation of wild-type FLT3 in 
trans257. The ultimate consequence of this is sustained proliferative signalling, driving the 
survival and growth of affected cells252. 
Class II mutations slow or block normal myeloid differentiation, and often directly target 
TF genes. The mechanisms through which these mutations act include the inappropriate 
re-targeting of mutated TFs to oncogenic loci, or by disrupting the ability of mutated TFs 
to induce the expression of differentiation-specific genes that would normally be 
activated by the wild-type allele. The two best examples of class II mutations in AML 
affect the master regulator TF genes RUNX1 and CEBPA, and are explored in detail in 
1.5.4 and 1.5.5. 
The two-hit model was informative in developing an initial understanding of acute 
leukaemogenesis, but was also too simplistic to categorise certain other mutations which 
did not exert strict binary effects on either proliferation or differentiation. However, these 
other mutations shared a common effect of deregulating the epigenome to aberrantly 
maintain self-renewal. Thus, a third class of AML mutation was devised for epigenetic 
regulators258. Class III mutations act via diverse mechanisms, but commonly involve 
deregulation of DNA methylation or histone modification processes, leading to ectopic 
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repression of tumour suppressors and/or activation of oncogenes. Such mutations may 
overtly affect such regulators – as in DNMT3A mutations which directly impair DNA 
methylation - or they may deregulate epigenetic processes via indirect mechanisms. The 
best examples of indirect class III mutations are those that affect the isocitrate 
dehydrogenase enzyme genes IDH1 and IDH2, occurring in up to 20% of de novo 
AMLs259. These enzymes are essential for mitochondrial oxidative phosphorylation, 
catalysing the decarboxylation of the TCA cycle intermediate isocitrate into α-
Ketoglutarate. However, mutation to either of these genes occurs in up to 20% of de 
novo AMLs and causes dominant negative inhibition of wild-type IDH1 and IDH2, and 
accumulation of the oncometabolite D-2-hydroxyglutarate (2HG). 2HG accumulation 
leads to hypermethylation of 5mC across the genome and the parallel inhibition of TET2-
mediated hydroxymethylation, resulting in the global repression of myeloid-specific 
genes, particularly those driven by CpG promoters. 
The most common examples of the three mutation classes are summarised in   
Table 1:2.  
Table 1:2 Commonly occurring mutations in AML and their consequences. 
Mutations in AML commonly alter the function of signalling molecules, transcription factors or 
epigenetic regulators. However, many frequently occurring mutations do not fall strictly into one 
category; NPM1 and MLL mutations are notable examples. The maximum reported clinical 
frequencies for each mutation in de novo AMLs are indicated in brackets251,258,260. 
Class I mutations 
Signal transduction 
Proliferative advantage 
Class II mutations 
Transcription factors 
Differentiation block 
Class III mutations 
Epigenetic regulators 
Diverse Consequences 
(30%) MLL rearrangement MLL rearrangement MLL rearrangement 
(21%) NPM1 NPM1 NPM1 
(22%) RUNX1 point mutation RUNX1 point mutation (23%)TET2 
(25%) FLT3-ITD (20%) C/EBPα pt. mutation (33%) IDH 
(4%) FLT3-TKD (5%) CBFβ/MYH11 (22%) DNMT3A 
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(10%) NRAS (10%) RUNX1/ETO (5%) ASXL2 
(2%) KIT  (N.D.%) Cohesin family 
1.5.2 Clonal evolution of AML most commonly begins with pre-leukaemic 
mutations in the HSC compartment 
Despite a more detailed knowledge of the types of genetic abnormalities present in AML, 
the question of which cell population sustained the first pre-leukaemic mutation remained 
unresolved. Even prior to the identification of class III mutations, it was presumed that 
the sheer numbers of leukaemic blasts produced in AML must require self-renewal, a 
property lost beyond the ST-HSC compartment in normal haematopoiesis209. Thus, it 
was suggested that the first mutational event in AML occurred in HSCs. At the time, this 
proposal seemed inconsistent with existing evidence that HSCs were protected against 
mutation, but more recently it has been demonstrated that quiescent HSCs do 
accumulate potentially deleterious DNA lesions during aging that could promote the initial 
propagation of pre-leukaemic clones261. 
The first compelling evidence that leukaemogenic transformation begins in the HSCs 
emerged from studies by the Dick laboratory, which demonstrated that leukaemia 
initiating cells from human AML patients bore the same immunophenotype of normal 
blood-reconstituting cells. These cells, termed SCID leukaemia initiating cells (SL-ICs) 
for their ability to engraft leukaemias in SCID xenograft mice, featured a common 
CD34+CD38- primitive normal cell immunophenotype, regardless of the subtype of AML 
from which they were derived. Critically, serially transplanted SL-ICs differentiated in vivo 
to leukaemic blasts, suggesting that the development of AML is a hierarchical process 
not unlike normal haematopoiesis262. 
A more recent single cell analysis of de novo AMLs revealed that genetically-distinct 
leukaemic sub-clones featured common ‘founder’ mutations already present in pre-
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leukaemic HSCs263. These founder mutations commonly affected epigenetic regulators, 
abnormally maintaining self-renewal beyond the HSC compartment. Further mutations 
required for complete transformation were acquired in a stepwise manner, giving rise to a 
heterogeneous landscape of individual leukaemic clones sustained by diverse 
abnormalities.  
The clonal evolution model of AML development has important implications for therapy. 
Firstly, it explains why many AML patients may initially respond to chemotherapy but 
then develop resistant disease. Primary treatment may effectively target the dominant 
population of therapy-sensitive leukaemic clones, but in the process imposes a selective 
pressure on residual clones that can promote further transformation. Relapse can be 
driven either by pre-existing therapy-resistant clones emerging as the new dominant 
clone, or by further mutation of therapy-sensitive cells to acquire resistance264. These 
two mechanisms of relapse were both confirmed to occur in a very recent study 
comparing paired presentation/relapse AML samples265. Above all, the clonal evolution 
model highlights a need to better understand the underlying clonal composition of 
leukaemias at presentation, as bulk analyses may not be sensitive enough to detect 
minor sub-clones that act as a reservoir for relapse following primary treatment. 
Although it is now thought that most de novo AMLs form from pre-leukaemic clones 
derived from the HSC compartment, exceptions do exist. Perhaps the best example is 
Acute Promyelocytic Leukaemia (APL), a subtype of AML driven by the PML-RARA 
fusion gene. Despite PML-RARA being the primary leukaemia-initiating mutation in APL, 
in one study the fusion transcript was detected only in the more mature CD34+CD38+ 
compartment, suggesting that these cells became transformed at a much later stage in 
myeloid differentiation than other subtypes of AML266. There is still evidence that pre-
leukaemic APL cells evolve clonally like other AMLs, except that the ‘founder clone’ is 
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already at a more differentiated state than an HSC. This exceptional characteristic of 
APL likely accounts for the unusually favourable prognosis compared to other AMLs267.  
Whilst a mature cell of origin in APL represents a comparatively rare event in acute 
myeloid leukaemias, other haematological malignancies commonly arise from more 
differentiated founder cells. For example, perhaps half of chronic lymphocytic leukaemia 
(CLL) cases are thought to originate from mature B cell precursors which have already 
undergone somatic hypermutation268. Furthermore, cases of both acute B and T 
lymphoblastic leukaemias have been reported to arise from cells that have already left 
the HSC compartment269,270. 
1.5.3 The development of AML involves deregulation of critical haematopoietic 
transcription factors 
As described in 1.4.4, myelopoiesis is tightly regulated by the stage-specific expression 
and activity of TFs, underlining their importance in normal myeloid development. A 
common feature of cellular transformation in AML is the disruption of these and other 
TFs, resulting in the ectopic activation of proliferation and self-renewal genes, and the 
repression of terminal myeloid differentiation genes. Deregulation of TF function can 
either result directly from mutation in the case of class II lesions which affect TF genes 
themselves, or it can be an indirect consequence of signalling or epigenetic regulator 
mutations. 
Although class I mutations affect signalling proteins, the downstream targets of 
deregulated signalling pathways in AML are often themselves TFs. An excellent example 
of this is the found in AMLs with FLT3 ITD mutations. Chronic FLT3-ITD signalling leads 
to hyperactivation of downstream signalling pathways, predominantly MAP kinase, 
causing inappropriate activation of TFs including AP-1 proteins and RUNX1 and the 
induction of leukaemogenic target genes271.  
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Class III mutations also indirectly affect TF function. For example, genome-wide DNA 
hypermethylation in AMLs with IDH mutations disrupts the binding of GATA factors and 
EVI1 to target myeloid-specific genes, suppressing normal myeloid differentiation259. In 
the context of glioma, ectopic genome methylation resulting from IDH mutations 
abrogates the recruitment of CTCF to critical insulator sequences and causes to the 
ectopic activation of PDGFRA194 (Figure 1:18). Although such specific examples of 
insulator dysfunction have not been described in the context of AML, it is almost certain 
that these are recurring phenomena that occur in leukaemic transformation. 
 
Figure 1:18 Disruption of insulators can promote the ectopic activation of oncogenes. 
Processes which perturb normal insulator function, including hypermethylation/mutation of CTCF 
binding sites, can ablate insulated neighbourhoods partitioning silent oncogenes from the nearby 
active genes, leading to ectopic expression. Adapted from Hnisz et al. (2016).  
 
1.5.4 Disrupted RUNX1 activity is a recurrent feature in leukaemogenesis 
Given the critical roles for RUNX1 in myelopoiesis described in 1.4.4, it is unsurprising 
that RUNX1 is among the most commonly mutated TFs in AML, occurring in ~10% of all 
cases272,273. Generally speaking, mutations directly affecting RUNX1 function are class II, 
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presenting a differentiation block274. However, deregulation of wild-type RUNX1 function 
also frequently results from class I and class III mutations258,271. 
The most common cytogenetic abnormalities in AML affect RUNX1 or its essential co-
factor CBFB, generating a range of chimeric proteins including RUNX1-ETO, RUNX1-
EVI1 and CBFß-SMMHC (Figure 1:19). The t(8;21) chromosomal translocation creates 
RUNX1-ETO, fusing the Runt domain of RUNX1 to the near-complete ETO 
polypeptide275, with several consequences that block myeloid differentiation. Firstly, the 
repressive functions of wild-type ETO are combined with the DNA-binding activity of 
RUNX1, resulting in the targeted recruitment of the NCOR1/HDAC co-repressor complex 
to myeloid genes usually activated by wild-type RUNX1, including CEBPA276–278. 
Secondly, recent genome-wide surveys of RUNX1-ETO binding in AML demonstrated 
that the RUNX1-ETO outcompetes wild-type RUNX1 activity at pre-existing open 
chromatin sites279. An important contributor to this competitive binding is the ability of 
RUNX1-ETO to multimerise at target loci, stabilising a higher order complex containing 
the fusion oncoprotein280. RUNX1-ETO also directly inhibits the myeloid regulators PU.1 
and C/EBPα via protein-protein interactions, suppressing the activation of differentiation-
specific target genes281. The profound effects of RUNX1-ETO in AML were demonstrated 
to be reversible following targeted knockdown of the fusion protein, resulting in 
widespread epigenetic reprogramming, loss of self-renewal and induction of myeloid 




Figure 1:19 RUNX1 and its binding partner, CBFβ, are frequently rearranged in AML. 
Over a quarter of adult AML cases are characterised by translocations that disrupt the function of 
RUNX1 through diverse mechanisms. Figure from Speck and Gilliland (2002). 
Another genomic rearrangement affecting RUNX1 in AML is the t(3;21) translocation, 
fusing the Runt domain of RUNX1 to the entire EVI1 protein to generate the RUNX1-
EVI1 oncoprotein283. EVI1 contains two zinc-finger DNA-binding domains and a 
conserved SET domain with histone methyltransferase activity284. Knockout experiments 
have demonstrated that wild-type Evi1 is an essential positive regulator of self-renewal in 
HSCs285. Similar to RUNX1-ETO, the main consequence of RUNX1-EVI1 is a block in 
myeloid differentiation via downregulation of myeloid genes including CTSG, CSF1R and 
CEBPA. This is accompanied by the parallel upregulation of self-renewal genes including 
HOXA9 and MEIS1 via ectopic recruitment of GATA2 by the EVI1 portion of the 
oncoprotein.   
Other chromosomal abnormalities disrupting normal RUNX1 activity include the 
chromosome 16 inversion, which fuses the RUNX1-binding domain of CBFß to the 
coiled-coil domain of SMMHC, generating the CBFB-MYH11 fusion gene. The 
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oncoprotein product exerts a dominant negative function over wild-type CBFß by 
disrupting its ability to associate with RUNX1 and stabilise its DNA-binding activity286,287. 
Critically, the reliance of AML cells on these diverse oncoproteins make them attractive 
candidates for targeted drug therapies. Structure-based design studies led by the 
Bushweller group aim to address these opportunities to improve patient outcomes in the 
clinic288.  
In addition to being deregulated through chromosomal rearrangements, hetero- and 
homozygous point mutations to RUNX1 can also lead to the development of AML 
through similar downstream effects289. Finally, roles for wild-type RUNX1 in 
leukaemogenesis have also been documented. For example, in AML patients with FLT3-
ITD signalling mutations, constitutive MAP kinase activity leads to chronic activation of 
AP-1 proteins and their target genes, including the RUNX1 locus. Genome-wide 
analyses of accessible chromatin and RUNX1 binding revealed that DHSs specifically 
activated by FLT3-ITD mutations were also occupied by RUNX1 and featured 
enrichment of AP-1 motifs, strongly suggesting AP-1 and RUNX1 functionally co-operate 
in response to FLT3-ITD signalling to promote leukaemogenesis271. Critically, this study 
also identified FOXC1 as a downstream target of RUNX1 in FLT3-ITD AML patients, a 
gene which will be explored further in 1.5.6. 
1.5.5 C/EBPα dysfunction also occurs frequently in the development of 
leukaemia 
In addition to the indirect consequences of RUNX1 affecting C/EBPα function, the 
CEBPA gene is also mutated in ~10% of AMLs290. The most common CEBPA mutations 
with deleterious effects occur in the N-terminal region, generating frameshifts that 
abrogate the full-length 42 kDa (p42) isoform but still permit translation of a shorter 30 
kDa (p30) isoform initiated downstream291.  
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Expression of the p30 isoform of C/EBPα alone is sufficient to form GMPs in mice, but 
p42 is important to restrict excessive proliferation of the myeloid progenitor compartment. 
This function of p42 is underlined in mouse knockout studies, where targeted deletion of 
the p42 isoform alone gave rise to GMPs with aberrant self-renewal and subsequently a 
fully penetrant AML292. In AML, the p30 isoform alone exerts a dominant negative 
function over wild-type C/EBPα, causing downregulation of normal myeloid target 
genes292,293. A recent study also found the p30 isoform antagonises wild-type C/EBPα to 
de-repress the oncogenic lncRNA UCA1, droving proliferation of AML cells by 
downregulating the cell cycle inhibitor CDKN1B 294. 
1.5.6 An emerging role for FoxC1 in AML 
FoxC1 belongs to the Forkhead family of TFs introduced in 1.3.6, and features the 
winged-helix DNA binding domain common to all family members122. In vitro studies have 
demonstrated that FoxC1 preferentially recognises the 5’-TGTTTAR-3’ variant of the 
Forkhead consensus sequence295.  
In embryogenesis, expression of FoxC1 or its closely-related paralogue FoxC2 at the 
correct level is essential for normal development of the ocular, skeletal, renal and 
cardiovascular systems. These roles are demonstrated in Foxc1 and Foxc2-null mice, 
which are embryonic lethal, or conditional knockout animals which die at birth or soon 
after with skeletal, cardiovascular, renal and eye defects, and hydrocephalus296. 
Consistent with observations in mice, humans with heterozygous FOXC1 mutation or 
deletion have haploinsufficiency phenotypes including Axenfeld-Rieger syndrome, a 
heritable ocular disorder, and congenital hydrocephalus297,298. In adult cells, FoxC1 
expression is predominantly restricted to mesenchymal lineages including the bone and 
eyes, but also hair follicle stem cells, where it promotes quiescence299.  
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Interestingly, Foxc1 expression is also necessary for correct formation of the endosteal 
HSC niche in mice, but is notably not significantly expressed in any normal 
haematopoietic cell type300,301. Inducible deletion of FoxC1 in both embryos and adults 
led to a depletion of HSPCs, strongly suggesting that its expression is necessary for 
maintenance of the HSC niche. Critically, FoxC1 is not normally expressed in any 
haematopoietic lineage in both mice and humans. 
FoxC1 is frequently overexpressed in many solid malignancies, including those of the 
breast, liver, pancreas and skin302–305. In all of these cases, higher FOXC1 mRNA 
expression correlates with an unfavourable prognosis and is associated with the 
epithelial-to-mesenchymal transition306. Critically, aberrant expression of FOXC1 was 
more recently identified to be a feature of AML development. In one study, accessible 
chromatin and transcriptomic profiling of highly-purified AML patient blast cells found that 
FOXC1 was specifically upregulated in patients with FLT3-ITD signalling mutations271. In 
parallel analyses, the authors of this study also identified a subset of DHSs upregulated 
in a FLT3-ITD-dependent manner and associated with FLT3-ITD-specific upregulated 
genes that were specifically enriched for occupied FOX:E-box (FOX:E) composite sites, 
increasing confidence that FoxC1 may play a direct role in the activation of leukaemia-
specific genes. 
At the same time, work from the Somervaille laboratory found that inappropriate FOXC1 
expression occurred more widely in AML patients with other mutations300. Based on 
analyses of large AML patient cohort RNA expression data, FOXC1 upregulation was 
associated not just with FLT3-ITD mutations, but also NPM1 signalling mutations and 
t(6;9) chromosomal translocations. Significantly, FOXC1 expression in human AML 
strongly correlated with high HOX gene expression, in particular that of HOXA9.  
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1.5.7 FoxC1 enhances the clonogenic potential of human AML cell lines 
The functional significance of FOXC1 overexpression in AML has been validated by 
experiments in cell lines. shRNA-mediated depletion of FOXC1 expression in various 
AML cell lines caused a reduction in clonogenic potential resulting from G1 cell cycle 
arrest and induction of morphological differentiation. Furthermore, forced differentiation 
of HL-60 cells into either monocytes or granulocytes was accompanied by a dramatic 
reduction in FoxC1 protein300. 
 
Figure 1:20 Phenotypic interrogation of FOXC1 in the context of AML. 
A-B: shRNA mediated knockdown of FOXC1 in THP-1 AML cells depletes both mRNA and protein 
expression. In the Western blot analyses of protein expression shown in B, β-actin (ACTB) is used as 
a loading control. 
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C: Depletion of FOXC1 was associated with a significant reduction in colony forming frequency of 
THP-1 cells. 
D: Loss of the Leukaemia Stem Cell (LSC) marker CD117 surface expression following depletion of 
FOXC1 was associated with a parallel upregulation of the myeloid marker CD11b. 
E-F: Forced expression of FOXC1 in mouse BM HSPCs induced a [transient] myeloid differentiation 
block. 
From Somerville et al. (2015) 
 
1.5.8 FoxC1 collaborates with HoxA9 to drive leukaemogenesis in mice 
In mice, forced expression of FOXC1 in normal BM HSPCs induced a transient myeloid 
differentiation block and enhanced proliferation, but was not sufficient to induce 
leukaemia300. Furthermore, it has previously been reported that HoxA9 overexpression in 
mouse HSPCs alone generates a myeloproliferative disorder, but is insufficient for full 
leukaemic transformation307. However, co-expression of FOXC1 with HoxA9 in BM 
HSPCs was sufficient to generate aggressive serially-transplantable leukaemias in sub-
lethally irradiated recipient mice (Figure 1:21).  
 
Figure 1:21 Overview of the Somervaille Hoxa9+FoxC1-dependent AML mouse model. 
This schematic illustrates the key aspects of the syngeneic transplantation model used to gain 
extensive phenotypic insights into the consequences of forced Hoxa9 and FOXC1 expression in 




Leukaemias in these mice were characterised by a monocyte differentiation block and 
extensive leukaemic blast cell infiltration of the bone marrow, liver and spleens. 
Furthermore, HoxA9/FOXC1 AML cells were determined to be more enriched for actively 
cycling cells in the S/G2/M phases of mitosis compared to leukaemic cells from the well-
defined Hoxa9/Meis1 mouse model.  
The authors also determined that Klf4, a TF associated with terminal myeloid 
differentiation, was downregulated in Hoxa9/FOXC1 mice, and showed in human AML 
cells that knockdown of FOXC1 led to restoration of KLF4 expression. Conversely, 
forced expression of KLF4 in Hoxa9/FOXC1 AML cells significantly decreased their 
colony-forming capacity, suggesting downregulation of Klf4 to be an important event in 
leukaemic transformation. However, despite these analyses revealing Klf4 and general 
repression of monocyte/macrophage genes to be a consequence of Hoxa9 and FOXC1 
over-expression, the direct targets of FOXC1 in this context remained unknown. 
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1.6 Aims and Objectives 
Previous studies of the Hoxa9+FoxC1-dependent mouse AML model clearly 
demonstrated a robust phenotypic contribution made by FoxC1 during leukaemogenesis. 
However, these studies did not extend to a full characterisation of the gene network 
activated in response to Hoxa9+FoxC1. Therefore, a primary aim of this work was to 
perform an integrative analysis of accessible chromatin, genomic occupancy and gene 
expression in Hoxa9+FoxC1 cells in order to gain an understanding of potential 
pathways and target genes that are modulated in a FoxC1-dependent manner. These 
aims are explored in the first results chapter. 
A second aim of this work was to identify suitable cell models in which to study the 
consequences of FoxC1 expression in human AMLs. To address this, we performed a 
detailed analysis of FUJIOKA AML cells, which were found to express comparatively 
high levels of FOXC1. This is the focus of the second results chapter. 
Finally, although previous studies in this laboratory suggested that FOXC1 may 
contribute to the activation of FOX:E composite sites within DHSs in primary FLT3-ITD 
AMLs,  these putative cis-regulatory elements had not been functionally interrogated. 
Thus, the principal aim of the work presented in the third results chapter was to use cell 
line models to further explore the potential significance of FOX:E composite DHSs in the 




Chapter 2: Materials and Methods 
 
Table 2:1 Specialist Lab Equipment 
Product Manufacturer Software (if applicable) 
ABI 7500 real-time PCR 
System Applied Biosystems StepOne™ Plus 
Bioruptor™  Diagenode  
CyAn™ ADP flow cytometer Beckman Coulter Summit v4.3 
Dounce homogeniser (15 ml) Sigma Aldrich  
DynaMag™-2 magnetic rack Thermo Fisher Scientific  
FACSAria™ II BD Biosciences  
GD 2000 Gel Drier Hoefer   
Gel Doc XR+ Bio-Rad Image Lab™  
Gene Pulser Xcell Bio-Rad  
GloMax® Multi+ Microplate 
Multimode Reader Promega  
HiSeq 2500 Illumina  




Infors HT  
NanoDrop™ 2000 Thermo Fisher Scientific NanoDrop™ 2000 
NextSeq 500 Illumina  
Optima™ MAX-XP Benchtop 
Ultracentrifuge Beckman Coulter  
Orbital Shaking Incubator 
SSL1 Stuart Lab  
Personal Molecular Imager Bio-Rad Quantity One®  
Prime Gradient Thermocycler Techne  
Storage Phosphor Screen Kodak  
T3000 96-well Thermocycler Biometra  
ThermoMixer® C Eppendorf  
TLN-100 Near-Vertical 
Ultracentrifuge Rotor Beckman Coulter  
Trans-blot Turbo Transfer 





Table 2:2 Reagents and Suppliers 
Product Manufacturer 
2100 High Sensitivity DNA Kit Agilent 
Acetic Acid VWR 
Acrylamide/Bisacrylamide 37.5:1, 40% Bio-Rad 
Adenoside Triphosphate (ATP) New England Biolabs 
Agar  Thermo Fisher Scientific 
Agarose Thermo Fisher Scientific 
Amersham ECL Western Blotting Detection 
Reagent Kit GE Healthcare 
Ammonium Persulphate Sigma Aldrich 
Ampicillin Thermo Fisher Scientific 
AMPure® XP beads Beckman Coulter 
Aprotinin Sigma Aldrich 
BamHI New England Biolabs 
BbsI New England Biolabs 
BglII New England Biolabs 
Bradford Reagent, Ready to Use Bio-Rad 
Bromophenol blue Sigma Aldrich 
BSA (Bovine Serum Albumin) New England Biolabs 
Buffer 2.1 New England Biolabs 
Caesium Chloride (CsCl) Sigma Aldrich 
Calcium Chloride Sigma Aldrich 
Calcium ionophore, A23187 (CaI) Sigma Aldrich 
Calf Intestinal Phosphatase  New England Biolabs 
Carbenicillin Selleck Chemicals 
CD117 MicroBead kit Miltenyi Biotec 
CD34 MicroBead kit Miltenyi Biotec 
Centricon® Plus-70 (100kDA NMWL) Millipore 
Cetyl Trimethylammonium Bromide (CTAB) Sigma Aldrich 
Chloroform VWR 
Citric Acid Sigma Aldrich 
cOmplete™ Protease Inhibitor Cocktail Roche 
Cutsmart™Buffer New England Biolabs 
Deoxyadenoside triphosphate (dATP) New England Biolabs 
Deoxycytosine triphosphate (dCTP) New England Biolabs 
Deoxyguanosine triphosphate (dGTP)  New England Biolabs 
Deoxynucleotide (dNTP) solution mix New England Biolabs 
Deoxythymidine triphosphate (dTTP) New England Biolabs 
Disodium hydrogen phosphate (Na2HPO4) Sigma Aldrich 
Disuccinimidyl glutarate (DSG) Sigma Aldrich 
Dithiothreitol (DTT) Sigma Aldrich 
DNase I  Worthington 
Dual-Luciferase Repoter Assay System Kit Promega 
Dynabeads™-Protein G Thermo Fisher Scientific 




Ethidium Bromide Thermo Fisher Scientific 
Ethylene-bis(oxyethylenenitrilo)tetraacetic acid 
(EGTA) Sigma Aldrich 
Ethylenedinitrilotetraacetic acid (EDTA) Sigma Aldrich 
Foetal Calf Serum Thermo Fisher Scientific 
Formaldehyde, 16% Thermo Fisher Scientific 
Glutamine Thermo Fisher Scientific 
Glycerol Sigma Aldrich 
Glycine Sigma Aldrich 
HEPES Thermo Fisher Scientific 
HyClone™ Ultra-pure water Thermo Fisher Scientific 
Hydrochloric Acid VWR 
Hyper Prep Kit (Illumina) KAPA Biosystems 
Illumina Library Quantification Kit KAPA Biosystems 
Illustra Probequant G-50 Spin Columns GE Healthcare 
IMDM Thermo Fisher Scientific 
Isopropanol VWR 
JM109 (E. coli) Promega 
LB Broth Base Sigma Aldrich 
Leupeptin Sigma Aldrich 
Lithium Chloride Sigma Aldrich 
Lymphoprep™ STEMCELL Technologies 
MACS® buffer Miltenyi Biotec 
Magnesium Chloride Sigma Aldrich 
Marvel Dried Skimmed Milk Powder Premier Foods 
MicroPlex Library Preparation™ Kit v2 Diagenode 
MinElute® Gel Extraction Kit Qiagen 
MinElute® PCR Purification Kit Qiagen 
MiniMACS™column Miltenyi Biotec 
Mini-PROTEAN® TGX Stain-Free Precast Gel, 
4-20% Bio-Rad 
n-Butanol VWR 
NP-40 Sigma Aldrich 
NucleoBond®Xtra Midi EF Macherey Nagel 
NucleoSpin® RNA kit Macherey Nagel 
OptiMEM™ Thermo Fisher Scientific 
Penicillin/Streptomycin, 1% Thermo Fisher Scientific 
Phenol VWR 
Phenylmethylsulfonyl fluoride (PMSF) Sigma Aldrich 
Phorbol 12-myristate 13-acetate (PMA) Sigma Aldrich 
Phosphate buffered saline, sterile (PBS) Thermo Fisher Scientific 
PhosStop™complete phosphatase inhibitor Roche 
Phusion® High-fidelity PCR master mix New England Biolabs 
Poly(deoxyinosinic-deoxycytidyic) acid (polyIC) Sigma Aldrich 
Polynucleotide Kinase (PNK) New England Biolabs 
Polynucleotide Kinase Buffer New England Biolabs 
Potassium Chloride Sigma Aldrich 
Proteinase K Sigma Aldrich 
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Purple Gel Loading Buffer, 6X New England Biolabs 
QIAprep® spin miniprep kit Qiagen 
QIAquick® gel extraction kit Qiagen 
Rainbow Molecular Weight Marker (High-
Range) GE Healthcare 
RNase A Worthington 
RPMI+GlutaMAX™ Thermo Fisher Scientific 
SOC medium Thermo Fisher Scientific 
Sodium Acetate (NaAc) Sigma Aldrich 
Sodium bicarbonate (NaHCO3) Sigma Aldrich 
Sodium Chloride (NaCl) Sigma Aldrich 
Sodium deoxycholate Sigma Aldrich 
Sodium dodecyl sulfate (SDS) Sigma Aldrich 
Sodium Fluoride (NaF) Sigma Aldrich 




Spectra/Por MWCO 3500 dialysis tubing Spectrum Labs 
Sucrose Sigma Aldrich 
SuperScript II Reverse Transcriptase Kit Thermo Fisher Scientific 
SYBR® Green PCR master mix Thermo Fisher Scientific 
T4 DNA ligase New England Biolabs 
T4 DNA ligase buffer New England Biolabs 
T4 DNA Polymerase New England Biolabs 
TE, 1X Thermo Fisher Scientific 
Terrific Broth Base Sigma Aldrich 
Tetramethylethylenediamine (TEMED) Sigma Aldrich 
Trans-Blot® Turbo™ Mini Nitrocellulose 
Transfer Packs Bio-Rad 
TransIT®-293 Mirius 
Tris base Sigma Aldrich 
Triton™ X-100 Sigma Aldrich 
TRIzol® Thermo Fisher Scientific 
TruSeq RNA sample preparation kit, v2 Illumina 
Trypan Blue Solution, 0.4% Thermo Fisher Scientific 
TWEEN® 20 Sigma Aldrich 
Whatman® 3MM blotting paper Sigma Aldrich 
XhoI New England Biolabs 










Table 2:3 Buffer compositions 
Buffer Composition 
SDS Running Buffer (1X) 
25 mM Tris-HCl pH 8.0 
192 mM Glycine 
0.1 % (v/v) SDS 
TAE (1X) 40 mM Tris-Acetate 1 mM EDTA 
DNase I Nuclei Digestion Buffer (2X) 
120 mM KCl 
30 mM NaCl 
10 mM MgCl2 
20 mM Tris-HCl pH 7.4 
Western Blot Sample Loading Buffer 
(2X) 
0.1 M Tris-HCl pH 8.0 
0.2 M DTT 
4 % (v/v) SDS 
0.3 μM Bromophenol blue 
20 % (v/v) Glycerol 
EMSA Binding Buffer (4X) 
20 % (v/v) Glycerol 
60 mM HEPES 
20 mM KCl 
45 mM NaCl 
20 μg/ml Aprotinin 
20 μg/ml Leupeptin 
Polyacrylamide Gel (4%) for EMSA 
25 mM Tris base 
0.5 mM EDTA 
25 mM Boric Acid 
4 % (v/v) Acrylamide/bisacrylamide (37.5:1) 
0.06% (v/v) Ammonium Persulphate 
0.3% (v/v) TEMED 
TBE Buffer (5X) 
250 mM Tris base 
5 mM EDTA 
250 mM Boric Acid 
EMSA phosphatase inhibitor cocktail 
(8X) 
8 mM DTT 
0.8 mM PMSF 
80 mM NaF 
80 mM Na2 β-glycerophosphate 
8 mM Na3VO4 
Agarose gel for electrophoresis 
x % (w/v) Agarose 
0.5 μg/μl Ethidium Bromide 
40 mM Tris-Acetate 
1 mM EDTA 
ChIP Buffer A 
10 mM HEPES pH 8.0 
10 mM EDTA pH 8.0 
0.5 mM EGTA pH 8.0 
0.25 % (v/v) Triton™X-100 
0.1 mM PMSF 
1:100 (v/v) cOmplete™ Protease Inhibitor Cocktail 
ChIP Buffer B 10 mM HEPES pH 8.0 0.2 M NaCl 
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1 mM EDTA pH 8.0 
0.5 mM EGTA pH 8.0 
0.01 % Triton™X-100 
0.1 mM PMSF 
1:100 (v/v) cOmplete™ Protease Inhibitor Cocktail 
ChIP Elution Buffer 100 mM NaHCO3 1 % (v/v) SDS 
ChIP IP Buffer 1 
25 mM Tris-HCl pH 8.0 
150 mM NaCl 
2 mM EDTA pH 8.0 
0.25 % (v/v) SDS 
0.1 mM PMSF 
1:100 (v/v) cOmplete™ Protease Inhibitor Cocktail 
ChIP IP Buffer 2 
25 mM Tris-HCl pH 8.0 
150 mM NaCl 
2 mM EDTA pH 8.0 
7.5 % (v/v) Glycerol 
0.1 mM PMSF 
1:100 (v/v) cOmplete™ Protease Inhibitor Cocktail 
ChIP LiCl Buffer 
10 mM Tris-HCl pH 8.0 
250 mM LiCl 
1 mM EDTA pH 8.0 
0.5 % (v/v) NP-40 
0.5 % (v/v) Na deoxycholate 
ChIP TE/NaCl Buffer 
10 mM Tris-HCl pH 8.0 
50 mM NaCl 
1 mM EDTA pH 8.0 
ChIP Wash Buffer 1 
20 mM Tris-HCl pH 8.0 
150 mM NaCl 
2 mM EDTA pH 8.0 
1 % (v/v) Triton™X-100 
0.1 % (v/v) SDS 
ChIP Wash Buffer 2 
20 mM Tris-HCl pH 8.0 
0.5 M NaCl 
2 mM EDTA pH 8.0 
1 % Triton X-100 
0.1 % (v/v) SDS 
Citrate Phosphate Buffer 50 mM Na2HPO4 pH to 5.6 with Citric Acid 
DNase I cell lysis buffer 
0.3 M NaAc 
10 mM EDTA pH 7.4 
1 % (v/v) SDS 
DNase I resuspension buffer 
60 mM KCl 
15 mM NaCl 
5 mM MgCl2 
10 mM Tris-HCl pH 7.4 
0.3 M Sucrose 
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EMSA buffer A 
10 mM HEPES 
10 mM KCl 
1.5 mM MgCl2 
0.5 mM DTT 
5 μg/ml Aprotinin 
5 μg/ml Leupeptin 
0.5 mM PMSF 
1X PhosStop 
EMSA buffer C 
20 mM HEPES 
0.42 M NaCl 
1.5 mM MgCl2 
0.2 mM EDTA 
0.5 mM DTT 
5 μg/ml Aprotinin 
5 μg/ml Leupeptin 
0.5 mM PMSF 
10 mM NaF 
10 mM Na2 β-glycerophosphate 
1 mM Na3VO4 
EMSA buffer D 
20 mM HEPES pH 7.9 
100 mM KCl 
0.5 mM DTT 
20% (v/v) Glycerol 
0.5 mM PMSF 
1 μg/ml Leupeptin 
10 mM NaF 
10 mM Na2 β-glycerophosphate 
1 mM Na3VO4 
Maxi-prep Alkaline Lysis Buffer 1 % (v/v) SDS 200 mM NaOH 
Maxi-prep CsCl/TE Buffer 50% (w/v) CsCl 0.5 X TE 
Maxi-prep Neutralisation Buffer 3 M KAc 2 M Acetic Acid 
Maxi-prep Resuspension Buffer 50 mM Tris-HCl pH 8.0 10 mM EDTA 
Western Blot Blocking Buffer 
5% (w/v) Marvel Milk Powder 
10 mM Tris-HCl pH 7.5 
15 mM NaCl 
Western Blot Washing Buffer 
20 mM Tris-HCl pH 8.0 
150 mM NaCl 
0.1% TWEEN® 20 
LB/amp 2 % (w/v) LB Broth base 
100 μg/μl Ampicillin 
TAE/EtBr 
40 mM Tris-Acetate 
1 mM EDTA  
0.5 μg/ml Ethidium Bromide 
LB agar/amp 
2 % (w/v) LB Broth base 
1.5 % (w/v) Agar 




4.76% (w/v) Terrific Broth base 
0.8 % (v/v) Glycerol 




Table 2:4 Antibodies 
Antibody Manufacturer Catalogue Experimental Conditions 
Flow Cytometry 
Mouse anti-mouse CD45.1 
(e450-conjugated) 
Thermo Fisher 
Scientific 47-0453-82 1:100 
Mouse anti-mouse CD45.2 
(e780-conjugated) 
Thermo Fisher 
Scientific 47-0454-82 1:100 
Mouse anti-mouse CD11b 
(PE-Cy7-conjugated) 
Thermo Fisher 
Scientific 25-0112-82 1:100 
Mouse anti-mouse Gr1 
(FITC-conjugated) 
Thermo Fisher 
Scientific 11-5931-82 1:100 
Mouse anti-mouse B220 
(APC-conjugated) 
Thermo Fisher 
Scientific 17-0452-82 1:100 
Mouse anti-mouse CD43 
(PE-conjugated) 
Thermo Fisher 
Scientific 12-0431-82 1:100 
Mouse anti-mouse CD4 
(PE-Cy5-conjugated) 
Thermo Fisher 
Scientific 15-0042-82 1:100 
Mouse anti-mouse CD8 
(APC-conjugated 
Thermo Fisher 
Scientific 17-0081-82 1:100 
Mouse anti-human CD34 
(FITC-conjugated) BioLegend 343504 1:100 
Mouse anti-human CD117 
(PE-conjugated) BioLegend 313204 1:100 
ChIP-seq 
Goat anti-human FoxC1 Abcam ab-5079 5 μg per IP (overnight) 
Goat anti-human C/EBPα Santa Cruz sc-61-X 1 μg per IP (2 h) 
Rabbit anti-human RUNX1 Abcam ab23980 2 μg per IP (overnight) 
EMSA Supershift Assays 
Goat anti-human FoxC1 Abcam ab-5079 1 μg per assay 
Goat anti-human FoxC1 Santa Cruz sc-2139-X 1 μg per assay 
Rabbit anti-human FoxO3a Cell Signalling Technology  75D8 1 μg per assay 
Mouse anti-human FoxP1 Santa Cruz sc-398811-X 1 μg per assay 
Mouse anti-human IgG Santa Cruz sc-66931-X 1 μg per assay 
Rabbit anti-human E2A Santa Cruz sc-763-X 1 μg per assay 




Rabbit anti-human GAPDH Cell Signalling Technology 14C10 
1:4000 per membrane 
(overnight, 4°C) 
Rabbit anti-human FoxO3a Cell Signalling Technology  75D8 
1:500 per membrane 
(overnight, 4°C) 
Mouse anti-Rabbit IgG  
(HRP-conjugated secondary) Rockland 18-8816-31 1:2000 (1 h, RT) 
 
 
Table 2:5 Expression vector backbones 
Vector Backbone Source 
Luciferase Reporter Gene Assays 
pXPG-TK229 Bert et al. (2000) Plasmid 44(2) 
pRL-TK750 Promega 
CRISPR/Cas9 Genome Editing 
pX458-sSpCas9(BB)-2A-GFP Ran et al. (2013) Nature Protocols 8(11) 
shRNA-mediated knockdown 
LeGO-iG Weber et al. (2008) Molecular Therapy 16(4) 
Tat 





Table 2:6 Oligonucleotides 
Name Forward Sequence (5' - 3') Reverse Sequence (5' - 3') 
Gene Expression – qPCR primers 
hFOXC1 CCCTCTCTTGCCTTCTTCCT CGTCAGGTTTTGGGAACACT 
hGAPDH CCTGGCCAAGGTCATCCAT AGGGGCCATCCACAGTCTT 
DNase I – qPCR validation primers 
Human  
TBP promoter CTGGCGGAAGTGACATTATCAA GCCAGCGGAAGCGAAGTTA 
ACTB gene body GCAATGATCTGAGGAGGGAAGGG GTGTCTTTCCTGCCTGAGCTGAC 
Chr18 ACTCCCCTTTCATGCTTCTG AGGTCCCAGGACATATCCATT 
TBP promoter  
(short amplicon)  
CTGGCGGAAGTGACATTATCAA CCCGACCTCACTGAACCC 









Tbp promoter TGCAGTCAAGAGCGCAACTG CACCGCTACCGGACTCGAT 
Actb gene body CAAGACAAGATGGTGAATGGTGAG GTAAGCTAAGCATCCTTAGCTTGG 
Chr1  TGCTCCACAGTGTCCATGTACA AGCAATTTCATGGGTGAGAGAAG 
Tbp promoter  
(short amplicon)  
GGCGGAAGTGACGGCATCAG CACCGAACGCCTGACGCAC 






ChIP-seq – qPCR validation primers  
FoxC1 ChIP – putatively positive regions 
DUSP6 -130 kb DHS GGATACATTCTCCGGGCCAG GTTTGCACTGGGGCTTATCC 
GTF2A1 promoter  TTAAATGGAGAGGCGGTGAC CCTTTGGCTGCCCTGTTTAT 
C/EBPα and RUNX1 ChIP – validated positive regions 
SPI1 -14 kb enhancer   AACAGGAAGCGCCCAGTCA TGTGCGGTGCCTGTGGTAAT 
IGFBP7 promoter GTCAAGCACTAAAAGGACAAACCG TGAATGCCACTGGGAGACAAAG 
Negative Control regions for all ChIP assays 
IVL promoter GCCGTGCTTTGGAGTTCTTA CCTCTGCTGCTGCCACTT 




































































IL2RA(DHS 1) TAAGGGATCCGGTACCTTTGTCTTCTGAGTGC 
CTTACTCGAGCACCAGGGATGAA
ATTAGCCT 
IL2RA(DHS 2) TAAGGGATCCGCTGGAACTATAGGCGTGCG 
CTTACTCGAGAGTCATCCCCAACT
GGCAA 
General Plasmid Sequencing Primers 
pXPG sequencing 
primer TATCGCTACGTGACTGGGTC  
U6 promoter 
sequencing primer GAGCTCACAACCCCTCACTC  
CRISPR deletion of FOXC1 – sgRNA cloning and PCR screening  
sgRNA 5' guide 1 CACCGAGAGCTACTACCGCGCGG AAACCCGCGCGGTAGTAGCTCTC 
sgRNA 5' guide 2 CACCGCTGCTCGCCGCCGAGGTA AAACTACCTCGGCGGCGAGCAGC 
sgRNA 3' guide 1 CACCGGATTTAGTTCGGCTTTGA AAACTCAAAGCCGAACTAAATCC 
sgRNA 3' guide 2 CACCGCGATTTAGTTCGGCTTTG  AAACCAAAGCCGAACTAAATCGC 
PCR Primer 1 GTTTGCGCCTGGAAGCT  
PCR Primer 2 ATGGTGATGAGCGCGATGTA  
PCR Primer 3 CAGCAGCAGAACTTCCACTC  
PCR Primer 4 AGGTCTCTGAAAAGCAAGAAGA  
FoxC1 shRNA knockdown 





























Integrated Genomics Viewer 2.4 




R package: ChIPpeakAnno 3.11.6 
R package: Limma 3.28.14 
R package: pheatmap 1.0.8 










2.1 Cell line culture 
2.1.1 General cell culture 
Leukaemia cell lines were maintained in RPMI/GlutamaxTM supplemented with 10% 
heat-inactivated foetal calf serum and 1% penicillin/streptomycin in a humidified 
incubator at 37°C and 5% CO2. All cell lines were maintained at densities recommended 
by the cell bank from which the cells originated (Table 2:8). 
Table 2:8 Cell lines used in this study 











2.1.2 Cell stimulation 
 
A 100 X stock of calcium ionophore A23187 (CaI) and phorbol 12-myristate 13-acetate 
(PMA) was prepared in cell media immediately prior to stimulation. Cells were stimulated 
by addition of a 1/100 volume of this stock, to give a final concentration of 2 μM CaI and 
20 ng/ml PMA.  
Depending on the downstream analyses required, cells were stimulated for 4 hours (for 
nuclear extracts to use in EMSAs) or 8 hours (for luciferase reporter gene assays).   
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2.1.3 Preparation of conditioned medium for single cell CRISPR clone culture 
FUJIOKA cells in exponential growth (i.e. with a density of 3.0-5.0x105/ml) were 
harvested from culture by centrifugation (400 xg, RT, 5 min). The conditioned medium 
was aspirated and passed through a 0.22 μm pore filter to remove residual cells.  
Filtered conditioned medium was with fresh RPMI+GlutamaxTM supplemented with 20% 
heat-inactivated foetal calf serum and 1% penicillin/streptomycin to give a final 
concentration of 40% conditioned medium for use in culture. 
2.2 Processing of primary AML patient samples 
Use of human tissue in this study was in compliance with the ethical and legal framework 
of the United Kingdom’s Human Tissue Act of 2004. 
Peripheral blood samples from primary AML patients were obtained from the University 
Hospitals Birmingham NHS Foundation Trust (source) and diluted to a maximum density 
of 1x107 cells/ml with sterile PBS. Blood samples were carefully overlaid onto an equal 
volume of LymphoprepTM in 50 ml Falcon tubes prior to centrifugation (800 xg, RT, 20 
min, brake off). The upper plasma layer was carefully discarded, then the 
plasma:LymphoprepTM interface layer, containing peripheral blood mononuclear cells 
(PBMCs), was transferred to a new Falcon tube and diluted with 50 ml sterile PBS. Cells 
were recovered by centrifugation (500 xg, RT, 10 min, brake on). 
AML blast cell purity was determined by flow cytometry analysis (2.4). If the surface 
expression of CD34 or CD117 was below 92%, cells were further purified using either a 
CD34 or CD117 MicroBead kit and a MiniMACSTM column, according to the 
manufacturer’s instructions. Purified PBMCs were aliquoted for RNA-seq, DNase-seq 
and ChIP-seq analyses (2.5, 2.6 and 2.7). 
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2.3 Processing of murine AML samples 
Cryopreserved spleen cells from murine AML samples generated by methods described 
in Somerville et al. (2015) were obtained from Tim Somervaille (Cancer Research UK 
Manchester Institute). Mouse experiments were approved by the Cancer Research UK 
Manchester Institute’s Animal Ethics Committee and performed under a United Kingdom 
Home Office project, in adherence to the Animal Scientific Procedures Act of 1986. 
Samples were thawed in 30 ml of IMDM with 10% heat-inactivated foetal calf serum, and 
a 5 μl aliquot was removed and mixed 1:1 with 0.4% Trypan blue solution to determine 
cell density and viability. Cell suspensions were aliquoted for subsequent RNA-seq and 
DNase-seq analyses (2.5 and 2.6). 
2.4 Flow cytometry 
1x105 cells per analysis were collected by centrifugation (400 xg, RT, 5 min). Pellets 
were washed twice in 1 ml of MACS buffer then re-suspended in 200 μl of supernatant. 2 
μl of antibody was added and cell suspensions incubated in the dark at 4°C for 15 min. 
Cell suspensions were washed with a further 1 ml of MACS buffer prior to analysis with a 
CyAnTM ADP flow cytometer.  
2.5 Analysis of gene expression 
2.5.1 RNA isolation 
5x106 cells were centrifuged (300 xg, 4°C, 5 min) then lysed by addition of 1 ml of 
TRIzolTM reagent. Samples were incubated at RT for 5 min prior to addition of 200 μl of 
chloroform and a further incubation at RT for 3 min. Samples were centrifuged (12000 
xg, 4°C, 5 min) and the upper aqueous phase containing RNA transferred to a new tube. 
RNA was then purified using a NucleoSpin® RNA kit, with the optional on-column DNase 
digestion step, according to the manufacturer’s instructions. RNA was quantified by 260 
nm absorbance using a NanoDropTM 2000. 
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2.5.2 cDNA synthesis 
1 μg of total RNA was used in cDNA synthesis reactions with a SuperScript II Reverse 
Transcriptase kit and 0.5 μg of included Oligo(dT)12-18 primers, according to the 
manufacturer’s instructions. 
2.5.3 Quantitative PCR 
cDNA was quantified by real-time PCR in 10 μl reactions, using 200 nM of forward and 
reverse transcript-specific primers (Table 2:6) and SYBR® Green PCR master mix, 
according to the manufacturer’s instructions. Analysis was performed on an ABI 7500 
real-time PCR system using StepOneTM Plus software. 
Target gene expression was calculated relative to GAPDH expression, using transcript-
specific standard curves generated using the following dilution series: 1:10, 1:50, 1:250, 
1:1,250 and 1:6,250 of sample cDNA diluted with water. cDNA to be quantitated was 
diluted 1:10 or 1:50 times for low- or high-abundance transcripts, respectively.  
2.5.4 RNA-seq library preparation 
RNA-seq libraries were generated from 500 ng of total RNA using a TruSeq RNA sample 
preparation kit v2, following the manufacturer’s instructions. Library synthesis efficiency 
was assessed using a 2100 High Sensitivity DNA Kit and library concentration 
determined using an Illumina Library Quantification Kit, both according to the 
manufacturer’s instructions. Libraries were pooled with complementary indices at 
equimolar ratios for multiplexed paired-end sequencing on a NextSeq 500 high-
throughput sequencer by the University of Birmingham Genomics Facility.  
2.5.5 RNA-seq data processing  
Raw paired-end reads were processed with Trimmomatic308 to remove low-quality reads 
and adapter sequences. Reads were then mapped to the mouse genome assembly 
mm10 or human genome assembly hg19 using HiSat2309, using default parameters. 
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RefSeq transcript abundances were calculated as Transcripts Per Million (TPM) using 
StringTie309. Only genes with a TPM > 1 in at least one sample were considered 
expressed and were retained for further analyses.  
2.5.6 Correlation clustering of RNA-seq data 
Hierarchical clustering of samples based on their gene expression profile was carried out 
using log-transformed TPM values (log2 TPM + 1). Pearson correlation values were 
calculated for each pair of samples using R. This correlation was then converted to a 
distance (1 – Pearson correlation), and clustered using average linkage hierarchical 
clustering. The result of this was plotted as a heatmap using the pheatmap package in R.  
2.5.7 Differential gene expression analyses 
Differential gene expression was conducted using the Limma package in R310. A gene 
was considered significantly differentially expressed if it had a fold-change > 2, and an 
adjusted p value < 0.05 between the two conditions tested. Adjusted p-values were 
calculated using the Benjamini-Hochberg method. KEGG pathway analyses were carried 
out using DAVID v6.8311. KEGG pathways with a Benjamini-Hochberg adjusted p value < 
0.05 were considered significantly enriched.  
2.6 DNase I hypersensitive site mapping 
2.6.1 DNase I assay 
2 - 3.5x107 cells were used per cell type tested, to allow a titration series of DNase I 
enzyme, and capture digestion points within the optimal range for efficient detection of 
both constitutive and inducible DHSs.  
4.5x106 cells per DNase I digestion point were centrifuged (300 xg, RT, 5 min), washed 
in PBS and then re-suspended at 3x107 cells/ml in DNase I resuspension buffer. 150 μl 
aliquots of cells were equilibrated in 1.5 ml Eppendorf tubes to 22°C in a water bath for 3 
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min prior to nuclei digestion. Following this, an equal volume of 2X DNase I nuclei 
digestion buffer was added, with a final enzyme concentration generally ranging from 1 
to 10 μg/ml, and samples were incubated at 22°C for exactly 3 min. Digestions were 
terminated by addition of 300 μl of DNase I cell lysis buffer, and samples were incubated 
overnight at 45°C. 
2.6.2 Analysis of DNase I digestion points by agarose gel electrophoresis 
100 μg/ml of RNase A was added to samples and incubated at 37°C for 1 h. 6 μl of each 
sample (1% of 4.5x106 cells = ~225 ng DNA) were loaded with 1X Purple Gel Loading 
Buffer in an 18 μl volume onto a 0.8% agarose gel with 1X TAE buffer and 0.5 μg/ml 
ethidium bromide (TAE/EtBr). Electrophoresis was performed at 30 V for 16 h and DNA 
fragments visualised by UV trans-illumination using a Gel Doc XR+ and Image Lab 
software. A representative gel analyses is shown in Figure 2:1A. 
2.6.3 DNA purification 
The following morning, a further 100 μg/ml of RNase A was added to samples 
determined by gel electrophoresis analyses to possibly be close to the optimal DNase I 
digestion point, and incubated at 37°C for 30 min. An equal volume of phenol was added, 
and the mixture incubated with rotation at RT for 1 h. Samples were centrifuged (18,500 
xg, RT, 5 min) and the upper aqueous phase transferred to new 1.5 ml Eppendorf tubes. 
An equal volume of 1:1 phenol:chloroform solution was added and incubated with 
rotation at RT for 30 min then centrifuged as previously. The aqueous phase was 
transferred to a new tube, an equal volume of chloroform added and incubated with 
rotation at RT for 30 min before centrifugation. The purified DNA was precipitated from 
the final aqueous phase by addition of two volumes of 100% ethanol and 50 mM NaCl, 
and stood on ice for 15 min.  
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Precipitated DNA was pelleted by centrifugation (18,500 xg, 4°C, 15 min), pellets washed 
in 500 μl 75% ethanol then recovered by centrifugation (18,500 xg, 4°C, 5 min). The 
supernatant was discarded and pellets were air-dried for 10-15 min at RT prior to re-
suspension in 30 μl of 1X TE. Samples were stood overnight to allow complete 
dissolution, then quantitated by 260 nm absorbance using a NanoDropTM 2000 
spectrophotometer. 
2.6.4 DNase-seq library preparation 
Favourable digestion points were identified by qPCR analyses (2.5.3), using DNase 
digestion points as the template and genomic DNA for standard curves. The ratio of PCR 
signal was determined between a previously defined active region at the TBP promoter, 
which was expected to be DNase I hypersensitive, and an inactive region at either 
chromosome 1 (Chr1, for murine samples) or chromosome 18 (Chr18, for human 
samples), which was not expected to be hypersensitive. Optimally digested samples 
gave an active/inactive ratio of between ~0.4 to 0.7. A representative example of these 
qPCR analyses are shown in Figure 2:1A. 
≥ 5 μg of DNA from the most favourable samples were loaded with 1 X Purple Gel 
Loading Buffer on a 1.5% agarose gel with TAE/EtBr, and separated by electrophoresis 
at 80 V for 2 h. DNA fragments of ~80 - 250 bp were excised using a clean scalpel then 
purified using a MinElute® Gel Extraction kit, according to the manufacturer’s 
instructions.  
Size-selected DNA fragments were validated again by qPCR, this time using shorter 
amplicon PCR primers for control active regions at TBP and ACTB promoters, and 
control inactive Chr1/Chr18 loci as appropriate. Samples showing the highest TBP/ACTB 
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and TBP/inactive enrichments were selected for genome-wide sequencing. Figure 2:1B 
presents representative examples of these steps in the protocol. 
DNase-seq libraries were prepared using a MicroPlex Library Preparation kit v2, 
according to the manufacturer’s instructions. Amplified libraries were loaded with 1X 
green gel loading buffer and separated by electrophoresis on a 1.5% agarose gel with 
TAE/EtBr at 80 V for 2 h. Library fragments of ~170 - 300 bp were purified using a 
MinElute® Gel Extraction kit according to the manufacturer’s instructions, and eluted in a 
final volume of 12 μl. Representative examples of DNase-seq library size selection are 
presented in Figure 2:1C. 
2.6.5 Quality control and pooling of DNase-seq libraries 
To assess library quality for sequencing, libraries were re-validated using the short 
amplicon primers by qPCR. If the active/inactive enrichment was deemed to be 
satisfactory, the average library fragment size was determined using a 2100 High 
Sensitivity DNA Kit and library concentration quantified with an Illumina Library 
Quantification Kit, according to the manufacturer’s instructions. Representative examples 
of these steps are shown in Figure 2:1C. 
Libraries were pooled with complementary indices at equimolar ratios for multiplexed 
single-end sequencing on a NextSeq 500 high-throughput sequencer (Illumina). For 
ultra-high depth sequencing as required for digital DNase I footprinting analyses, libraries 
were re-sequenced using a HiSeq 2500 ultra-high-throughput sequencer (Illumina). 




Figure 2:1 Overview of DNase I digestion assay and sequencing library preparation steps as 
described in 2.6.1 to 2.6.5. 
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2.6.6 DNase-seq data processing 
Raw DNase-seq reads were processed with Trimmomatic308 to remove low-quality reads 
and sequencing adapters. Reads were then mapped to the mouse genome assembly 
mm10 or human genome assembly hg19 using Bowtie2312, using the parameter –very-
sensitive-local. Regions of enrichment corresponding to open chromatin (peaks) were 
identified with MACS313 using the options –g –keep-dup=all –w –S. Peaks were 
annotated to their closest gene using the annotatePeaks.pl function of Homer314, and 
further annotated to a gene promoter if they were within 2 kb up or down-stream of the 
gene transcription start site (TSS) and as distal peaks if otherwise. Promoter and distal 
peaks were treated separately in further analyses.  
Peak unions were constructed by merging peaks that had summits within 400 bp of each 
other using the merge function in BEDtools315. In these cases, a new summit position 
was calculated as the mid-point between the summits of the original peaks. This average 
summit position was used in further downstream analysis.  
2.6.7 DNase-seq correlation analyses 
Hierarchical clustering of DNase-seq data was carried out on the union of all peaks 
across all datasets. The number of mapped reads (tag density) for each peak was 
calculated for 400 bp windows centered on the peak summits using the annotatePeaks.pl 
function in Homer, and normalized by total tag count across all peaks. Tag counts were 
log-transformed (using log2 tag-count + 1) prior to calculation of Pearson correlation 
values for each pair of samples in R. These correlation values were then converted to a 
distance (1 – Pearson correlation value), and clustered using average linkage 
hierarchical clustering. The result of this clustering was plotted as a heatmap using the 
pheatmap package in R.   
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2.6.8 Identification of sample-specific DNase-seq peaks 
To identify shared and specific sets of peaks, the tag density for each peak was 
calculated across 400 bp windows centred on the summits of the peak union, and 
normalized by total tag density in all peaks. A peak was considered specific to a 
condition if the normalized tag count was at least 4-fold higher in one condition relative to 
another, and as shared between conditions if otherwise.  
2.6.9 DNase-seq motif enrichment analyse 
A de novo motif search for TF binding motifs was conducted within the shared and 
specific populations of peaks using the findMotifsGenome.pl function in Homer, 
considering motif lengths of 8, 10 and 12 bp. Density plots were generated by ranking 
peaks according to their fold-difference, and then calculating the tag density across a 2kb 
window using annotatePeak.pl from Homer with the parameters –size 2000 –hist 10 –
ghist followed by visualisation using Java TreeView316. Average profiles for the shared 
and specific peaks were plotted in R using the tag densities calculated by Homer, 
normalized by number of tags per million.   
2.6.10 DNase-seq motif co-localisation analyses 
Specific and shared populations of DHSs were identified from high read-depth DNase-
seq experiments as described for low-depth samples. Genomic coordinates for TF 
binding motifs within these DHSs were retrieved using the annotatePeaks.pl function in 
Homer, and exported as BED files using the –mbed option. These motif searches were 
carried out using the motif probability weight matrices provided by the Homer database. 
Motif co-localization within the specific DHS populations was measured by counting the 
number of pairs of motifs within 50 bp of each other using the intersection_matrix 
function in pybedtools317. 
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To assess the significance of co-localized motifs within the specific populations of DHSs, 
we carried out a bootstrapping analysis whereby a random set of DHSs were sampled 
with replacement from the union of all DHSs in Hoxa9+FoxC1 and Hoxa9+MMTV cells. 
This procedure was repeated 1000 times, and the number of co-localized motif pairs was 
counted in each of these bootstrap replicates. The mean and standard deviation of the 
counts across all replicates was then used to calculate a Z-score for each pair of motifs. 
Hierarchical clustering of the resulting Z-score matrix was performed using complete 
linkage clustering of the Euclidean distances, and plotted as a heatmap using the 
pheatmap package in R.  
2.6.11 High-resolution digital DNase I footprinting analyses 
Libraries corresponding to the highest-quality samples were re-sequenced on an Illumina 
HiSeq (University of Birmingham Genomics Facility) until a minimum number of 
400,000,000 total reads per sample were obtained. Raw sequencing data from high-
depth DNase-seq experiments were processed as described for low-depth samples. 
Digital genomic footprints were identified with the Wellington algorithm (Piper et al. 2013) 
using the parameter --fdrlimit -10. Shared and specific sets of footprints were identified 
using the bedtools intersect function. A footprint was considered specific to an 
experimental condition if it did not overlap with a footprint in any other condition, and as 
shared if otherwise. A de novo motif search was carried out in specific footprints using 
Homer’s findMotifsGenome.pl function with the parameter –size given. DHS cut tracks 
showing the strand imbalance in DNase I cut sites within footprinted regions were 
created using the dnase_wig_tracks.py function in Wellington, and visualized using the 
Integrated Genomics Viewer318.  
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2.7 Chromatin Immunoprecipitation (ChIP) 
2.7.1 Chromatin preparation 
3x107 cells were centrifuged (400 xg, RT, 5 min) and pellets washed thrice with 50 ml 
PBS. The washed pellet was re-suspended to 1x107 cells/ml with PBS and cross-linked 
with 0.83 mg/ml DSG on a rotating wheel at RT for 45 min. Single-crosslinked cells were 
washed three times, each with 50 ml PBS, then re-suspended in 15 ml PBS prior to 
addition of 1% formaldehyde (~0.34 M) for a second cross-linking step on gentle rotation 
at RT for 10 min.  
Crosslinking reactions were immediately quenched by addition of 0.4 M glycine and 
incubated on ice for 5 min. Double-crosslinked cells were centrifuged (400 xg, 4°C, 5 
min) then washed twice with 50 ml ice-cold PBS prior to re-suspension to 1x107 cells/ml 
with 3 ml ice-cold buffer A. Cells were lysed on a rotating wheel at 4°C for 10 min and 
nuclei centrifuged (500 xg, 4°C, 5 min). The supernatant was discarded and pellets re-
suspended to 1x107 nuclei/ml in 3 ml ice-cold buffer B for incubation on a rotating wheel 
at 4°C for 10 min. Chromatin was pelleted by centrifugation (500 xg, 4°C, 5 min) and re-
suspended to 2x107 nuclei/ml 1.5 ml in ice-cold IP buffer I. 330 μl aliquots of chromatin 
were transferred to 1.5 ml Eppendorf tubes for sonication (‘high’ power setting, 30 
second on/off cycles) using a BioruptorTM. The number of sonication cycles were 
determined empirically for each cell type to give a modal DNA fragment size of ~500 bp, 
and ranged from ~25 - 40 cycles.  
Sonicated chromatin was cleared by centrifugation (16,000 xg, 4°C, 10 min) and the 
supernatant diluted with 2 volumes of IP buffer II. 100 μl of chromatin was reserved as an 
input control, and DNA isolated by addition of 0.2 M NaCl and 0.5 mg/ml Proteinase K 
and overnight incubation at 65°C then sequential phenol/phenol:chloroform/chloroform 
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extraction as described in 2.6.3. To confirm optimal sonication results, 10 μl of DNA input 
was analysed by electrophoresis on a 1.5% agarose gel with TAE/EtBr. 
2.7.2 ChIP 
10 μl of DynabeadsTM-Protein G per IP were washed in 500 μl citrate phosphate buffer 
and stood on a DynaMagTM-2 magnetic rack at RT until clear. The supernatants were 
discarded and beads re-suspended in 15 μl of citrate phosphate buffer with ChIP-grade 
antibody at the appropriate concentration (Table 2:4) and 0.5% BSA. Antibodies were 
pre-conjugated to beads on a rotating wheel at 4°C for 2 h. Pre-conjugated beads were 
washed in 500 μl citrate phosphate buffer to remove unbound antibody, then re-
suspended in 15 μl citrate phosphate buffer/0.5% BSA. 500 μl of chromatin was added to 
the pre-conjugated beads and incubated on a rotating wheel at 4°C from 2 h - overnight 
(Table 2:4). 
For FoxC1 ChIP-seq only, an additional pre-clearing step was performed prior to 
immunoprecipitation: 500 μl of chromatin was incubated with 10 μl of DynabeadsTM-
Protein G (without antibody) on a rotating wheel at 4°C for 1 h. Beads were isolated 
using a DynaMagTM-2 magnetic rack and the supernatant added to α-FoxC1-conjugated 
beads as for other immunoprecipitations. 
ChIP reactions were washed on a DynaMagTM-2 magnetic rack using 500 μl volumes of 
buffers in the following order: wash buffer I (once); wash buffer II (twice); LiCl wash 
buffer (once); TE/NaCl wash buffer (twice). All wash steps were carried out on ice by 
gentle addition of the wash buffer and two 180° rotations of each sample tubes, still in 
the magnetic rack. Beads were re-suspended in 50 μl ChIP elution buffer and incubated 
on a ThermoMixer® C at 65°C and 500 rpm for 15 min. The first eluate was reserved and 
a second elution step was performed under the same conditions. Eluates were pooled 
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and 0.2 M NaCl and 0.5 mg/ml proteinase K added for reverse crosslinking at 65°C for > 
4 h.  
DNA was purified using AMPure® XP beads, using a 1.8X single-sided clean-up 
according to the manufacturer’s instructions. ChIP efficiency was determined by qPCR 
as described in Quantitative PCR, using a standard curve prepared from sonicated 
chromatin input and specific primers against positive and negative control regions (Table 
2:6). The fold-enrichment was calculated from the relative quantities of known/putatively 
positive-bound regions against control [negative] regions.  
2.7.3 ChIP-seq library preparation 
ChIP-seq libraries were prepared using a HyperPrep Kit for Illumina, according to the 
manufacturer’s instructions. Amplified libraries were loaded with 1X green gel loading 
buffer onto on a 1.5% agarose gel with TAE/EtBr and electrophoresed at 80 V for 2.5 h. 
Library fragments of ~170 - 600 bp were isolated using a MinElute® Gel Extraction kit, 
according to the manufacturer’s instructions, eluted in a final volume of 12 μl. 
Library qPCR validation, quality control and quantitation were performed essentially as 
described in 2.6.5, using ChIP-specific primers detailed in Table 2:6.  
2.7.4 ChIP-seq data processing  
For RUNX1 and C/EBPα ChIP-seq data, raw reads were processed with Trimmomatic to 
remove low-quality reads and sequencing adapters. Reads were then mapped to the 
human genome assembly hg19 using Bowtie2 using the parameter -sensitive-local. For 
FoxC1 ChIP-seq, raw reads were instead trimmed using cutadapt319 using -a 
ATATATATATATATATATAT as a parameter to remove artefactual repeats, then aligned 
using bowtie320 to the hg19 genome with the following parameters: --all --best --strata -v 
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3 -m 1 –S, so as to obtain only uniquely aligned reads. Aligned reads were converted to 
BAM format using the SAMtools321 view -S - -b -o command.  
For all ChIP-seq analyses, coverage track generation and peak calling were performed 
using MACS using -g hs --keep-dup=auto -w -S as parameters. To remove artefactual 
peaks, peaks were intersected against the hg19 ENCODE blacklist151 and UCSC simple 
repeats322 using bedtools intersect with the -v switch. 
2.7.5 ChIP-seq data analyses 
To determine overlap of ChIP-seq binding enrichment between datasets, the MACS .bed 
output containing peak summits was converted to genomic ranges in ChIPpeakAnno323, 
using the BED2RangedData function. ChIP peaks were considered to overlap if the 
summit points in either dataset were within 200 bp of each other. Overlaps between pairs 
of ChIP-seq datasets were visualised using the VennDiagram324 package in R. 
2.8 Electrophoretic Mobility Shift Assay (EMSA) 
2.8.1 Preparation of nuclear extracts 
5x107 cells were harvested by centrifugation (300 xg, RT, 5 min) and washed in 50 ml 
ice-cold PBS prior to re-centrifugation (300 xg, 4°C, 5 min). Cell pellets were re-
suspended in 10 ml ice-cold buffer A and mechanically disrupted using a chilled 15 ml 
Dounce homogeniser on ice. Nuclei were pelleted by centrifugation (300 xg, 4°C, 5 min).  
Nuclear pellets were re-suspended in 1/5 pellet volume of ice-cold buffer A, followed by 
very gradual addition of 5 pellet volumes of buffer C with thorough mixing. Nuclei were 
lysed by incubation on ice for 10 min with occasional shaking, and samples were cleared 
of insoluble chromatin by centrifugation (16,000 xg, 4°C, 10 min). Supernatants, 
containing soluble nuclear extracts, were transferred to pre-wetted Spectra/Por MYCO 
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3500 tubing for dialysis against buffer D at 4°C for 2 h. The protein concentration was 
determined by Bradford assay325 using Bradford reagent and a spectrophotometer. 
2.8.2 Preparation of EMSA probes 
100 μM of sense and antisense PAGE-purified oligonucleotides (Table 2:6) were mixed 
then annealed by heating to 95°C for 10 min and gradual cooling to RT. 2 pmol of 
annealed duplexes were end-filled in 10.5 μl reactions containing 1X T4 polymerase 
buffer, 10 μM each of dGTP, dATP and dTTP, 0.5 units T4 DNA polymerase and 5 μCi of 
α-32P dCTP. End-filling was carried out at RT for 10 min. α-32P dCTP-labelled probes 
were purified using an Illustra ProbeQuant G-50 micro column, according to the 
manufacturer’s instructions. Probes were eluted in 30 μl TE, then diluted to 320 μl 
(~0.005 pmol/μl, assuming 80% recovery) for direct use in EMSA binding reactions.  
2.8.3 EMSA assays 
A 4% polyacrylamide/0.5X TBE gel was prepared and allowed to set for at least 30 min. 
After this, the gel was pre-ran at 200 V for 1 h in 0.5X TBE, then allowed to cool prior to 
EMSA binding reactions. 
Binding reactions comprised the following components added in order: 4 μg of poly(IC), 
1X EMSA binding buffer, 0.5 mM DTT/PMSF, 1X EMSA Phosphatase Inhibitor Cocktail, 
4 μg nuclear extract and 0.02 pmol of labelled EMSA probe. For competition assays, 2 
pmol (i.e. a 100-fold excess relative to probe) of unlabelled EMSA duplex was added 
prior to nuclear extract and labelled probe. 
Binding reactions were carried out at RT for 10 min, then loaded into the pre-ran gel and 
electrophoresed at 200 V for 90 min. Gels were fixed by immersion in 0.1% (w/v) 
CTAB/50 mM sodium acetate pH 5.5 for 45 min, then sandwiched between two sheets of 
Whatman® 3MM blotting paper for drying at 80°C for 1 h with a GD 2000 Gel Drier. Dried 
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gels were exposed to a cleared Storage Phosphor screen in an exposure cassette 
overnight, and images developed using a Personal Molecular Imager and Quantity One 
software. 
2.9 Western blotting 
2.9.1 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
10 - 20 μg of nuclear extract of interest (prepared as in 2.8.1) were diluted to a volume of 
10 μl with molecular biology-grade water. An equal volume of 2X Western blot sample 
buffer was added to each sample prior to boiling at 95°C for 10 min. Samples were 
loaded into separate wells of 4-20% Mini-PROTEAN TGX Stain-Free precast gels, 
together with 10 μl of Rainbow Molecular Weight Ladder for subsequent size estimation. 
Gels were electrophoresed in a vertical tank filled with 1X SDS Running Buffer at 15 mA 
for ~5 min, to allow proteins to enter the gel, then ran at 30 mA for 45 – 60 min, 
according to target protein sizes. 
2.9.2 SDS-PAGE gel transfer, immunoblotting and visualisation of proteins 
Proteins separated by SDS-PAGE were transferred onto nitrocellulose membranes using 
the ‘Mixed MW’ setting on a Trans-blot Turbo Transfer System. Membranes were 
blocked in 10 ml of Western blot blocking buffer at RT for 1 h, then transferred to 
containers with 10 ml of primary antibody in 5% milk/TBST (Table 2:4) for overnight 
incubation with gentle rocking at 4°C. The following day, membranes were washed with 
three successive 10 ml volumes of TBST with gentle rocking at RT, then transferred into 
a container containing 10 ml of secondary antibody in 5% milk/TBST for a 1 h incubation 
at RT with gentle rocking. Blots were washed three times as previously. Residual wash 
buffer was removed from membranes by carefully holding the blot against a clean paper 
towel to draw buffer off by capillary action. 
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Membranes were cut into two pieces to separate the experimental and internal loading 
control proteins prior to addition of a 1:1 mixture of Detection reagents 1 and 2 from an 
Amersham ECL Western Blotting Detection Reagent Kit, following the manufacturer’s 
instructions. Membranes were briefly immersed in double distilled water prior to 
visualisation using a Gel Doc XR+ and Image Lab software. 
2.10 Luciferase enhancer reporter gene assays 
2.10.1 Generation of enhancer reporter plasmids 
A subset of FLT3-ITD-specific DHSs identified in Cauchy et al. (2015) were amplified by 
overlap extension PCR from 10 ng of Jurkat genomic DNA using Phusion® High-Fidelity 
PCR Master mix, 500 nM of PCR cloning primers (Table 2:6), in 50 μl reactions in a 
T3000 thermocycler. Reactions were carried out using the following thermocycler 
parameters: 
Table 2:9 Thermocycling conditions for amplification of DHS fragments by PCR 
“x” denotes the optimal annealing temperature, specific to each primer pair. This was determined by 
first performing an initial optimisation PCR varying the temperature of x in a Primer Gradient 
Thermocycler and assessing target amplification by agarose gel electrophoresis.  
 
Step Temperature Time Number of cycles 
Denaturing 98ºC 30 sec 1 
Genomic amplification 
98ºC 10 sec 
5 xºC 20 sec 
72ºC 30 sec 
Adaptor amplicon 
amplification 
98ºC 10 sec 
25 
72ºC 30 sec 
Terminal elongation 
72ºC 10 sec 




Alternatively, equimolar quantities of an single-stranded oligonucleotides corresponding 
to three copies of the FAM92A1 FOX:E composite site (Fox:Ex3) were annealed by 
heating to 95°C in a heatblock for 10 min then slowly cooling by removing the heatblock 
and placing on the bench. Cloning primers contained flanking sequences with BglII or 
BamHI/XhoI restriction sites to facilitate sticky-ended cloning into the parent vector, 
pXPG-TK229326. 
10 μl of each PCR product/annealed oligonucleotides were mixed with 1X purple gel 
loading buffer for electrophoresis on a 1.2% agarose gel with TAE/EtBr to confirm robust 
and specific target amplification. The remaining 40 μl of PCR products were cleaned up 
using a MinElute® PCR purification kit according to the manufacturer’s guidelines, then 
digested in a 20 μl reaction with 20 U each of the appropriate restriction enzyme at 37°C 
for 3 h.  
For each reporter construct to be prepared, 1 μg of pXPG-TK229 was digested with 20 U 
of restriction enzyme(s) in a 20 μl reaction at 37°C for 3 h. For constructs prepared via 
the BglII cloning strategy, 5’ ends of the vector DNA were dephosphorylated in parallel 
by 1 U calf intestinal phosphatase.  
Vector and insert DNA was purified from digest reactions using a QIAquick® PCR 
purification kit, according to the manufacturer’s instructions, then quantified by 260 nm 
absorbance using a NanoDropTM 2000 spectrophotometer. Ligations were carried out in 
20 μl reactions comprising: 100 ng DNA (as a 3:1 molar ratio of insert:vector), 1X T4 
DNA ligase buffer and 400 U T4 DNA ligase at RT for 1 h.  
2.10.2 Transformation of E. coli and plasmid screening  
50 μl of chemically-competent JM109 E. coli cells were transformed with 1 μl of ligation 
product by: incubation on ice for 20 min, heat shock at 42°C for 1 minute, recovery on ice 
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for 1 minute and incubation with 250 μl of SOC medium in an orbital shaking incubator 
(37°C, 250 rpm, 30 min).  Transformed cells were plated onto LB agar plates with 100 
μg/ml ampicillin (LB agar/amp) and placed in a static 37°C incubator overnight. 
Colonies were picked to inoculate 2 ml cultures of LB medium with 100 μg/ml ampicillin 
(LB/amp), which were placed in a shaking incubator (37°C, 250 rpm, overnight).  The 
following morning, 500 μl of each overnight culture was mixed with 500 μl of sterile 50% 
glycerol for long-term storage at -80°C. Plasmid mini-preps were made from the 
remaining 1.5 ml of overnight culture using a QIAprep® Miniprep kit, according to the 
manufacturer’s instructions.  Colonies were validated for correct insert sequence and 
orientation by Sanger sequencing (Source Bioscience) using the pXPG forward 
sequencing primer (Table 2:6). 
2.10.3 Preparation of transfection-grade reporter plasmid stocks 
Colonies verified to be positive for the desired plasmid were picked from master plates 
and re-streaked onto fresh LB agar/amp plates for propagation in a static 37°C incubator 
overnight. The following morning, a colony was picked to inoculate a 3 ml LB/amp starter 
culture in a shaking incubator (37°C, 250 rpm, 6 h). 100 μl of starter culture was 
introduced into a 200 ml LB/amp culture for larger-scale culture (37°C, 250 rpm, 
overnight). 
The following morning, bacteria were transferred to 225 ml Falcon tubes for collection by 
benchtop centrifugation (2630 xg, 4°C, 15 min). The supernatants were discarded and 
the pellets detached from the bottom of Falcon tubes by gentle vortexing. Pellets were 
resuspended in 8 ml of Maxi-prep Resuspension Buffer on ice, followed by addition of 15 
ml of Maxi-prep Alkaline Lysis Buffer. Samples were mixed by gentle inversion then 
stood on ice for 3 min. 10 ml of Maxi-prep Neutralisation Buffer was added to each 
 
101 
sample and samples gently inverted until evenly mixed. Samples were stood on ice for 
10 min then re-centrifuged (2630 xg, 4°C, 10 min). 
The supernatants were transferred to 50 ml Oakridge tubes, avoiding transfer of debris 
and bubbles, then centrifuged (20,000 rpm [Beckman JA-25 rotor], 4°C, 15 min). 28 ml of 
supernatant was removed and transferred to a 50 ml Falcon, to which 17 ml of 
isopropanol was added. These tubes were incubated at RT for 15 min then centrifuged 
(2,000 xg, RT, 20 min). The supernatants were discarded and pellets washed by 
vortexing in 20 ml of 70% ethanol, then re-centrifuged (2,000 xg, RT, 3 min). All traces of 
residual ethanol were removed using a pipette. Pellets were re-suspended in 2.6 ml of 
1X TE for 2 hours under vigorous shaking on an orbital platform. At this point, 2.9 g of 
CsCl were added to each tube, dissolved fully, followed by 120 μl of 10 mg/ml EtBr. 
Following addition of EtBr, tubes were protected from light by covering with foil when on 
the bench. Tubes were centrifuged (2,000 xg, RT, 5 min) and the contents transferred to 
3.3 ml Optiseal TLN100 tubes. Pairs of tubes were balanced to within 0.01 g of each 
other by addition of additional CsCl/TE solution. Samples were centrifuged at ultra-high 
speed (85,000 rpm [Beckman TLN-100 rotor], RT, 18 h, brake = 0).  
The following day, the lower visible band in the tube (comprising partially-purified plasmid 
DNA) was harvested from Optiseal tubes using a 1 ml syringe and 23 gauge needle and 
transferred to a fresh 3.3 ml Optiseal tube. The tubes were filled and made to within 0.01 
g of each other by addition of CsCl/TE solution with additional 1 mg/ml EtBr. Tubes were 
re-centrifuged (95,000 rpm [Beckman TLN.100 rotor], RT, 5 h, brake = 0) and high purity 
plasmid DNA harvested as described previously. 
Harvested plasmid DNA was transferred to 1.5 ml Eppendorf tubes and 200 μl of 
HyClone™ water added. An equal volume of n-butanol was added to each tube and 
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mixed vigorously. The lower aqueous phase was transferred to a fresh 1.5 ml Eppendorf 
tube using a pipette and this process was repeated a further six times. After seven n-
butanol extractions, samples were transferred to 15 ml Falcon tubes and made up to a 
volume of 2 ml with 50 mM NaAc. To this, 4 ml of 100% ethanol was added and mixed 
gently by rocking. Samples were incubated at -20°C for 10 min then centrifuged (2000 
xg, 4°C, 15 min). The supernatants were discarded and all traces of ethanol removed 
prior to the addition of 400 μl of 1X TE. Samples were incubated (37°C, 25 min) with 
occasional mixing, until the DNA pellets were fully dissolved.  
Dissolved plasmid DNA was transferred into 1.5 ml Eppendorf tubes, to which 20 μl of 3 
M NaAc and 900 μl 100% ethanol were added. Samples were gently mixed until an 
obvious fibrous precipitate of DNA appeared, then stood at RT for 5 min. DNA was 
pelleted by centrifugation (18500 xg, 4°C, 2 min), the supernatant discarded and the 
pellet washed in 500 μl of 70% ethanol. Washed pellets were re-centrifuged as before, 
supernatant removed and the pellets were left in a sterile tissue culture hood until dried, 
typically for ~20-30 min. At this stage, highly purified plasmid DNA was resuspended in 
500 μl of 1X TE and incubated at 37°C for 30 min to permit rapid dissolution. Samples 
were mixed gently and stood overnight prior to quantitation the following day by 260 nm 
absorbance using a NanoDropTM 2000. 
200 ng of purified plasmid were electrophoresed on a 0.8% agarose gel with TAE/EtBr, 
to confirm purification of high-quality, supercoiled plasmid. 
2.10.4 Dual Luciferase Transfection assay 
All reporter plasmids to be tested were re-quantitated prior to each experiment to ensure 
accurate amounts were used. FUJIOKA cells in exponential growth were counted and 
harvested by centrifugation (x300 g, RT, 5 min) and resuspended in media to give a cell 
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density of 11.25 x 106/ml. 400 μl of FUJIOKA cells (i.e. 4.5 x 106) were transferred to 0.4 
mm electroporation cuvettes. 5 μg of experimental plasmid (using the pXPG-TK229 
backbone) and 1 μg of normalisation control plasmid (pRL-TK750) were added to each 
cuvette and mixed gently, then incubated at RT for 10 min. Cells were electroporated 
(270 V, 950 μF, exponential decay) using a Gene Pulser Xcell™ electroporator system, 
then allowed to recover (RT, 5 min). Following this, transfected FUJIOKA cells were 
carefully transferred to 6 well plates containing 9.6 ml of media and returned to routine 
culture conditions. 
The following day, cells to be stimulated were treated as described in 2.1.2. Following 
stimulation, all cells were harvested (x300 g, RT, 5 min) and prepared for luciferase 
reporter assays using a Dual-Luciferase Reporter Assay System kit, according to the 
manufacturer’s instructions. Luciferase data were acquired using the ‘Dual-Luciferase’ 
setting of a GloMax®-Multi+ Microplate Multimode Reader. Normalised luciferase data 
were calculated by dividing the Firefly (experimental) luciferase signal by the internal 
Renilla normalisation control signal.  
2.11 CRISPR deletion of the FoxC1 locus 
2.11.1 CRISPR sgRNA Design 
sgRNA sequences were identified 3’ to the FoxC1 start codon and 3’ to the stop codon 
using the Zhang group online CRISPR design tool. Guide sequences computationally 
predicted by the design tool to have minimal off-target effects were selected, and the 5’ 
ends of each were truncated by 2 nt according to Fu et al (2014)327 to further improve 
cleavage specificity. These sequences were ordered as pairs of complementary 
oligonucleotides to be compatable with downstream cloning steps (Table 2:6).  
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2.11.2 Generation of CRISPR-Cas9 expression constructs 
100 μM of sense and antisense oligonucleotides were phosphorylated and annealed in 
parallel using 5 U of T4 Polynucleotide Kinase (New England Biolabs) and 1X T4 
Ligation Buffer (New England Biolabs) by incubation at 37°C for 30 min, 95°C for 5 min, 
before slowly cooling to RT.   
Annealed oligonucleotides were cloned into sSpCas9(BB)-2A-GFP using the Golden 
Gate assembly cloning strategy328 as follows: 100 ng of circular PX458, 1 μM of 
annealed oligonucleotide, 1X NEB Buffer 2.1, 20 U BbsI restriction enzyme, 10 mM ATP, 
5 μg BSA, 750 U T4 DNA ligase in a 50 μl reaction volume. Reactions were carried out in 
a T3000 thermocycler using the following programme: 20 cycles of 37°C for 5 min, 20°C 
for 5 min; 1 cycle of 80°C for 20 min. 
Chemically competent JM109 E. coli cells were transformed and colonies screened as 
described in 2.10.1, using the U6 promoter forward primer (Table 2:6) to verify positive 
clones by Sanger sequencing (Source Bioscience). 
Colonies verified by sequencing to contain the correct sgRNA insert sequence were used 
to inoculate a 2 ml starter culture of LB/amp (37°C, 250 rpm, 6 h). 100 μl of starter 
culture was used to inoculate 200 ml of LB/amp in an Erlenmeyer flask for maxi-prep 
culture (37°C, 250 rpm, overnight). Endotoxin-free plasmid maxi-preps were obtained 
using a NucleoBond® Xtra Midi EF kit, following the manufacturer’s instructions. 
2.11.3 Transfection of CRISPR reagents 
4.5x106 FUJIOKA cells were suspended in 400 μl of antibiotic-free RPMI and 10% heat-
inactivated foetal calf serum for transfection with either 5 μg of PX458 (WT) or 5 μg of 
pairs of constructs containing 5’ and 3’ sgRNAs for FOXC1 gene deletion. Cells were 
transferred to 0.4 cm gap width cuvettes for electroporation (325 V, 30 msec, 0.4 cm) 
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using a Gene Pulser Xcell™ electroporator system (Bio-Rad).  Cells were allowed to 
recover at RT for 10 min, then transferred to 6 well plates in a 10 ml final volume of 40% 
Fujioka-conditioned medium. 48 h post-transfection, single GFP-positive cells were 
sorted using a FACSAria™ II cell sorter into 96 well plates containing 100 μl of 40% 
Fujioka cell-conditioned media (2.1.3) per well. Cells were expanded for at least 14 days 
prior to screening for deletions. 
2.11.4 PCR screening of clones for deletions 
Cells from each clone were isolated by centrifugation (300 xg, RT, 5 min) and genomic 
DNA extracted as described in 2.6.3. 20 ng of genomic DNA per clone was screened 
using Phusion® High-Fidelity PCR Master mix, 1X GC buffer, 1 M betaine and 200 nM of 
PCR cloning primers designed against either side of the intended FOXC1 deletion sites 
(Table 2:6), in 20 μl reactions in a T3000 thermocycler.  
Table 1:1 Thermocycling conditions used for PCR screening of CRISPR clones 
Step Temperature Time Number of cycles 
Denaturing 98ºC 30 sec 1 
Genomic amplification 
98ºC 10 sec 
25 62ºC 20 sec 
72ºC 60 sec 
Terminal elongation 
72ºC 5 min 
1 10ºC ∞ 
 
Clones carrying deletions were cultured under normal conditions to give sufficient 
numbers for analyses of FOXC1 gene expression (2.5.3). 
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2.12 shRNA-mediated knockdown of FOXC1 expression 
2.12.1 Cloning of shRNA expression vectors 
shRNA sequences targeting the human FOXC1 transcript were designed using the 
Broad Institute’s Genetic Perturbation Platform and selected based on the software 
algorithm’s highest predicted knockdown scores. These sequences were modified to 
have HpaI and XhoI restriction sites compatible for cloning into the LeGO-iG vector 
immediately downstream of the U6 promoter (Table 2:5 and Table 2:6). 
1 μg of sense and antisense oligonucleotides corresponding to these sequences (table) 
were annealed by heating to 95°C in a heatblock for 5 min then cooling slowly to RT by 
placing the heatblock on the bench. Annealed oligonucleotides were then digested using 
10 units each of HpaI and XhoI (37°C, 4 h). 5 μg of empty LeGO-iG vector was digested 
under the same conditions, then dephosphorylated by addition of 1 unit of Calf Intestinal 
Phosphatase and incubation (37°C, 30 min). Digested LeGO-iG vector was purified by 
1% agarose gel electrophoresis and a MinElute® Gel Extraction Kit, according to the 
manufacturer’s instructions. 
Digested oligonucleotide duplexes and vector backbone were ligated in a 3:1 
insert:vector ratio using T4 DNA ligase (37°C, 2h), according to the manufacturer’s 
instructions. JM109 E. coli were transformed with ligation products as previously 
described (2.10.2) prior to plating onto LB agar/amp plates before incubation (37°C, 
overnight). The following morning, plates were put into short-term storage at 4°C. That 
evening, single colonies were picked to inoculate 2 ml cultures of Terrific broth with 100 
μg/ml carbenicillin (TB/carb) and placed in a shaking incubator (37°C, 250 rpm, 
overnight).  The following morning, 500 μl of each overnight culture was mixed with 500 
μl of sterile 50% glycerol for long-term storage at -80°C. Plasmid mini-preps were made 
from the remaining 1.5 ml of overnight culture using a QIAprep® Miniprep kit, according 
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to the manufacturer’s instructions.  Colonies were validated for correct insert sequence 
and orientation by Sanger sequencing (Source Bioscience) using the U6 forward 
sequencing primer (Table 2:6). 
Colonies verified to be positive for the intended sequence were picked to inoculate a 3 ml 
TB/carb starter culture in a shaking incubator (37°C, 250 rpm, 6 h). 100 μl of starter 
culture was introduced into a 300 ml TB/carb culture for larger-scale culture (37°C, 250 
rpm, overnight). The following morning, endotoxin-free maxi-preps were prepared using 
a NucleoBond® Xtra Midi EF kit, according to the manufacturer’s instructions. Plasmids 
were quantitated by A260 absorbance using a NanoDrop™2000 spectrophotometer. 
2.12.2 Production of lentivirus in HEK 293T cells 
HEK 293T cells were re-plated 24 h prior to transfection, to reach a confluency of 80-
90% at time of transfection. On the day of transfection, fresh DMEM supplemented with 
10% FCS, 2 mM glutamine and penicillin/streptomycin was exchanged with the previous 
media present on HEK 293T culture plates. Prior to transfection, TransIT®-293 was 
brought to RT. For each transfection, a DNA mix was prepared containing the shRNA 
expression vector (30 μg) and the packaging vectors: Gag/Pol (1.2 μg); Tat (1.2 μg); Rev 
(1.2 μg) and VSV-G (2.4 μg). For each small (15cm3) TC dish to be transfected, 2 ml of 
OptiMEM™ was mixed with 90 μl of TransIT®-293 and incubated (RT, 15 min). The DNA 
mix described was then added to the OptiMEM™:TransIT®-293 mixture and incubated 
further (RT, 15 min). After this, DNA:TransIT®-293 mixture was added dropwise to the 
HEK 293T plates. Viral supernatant was collected after 24 h and every 12 h thereafter for 
a total of 48 h. 
2.12.3 Concentration of Lentiviral Supernatants 
Viral supernatant collected from the previous step was centrifuged at (1,660 xg, 4°C, 15 
min) to pellet cell debris. Cleared supernatant was then passed through a 0.45Pm disc 
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filter to remove residual cells and concentrated using a Centricon® Plus-70 100kDa filter 
(Millipore). Prior to loading viral supernatant, the column was washed with sterile water 
then centrifuged (2000 xg, 4°C, 25 min). Viral supernatant was then concentrated 
according to the manufacturer’s instructions. 
2.12.4 Lentiviral transduction of FUJIOKA cells 
2x106 FUJIOKA cells were transduced with the lentiviral concentrates prepared from 30 
cm3 of transduced HEK 293T cells and 8 μg/ml of polybrene by spinoculation (1500 xg, 
32°C, 2 h) in non-tissue culture treated 6-well plates. Following spinoculation, cells were 
allowed to recover in an incubator under normal culture conditions overnight. The 
following morning, viral media was aspirated and exchanged with fresh media. 72 hours 
post-transduction, the efficiency of transduction was estimated by measuring the 
proportion of eGFP-positive cells using flow cytometry. Cell sorting for GFP positive cells 
was performed using a FACSaria II by the College of Medical and Dental Sciences Core 
Technology Cell Sorting facility. 
2.12.5 Growth analyses of transduced FUJIOKA cells 
Sorted GFP+ FUJIOKA cells were seeded at a concentration of 0.1x106/ml in 10 ml of 
media and returned to the incubator. Cells counts were taken every 3-4 days then 
passaged to 0.1x106/ml in 10 ml of media. Cell growth rates were determined by 
calculating the true cell number (assuming all cells were retained following each 




Chapter 3: FoxC1 co-operates with Hoxa9 to activate a specific 
chromatin and transcriptional signature in AML 
 
A major focus of this study was to search for epigenetic and transcriptional mechanisms 
underlying the leukaemogenic consequences of FoxC1 derepression in AML. In this 
chapter I will explore mechanisms whereby FoxC1 becomes activated in parallel with 
HOX family genes and cooperates with Hoxa9 to activate specific genes and promote 
the development of AML, focussing on a mouse model developed by Tim Somervaille’s 
laboratory. 
3.1 FOXC1 expression is associated with enhanced accessibility of the 
HOXA cluster in human primary AML patients and cell lines 
Given that FOXC1 mRNA expression is strongly correlated with HOXA9 expression in 
primary human AMLs300, we sought to investigate whether changes in FOXC1 
expression were associated with specific changes in the accessible chromatin landscape 
at the HOXA9 locus. To this end, we initially performed DNase-seq and RNA-seq on 
cells from a representative FOXC1high FLT3-ITD primary human AML sample and the 
FUJIOKA cell line, which features comparatively high expression of FOXC1 relative to 
other human AML cell lines (Figure 3:1). These data were compared with data from cells 
expressing low or modest levels of FOXC1, including a representative FLT3-WT primary 
AML sample (both CD34+ and CD34- populations), K562 cells, and normal CD34+ 




Figure 3:1 FOXC1 is substantially expressed in primary FLT3-ITD AML patient samples, but not 
cell lines with FLT3-ITD. 
Expression levels of FOXC1 mRNA were compared by qRT-PCR analyses of cDNA prepared from a 
panel of leukaemia cell lines with or without FLT3-ITD, and the CD34 enriched/negative fractions 
(CD34+ and CD34-, respectively) of a representative FLT3-ITD primary human AML sample, 
ITD/NPM1-2.  
N.B. both FLT3-ITD AML cell lines are driven by MLL rearrangement oncogenes (MLLr+): MOLM-14 
features the MLL-AF9 fusion oncogene, while MV4-11 carries the MLL-AF4 translocation. 
 
Firstly, we confirmed that robust expression of FOXC1 in primary FLT3-ITD AML cells 
and FUJIOKA cells correlated with increased chromatin accessibility at the FOXC1 
promoter-proximal region and gene body, as shown by DNase-seq analyses (Figure 3:2). 
By contrast, a representative primary FLT3-WT AML sample and CD34+ PBSCs were all 
substantially less hypersensitive at the FOXC1 promoter. However, despite only modest 
detectable expression of FOXC1 in K562 cells by qRT-PCR analyses, the promoter-
proximal region of FOXC1 was found to be hypersensitive in contrast to the gene body, 




Figure 3:2 The FOXC1 locus is accessible and transcribed in FLT3-ITD AML patients and the 
FUJIOKA cell line. 
UCSC genome browser view of the human FOXC1 locus, showing DNase-seq and RNA-seq data for 
the FoxC1high FUJIOKA cells and FoxC1low K562 cells, together with data from representative FLT3-
ITD and FLT3 wild-type (FLT3-WT) primary AML samples and normal control CD34+ PBSCs. The 
promoter-proximal region of FOXC1 is highlighted in blue. 
 
 
At the HOXA gene cluster (Figure 3:3), a broad increase in chromatin accessibility and 
HOXA gene expression across the entire ~100 kb chromatin domain was associated with 
elevated expression of FOXC1 in both primary human AML samples and FUJIOKA cells. 
These included at least seven DHSs that were present in the primary FLT3-ITD AML and 
FUJIOKA cells but not the representative FLT3-WT AML sample or K562 cells. However, 
manual inspection of these DHSs revealed an absence of the 5’-RYMAAYA-3’ FOX 
consensus binding motif in all but one of these DHSs (DHS 3) that may indicate direct 




Figure 3:3 The HOXA gene cluster is also accessible and actively expressed in leukaemia cell 
lines and patients expressing FOXC1. 
UCSC genome browser view of the human HOXA gene cluster, showing DNase-seq and RNA-seq 
data for the FoxC1high FUJIOKA cells and FoxC1low K562 cells, together with data from representative 
FLT3-ITD and FLT3 primary AML samples and normal control CD34+ PBSCs. The HOXA9 gene is 
highlighted in blue. DHSs specific to FoxC1high samples are highlighted in pink and numbered at the 
bottom.  
 
Having substantiated a previously described correlation between FoxC1 and HOXA9 
expression at the level of chromatin accessibility, we went on to perform a detailed 
molecular analysis of open chromatin, TF occupancy and gene expression in a 
Hoxa9+FoxC1-dependent mouse model of AML. 
3.2 FACS immunophenotyping confirms robust engraftment of donor 
leukaemia cells, abnormal myeloid bias and impaired B cell 
differentiation in Hoxa9+FoxC1 AMLs 
A significant aspect of studies published by Somerville et al. (2015) was the development 
of a mouse model of AML driven by the ectopic expression of human FOXC1 together 
with murine Hoxa9. As summarised in Figure 3:4, this mouse model was generated from 
donor BM cells transduced with retroviral expression vectors for Hoxa9 with empty 
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mouse mammary tumour virus (MMTV) vector, or in combination with either FOXC1 or 
Meis1, an extensively-documented leukaemogenic partner of HOX proteins330–333.  
 
Figure 3:4 Overview of the Somervaille Hoxa9+FoxC1-dependent mouse AML model and 
downstream molecular analyses conducted in this study. 
Cryopreserved neoplastic/AML samples from the spleens of moribund mice generated in Somerville et 
al. (2015) were subjected to phenotypic analyses by multicolour flow cytometry, followed by DNase-
seq and RNA-seq to identify changes in accessible chromatin and gene expression. 
 
Previous studies of this mouse model involved extensive characterisation of the 
phenotypic consequences arising from co-expression of these proto-oncogenes, but the 
cis-regulatory elements and target genes through which FoxC1 and Hoxa9 act to 
promote leukaemogenesis remained unknown. To address this gap in knowledge, we 
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established a collaboration with the Somervaille laboratory to perform genome-wide 
chromatin accessibility, genomic occupancy and gene expression profiling on 
cryopreserved spleen samples from these leukaemic mice. To ensure that the spleen 
cells under investigation were predominantly engrafted AML cells, the purity of leukaemic 
cells within these samples was verified by flow cytometry prior to any downstream 
analysis.  
First, we assessed the extent to which CD45.1+ donor cells engrafted into the recipient 
animals from which the spleen samples were prepared (Figure 3:5). These analyses 
revealed robust engraftment of CD45.1+ donor cells in samples from all three Hoxa9 co-
expression mouse models, with Hoxa9+FoxC1 recipient mice featuring the highest 
proportion of donor cells (90.3% in a representative sample). CD45.1+ donor cell 
engraftment in the Hoxa9+Meis1 and Hoxa9+MMTV recipients was extensive, but not as 
high as observed in Hoxa9+FoxC1 recipients. Typical engraftment populations for these 
mouse represented ~75.6% and 63.9% of all cells in samples from Hoxa9+Meis1 or 
Hoxa9+MMTV recipients, respectively. Next, we assessed myeloid lineage bias within 
the CD45.1+ donor fractions of cells by examining expression of the CD11b and Gr1 
myeloid surface markers. Our analyses revealed that the CD45.1+ fractions from all 
mouse models were overwhelmingly enriched for the CD11b+Gr1+ myeloid markers, 
ranging from 81.7% to 97.8% of double-positive cells. In the case of Hoxa9+FoxC1 
recipients, there was a near-total absence of any cells lacking these markers (97.8% 
CD11b+Gr1+), indicating a strong myeloid bias in the engrafted donor cell populations 
within recipient spleens. Furthermore, the CD11b+Gr1+ fraction of Hoxa9+FoxC1 donor 
cells almost completely lacked expression of the B cell lineage marker B220 (97.0% 
B220-Gr1+CD11b+). The overwhelming majority of Hoxa9+FoxC1 donor cells instead 
expressed the immature B cell precursor marker CD43 (96.7% CD43+Gr1+CD11b+), 
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which is not consistent with normal B cell differentiation. This contrasted with 
Hoxa9+Meis1 and Hoxa9+MMTV CD45.1+ donor cells, which both featured modestly 
higher surface expression of B220 (1.1% and 3.9% for Hoxa9+MMTV and Hoxa9+Meis1 
respectively).  
 
Figure 3:5 Hoxa9+FoxC1 recipient mice feature substantial splenic infiltration of leukaemic cells 
as measured by FACS. 
The proportion of engrafted neoplastic cells in cyropreserved spleen samples was determined as the 
proportion of CD45.1+ donor cells within bulk samples also containing CD45.2+ host cells. Myeloid 
lineage bias was ascertained from the proportion of neoplastic donor cells expressing both CD11b and 
Gr1 surface markers. Evidence of B or T cell differentiation was examined by measuring the surface 
expression of the immature B lineage markers CD43 and B220, or the T cell markers CD4 and CD8. 
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Finally, CD45.1+ donor cell fractions from all samples lacked expression of the T cell 
lineage markers CD4 and CD8. Together with the near-complete effacement of CD45.2+ 
recipient cells within Hoxa9+FoxC1 samples (6.4% CD45.2+), these observations 
confirmed an abnormal myeloid lineage bias in spleens harbouring Hoxa9+FoxC1 AML 
cells.  
In contrast, FACS analyses of the minor populations of contaminating CD45.2+ host cells 
(Figure 3:6) revealed comparatively lower surface expression of the myeloid markers 
CD11b and Gr1 (20.1% to 37.1% Gr1+CD11b+). Furthermore, CD45.2+ host cells for all 
samples featured higher, more variable surface expression of the immature B cell marker 
B220, ranging from 13.7% to 51.7%. We also observed a markedly greater abundance of 
normal B lineage precursors, including pre-pro B cells as defined by the CD43+B220+ 
immunophenotype (3.5% to 7.4%) and CD43-B220+ pro-B cells (10.2% to 53.4%), in all 
three mouse models, consistent with more normal B cell differentiation in the host cell 
compartment. As with the CD45.1+ donor cells for each of the three different models, all 
CD45.2+ host cells were devoid of CD4 expression, a marker used to broadly define all 
four of the most common subsets of T helper cells334. However, there was a greater 
abundance of host CD4-CD8+ cytotoxic T cells as compared to the CD45.1+ donor cell 
fractions from all mice.  
To summarise, the relative proportions of different sub-populations within the CD45.2+ 
host cell compartment – particularly those with B lymphoid markers – were more 
consistent with that of a normal spleen. However, these cells formed a much smaller 
proportion of the overall number of cells in these samples compared to the CD45.1+ 
donor cell fractions. Collectively, our FACS analyses support previous observations of 
BM from the same mice that indicated a disruption of residual host haematopoiesis and 




Figure 3:6 Minor populations of contaminating host cells exhibit more mature B and T lineage 
characteristics as measured by FACS 
The proportion of recipient host cells in cyropreserved spleen samples was determined as the 
proportion of cells carrying CD45.2 expression. Myeloid, B and T lymphoid lineage characteristics 
using the same combination of immunophenotypic markers as for donor leukaemia cells described in 








3.3 FoxC1 collaborates with Hoxa9 to activate a specific chromatin 
signature in AML 
To gain insights into changes in the accessible chromatin landscape arising from Hoxa9 
and FoxC1-dependent leukaemic transformation, we performed genome-wide DNase-
seq on the same bulk splenic cells that had been profiled by FACS. For each of the three 
mouse models studied, several biological replicates were used to increase the 
robustness and reliability of analyses. In each case, one representative sample for each 
mouse model was taken forward for high depth sequencing to serve as an anchor 
sample used to generate the highest quality data (defined here as Fox-1, MTV-1 and 
Meis-1). 
 
Figure 3:7 Hoxa9 and FoxC1 activate a specific chromatin signature in mouse AMLs. 
A: Profiles of DNase-seq signal for the anchor samples for each pairwise oncogene expression 
condition (Fox-1, MTV-1, Meis-1), presented as 2 kb windows centred on the summits of distal DHSs. 
This analysis includes the union of all peaks in either Hoxa9+FoxC1 or Hoxa9+MMTV, ranked in order 
of increasing Fox-1 / MTV-1 DNase-seq signal fold-difference. DHSs exhibiting greater than a +/- 4-
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fold change were classified as differential DHSs. Populations of differential DHSs enriched and 
depleted in Hoxa9+FoxC1 AMLs are indicated to the left. 
B: Average DNase-seq peak coverage profiles for the three populations of DHSs identified in A. 
 
 
Comparisons between these anchor DNase-seq samples revealed a substantial degree 
of FoxC1-specific changes in chromatin accessibility. Firstly, co-expression of Hoxa9 
with FoxC1 was associated with the specific 4-fold upregulation of 2618 distal DHSs and 
4-fold downregulation of 2270 DHSs compared to the Hoxa9+MMTV cells (Figure 3:7). 
Furthermore, the global DHS profile of cells co-transduced with Hoxa9+Meis1 looked 
remarkably similar to those for Hoxa9+MMTV.  
Correlation clustering analysis of DNase-seq data from each of the mouse AML samples 
confirmed that FoxC1-dependent differences in global chromatin accessibility was a 
recurring feature seen in all three biological replicates for each AML sample (Figure 3:8). 
These findings were underlined by the observation that the global DHS profiles for 
biological replicates of Hoxa9+MMTV and Hoxa9+Meis1 samples closely correlated with 
each other in clustering analyses, but not with the Hoxa9+FoxC1 samples, which instead 
formed a single discrete cluster (Figure 3:8). Finally, the FoxC1-specific accessible 
chromatin signature presented in Figure 3:7 using the anchor samples Fox-1, MTV-1 and 





Figure 3:8 Hoxa9+FoxC1 AMLs feature a common accessible chromatin pattern that is distinct 
from both Hoxa9+Meis1 and Hoxa9+MMTV cells. 
Hierarchical clustering of the Pearson correlation coefficient scores for distal DHSs across several 
biological replicates reveals two discrete clusters.  
The first comprises the Hoxa9+FoxC1 AML samples, which are less similar to either 




Figure 3:9 The global DNase-seq distal DHS patterns of samples is consistent across multiple 
biological replicates. 
DNase-seq profiles are plotted as 2 kb windows, centred on the distal DHS summits. DHSs in all 
samples are ranked against the same genomic co-ordinates, sorted by increasing Fox-1 / MTV-1 
DNase-seq signal fold difference, as in figure 3:6A. 
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3.4 FoxC1-specific DHSs are enriched for distinct classes of TF binding 
motifs 
To investigate whether particular TFs might contribute to the establishment of the 
chromatin patterns defined in the previous section, we performed de novo motif 
discovery on the FoxC1-specific populations of enriched and depleted distal DHSs using 
HOMER314. 
 
Figure 3:10 Hoxa9+FoxC1 AMLs are enriched for distinct classes of TF motifs as compared to 
Hoxa9+MMTV samples. 
A: Results of a HOMER de novo motif discovery analysis performed on 2,618 Hoxa9+FoxC1-specific 
distal DHSs. 
B: Results of a similar analysis as (A), but performed on 2,270 distal DHSs specific to Hoxa9+MMTV 
samples. 
 
First, focussing on the 2,618 distal DHSs enriched in Hoxa9+FoxC1 AML cells, we 
observed a differential enrichment of FOX binding motifs, consistent with ectopic 
expression of FOXC1 in these samples as compared to the other two mouse models 
(Figure 3:10). Furthermore, a substantial proportion of Hoxa9+FoxC1-specific DHSs 
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were also distinguished by binding sites for MYB and MEIS family proteins, both of which 
are expressed in normal myeloid precursors335. Finally, we also found an 
overrepresentation of binding motifs for other myeloid-associated TFs, including RUNX, 
C/EBP and ETS family proteins.  
 
Figure 3:11 Hoxa9+FoxC1-specific DHSs are enriched for specific TF binding motifs 
Alignment of HOMER de novo motif co-ordinates to DNase-seq data sorted by increasing Fox-1/MTV-
1 fold-difference reveals enrichment of TF binding motifs which are Hoxa9+FoxC1-specific (top), 
Hoxa9+MMTV-specific (bottom left) and commonly enriched in both samples (bottom right). 
 
Subsequent analyses looking at the global distribution patterns of these motifs revealed 
that DHSs containing FOX, MYB, MEIS and C/EBP motifs were most selectively 
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enriched in the Hoxa9+FoxC1 AMLs and not Hoxa9+MMTV cells (Figure 3:11). 
Conversely, PU.1:IRF motifs were selectively enriched in Hoxa9+MMTV cells, while 
RUNX and ETS sites were distributed more uniformly across all three groups of DHSs.  
Analyses of the 2,270 distal DHSs specific to Hoxa9+MMTV revealed differential 
enrichment for binding motifs of TFs classically involved in myeloid cell function or 
differentiation, including AP-1 and KLF family TFs, and IRF:PU-1 composite sites161,336,337 
(Figure 3:10). Similar to the Hoxa9+FoxC1-upregulated DHSs, Hoxa9+MMTV-specific 
DHSs also featured substantial enrichment of binding sites for ETS and C/EBP family 
proteins, although the enrichment of C/EBP motifs was much less substantial than in 
Hoxa9+FoxC1-specific sites. 
Finally, the 30,807 DHSs identified as common to Hoxa9+FoxC1 and Hoxa9+MMTV 
cells were enriched for CTCF sites, in addition to the RUNX and ETS sites that were 
detectable in all three groups of DHSs.   
3.5 DHSs upregulated in Hoxa9+FoxC1 AML cells are defined by co-
localisation of specific TF binding sites 
To examine trends in motif enrichment revealed by our de novo discovery analyses, we 
performed motif bootstrapping to reveal significant co-localisation of different TF binding 
sites within the group of 2,618 Hoxa9+FoxC1-specific DHSs (Figure 3:10). These 
analyses identified a cluster of FOX, HOX, C/EBP, FOX:E and MYB motifs which 
significantly co-localised in DHSs specific to Hoxa9+FoxC1 cells, but not DHSs shared 
with or specific to either Hoxa9+FoxC1 or Hoxa9+MMTV cells. We performed a similar 
parallel analyses of the 2,270 Hoxa9+MMTV-specific DHSs. The enrichment of PU.1:IRF 
binding motifs within these DHSs was so strong that any co-localisation patterns were 
initially difficult to detect (Appendix 3:1). After excluding this motif from a subsequent 
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analysis, we determined that Hoxa9+MMTV-specific DHSs were also distinguished by 
co-localisation of HOX motifs with RUNX and AP-1 sites (Figure 3:12). 
 
Figure 3:12 Motif bootstrapping analysis reveals specific patterns of TF binding site co-
localisation in Hoxa9+FoxC1 AML-specific DHSs. 
A: Hoxa9+FoxC1 AML cells are defined by a cluster of co-localised FOX, HOX, C/EBP, FOX:E and 
MYB motifs within the group of 2618 Hoxa9+FoxC1-upregulated DHSs described in Figure 3:7. 
B: Hoxa9+MMTV cells instead are distinguished by a cluster of HOX, AP-1 and RUNX motifs within 
the specific group of 2270 Hoxa9+MMTV-upregulated DHSs described in Figure 3:7. 
 
3.6 Hoxa9+FoxC1 AML cells feature distinctive transcription factor 
occupancy patterns  
To identify specific changes in TF occupancy states between the different mouse 
models, we re-sequenced the DNase-seq libraries for the three anchor samples (MTV-1, 
Meis-1 and Fox-1) at high read-depth to permit digital DNase footprinting338. These 
analyses identified a total of 109,421 TF footprints, of which 26,292 were uniquely 
present in Hoxa9+FoxC1 cells, while 37,416 footprints were commonly present in all 




Figure 3:13 Analyses of digital footprinting data reveals specific groups of differentially 
footprinted sites in Hoxa9+FoxC1, Hoxa9+Meis1 and Hoxa9+MMTV samples 
Venn diagram showing the overlap of footprints identified in Hoxa9+FoxC1, Hoxa9+Meis1 and 
Hoxa9+MMTV cells. 
 
De novo motif discovery analyses performed on the Hoxa9+FoxC1-specific footprints 
revealed an overwhelming preferential abundance of occupied C/EBP (26%) and CTCF 
(11%) sites, together with more modest numbers of occupied Sp1 and ETS sites (~3% of 
sites). In addition, we observed a very low frequency of occupied REST and NF1 motifs 
(less than 1%) in the Hoxa9+FoxC1-specific footprints that were not found in either the 
Hoxa9+MMTV or Hoxa9+Meis1-specific groups (Figure 3:14). In contrast, 
Hoxa9+MMTV-specific and Hoxa9+Meis1-specific footprints were both preferentially 
enriched for AP-1, KLF and E-box sites instead. Surprisingly, the Hoxa9+FoxC1 
footprints did not feature a significant enrichment of FOX sites. Furthermore, the 
footprinting analysis identified RUNX motifs in just 0.3% of the Hoxa9+FoxC1-specific 
footprints, even though 31% of the specific DHSs contained a RUNX motif. This 




Figure 3:14 Analyses of digital footprinting data reveals Hoxa9+FoxC1 AML-specific patterns of 
motif occupancy. 
A-C: HOMER de novo motif result for footprints specific to: Hoxa9+FoxC1 (A); Hoxa9+MMTV (B); 










3.7 FoxC1 expression is associated with global changes in gene 
expression 
Given that forced expression of FoxC1 with Hoxa9 led to extensive specific changes in 
the accessible chromatin features of transduced cells, we sought to investigate the 
impact on gene expression arising from the activity of these proto-oncogenes by 
performing RNA-seq analyses on a subset of the same AML samples. Consistent with 
comparative DNase-seq analysis, Hoxa9+FoxC1 AML samples featured a distinct gene 
expression profile, forming a discrete cluster in correlation clustering analyses with the 
other samples (Figure 3:15). These findings were corroborated by a principal component 
analysis of individual RNA-seq samples, which demonstrated that Hoxa9+FoxC1 
samples formed a closely related group that was separated from Hoxa9+Meis1 and 
Hoxa9+MMTV samples along the first principal component (Figure 3:15).  
 
Figure 3:15 Hoxa9+FoxC1 AMLs feature a specific gene expression pattern. 
A: Hierarchical clustering of Pearson correlation coefficient scores of RNA-seq data generated for 
each pairwise oncogene expression condition. 




Figure 3:16 FoxC1-specific changes in chromatin accessibility are associated with a specific 
pattern of differential gene expression. 
To the left are DNase-seq profiles ranked by increasing Fox-1/MTV-1 DNase-seq signal fold 
difference, shown in 2 kb windows centred on the peak of the DHS summits. To the right are the 
corresponding changes in average RNA expression for the nearest genes of the DHS summits. 
Changes in RNA expression are calculated as fold changes of Hoxa9+FoxC1 AMLs relative to either 
Hoxa9+MMTV or Hoxa9+Meis1 samples. 
 
3.8 FoxC1-dependent changes in chromatin accessibility correlate with 
specific changes in gene expression  
Next, we sought to examine how changes in chromatin accessibility specific to 
Hoxa9+FoxC1 AMLs related to observed shifts in gene expression by integration of our 
DNase-seq and RNA-seq data (Figure 3:16). These analyses revealed widespread 
FoxC1-dependent downregulation of genes associated with nearby DHSs that were 
either depleted in Hoxa9+FoxC1 AMLs or present in all three mouse models. 
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Conversely, the most Hoxa9+FoxC1-enriched group of DHSs were associated with the 
specific upregulation of nearby genes. This pattern was strikingly consistent, irrespective 
of whether gene expression patterns in the Hoxa9+FoxC1 samples were compared to 
Hoxa9+Meis1 or Hoxa9+MMTV samples. This observation was underlined further by 
Venn diagram analyses demonstrating substantial overlaps of differentially expressed 
genes in Hoxa9+FoxC1 AMLs as compared to either Hoxa9+Meis1 or Hoxa9+MMTV 
samples (Figure 3:17). 
 
Figure 3:17 FoxC1-dependent changes in gene expression are broadly similar when compared 
to either Hoxa9 alone or Hoxa9+Meis1 AML cells. 
A: Overlap of up-regulated genes from analysed RNA-seq data in Hoxa9+FoxC1 samples relative to 
either Hoxa9+MMTV or Hoxa9+Meis1. 






Figure 3:18 Pairwise comparisons of RNA-seq data reveal FoxC1-dependent changes in gene 
expression. 
XY scatter plots of normalised mRNA expression values [log2(TPM+1)] from RNA-seq data are shown 
as pairwise comparisons between the three ectopic oncogene expression combinations. Significantly 
upregulated genes are plotted in red, and significantly downregulated genes in green. Genes not 
significantly changing in expression between two groups are plotted in black. 
 
 
To confirm trends in mRNA expression patterns revealed by the above global analyses, 
we performed pairwise comparisons of RNA-seq data to identify differentially expressed 
genes between two biological replicates of all three mouse models. These analyses 
revealed a comparatively weaker correlation between Hoxa9+FoxC1 AMLs and either 
Hoxa9+Meis1 or Hoxa9+MMTV (Figure 3:18). Furthermore, Hoxa9+Meis1 AMLs and 
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Hoxa9+MMTV samples correlated more robustly with each other. In fact, when taking 
adjusted p values (<0.05) into account, no genes were differentially expressed at a 
significant level between Hoxa9+Meis1 AMLs and Hoxa9+MMTV cells. 
3.9 FoxC1 and Hoxa9 repress the expression of genes associated with 
normal myeloid cell differentiation and innate immunity 
To gain an insight into pathways significantly deregulated by FoxC1 and associated 
target genes in mouse AML, we performed KEGG pathway analyses339 on sets of 
significantly differentially up- and downregulated genes in Hoxa9+FoxC1 AMLs. 
Strikingly, very few KEGG pathway terms were significantly enriched in the upregulated 
gene list for Hoxa9+FoxC1 AMLs as compared to either Hoxa9+Meis1 or Hoxa+MMTV 
cells (Table 3:1). With the exception of “metabolic pathways”, none of the terms 
annotated to Hoxa9+FoxC1-upregulated genes seemed to be of direct relevance to 
leukaemia. 
By contrast, KEGG pathway analyses of Hoxa9+FoxC1-downregulated genes as 
compared to Hoxa9+MMTV and Hoxa9+Meis1 revealed several statistically-significant 
(adj. p <0.05) KEGG annotations overtly related to the AML pathogenesis. For example, 
terms normally associated with terminally differentiated myeloid cells, including “Toll-like 
receptor signalling", “Cytokine-cytokine receptor interaction” and “NF-κB signalling" were 
all downregulated in Hoxa9+FoxC1 AMLs, regardless of whether the differential gene 
expression comparison was made against Hoxa9+Meis1 AMLs or Hoxa9+MMTV. 
Furthermore, manual inspection of genes annotated with these terms confirmed 
comprehensive downregulation of several critical mediators of normal monocyte and 
macrophage function, including the C-C motif chemokine ligand genes Ccl3 and Ccl4, 
and cell-surface receptors associated with monocyte/macrophage differentiation, Cd14 
and Csf1r. Together with a marked decrease in the expression of mature myeloid 
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markers, we observed downregulation of 5 IRF-family and 3 KLF-family TF genes, which 
promote terminal differentiation of myeloid and/or lymphoid lineages in normal 
haematopoiesis340,341 (Figure 3:19). This was accompanied by a modest downregulation 
of the tumour suppressor gene Foxo1, which was previously documented as a direct 
activator of Klf4 during lymphoid development342,343. Finally, we observed a modest but 
significant downregulation of the tumour suppressor genes Rb1 and Pten in 
Hoxa9+FoxC1 AMLs as compared to either Hoxa9+MMTV or Hoxa9+Meis1. 
Table 3:1 KEGG pathway analyses of differentially regulated genes in Hoxa9+FoxC1 AMLs. 
KEGG pathway enrichment analyses were performed on all significantly up- or downregulated genes 





Figure 3:19 Genes downregulated in Hoxa9+FoxC1 AMLs include myeloid-specific markers, 
tumour suppressors and transcription factors involved in terminal haematopoietic 
differentiation. 
A: Downregulation of myeloid-specific marker genes and the tumour suppressors Rb1 and Pten in 
Hoxa9+FoxC1 AMLs relative to Hoxa9+MMTV or Hoxa9+Meis1. 
B: Downregulated TF genes expressed during myeloid or lymphoid differentiation in Hoxa9+FoxC1 
AMLs as compared to Hoxa9+MMTV or Hoxa9+Meis1. 
mRNA expression changes are calculated from normalised RNA-seq data as the average fold change 
between Hoxa9+FoxC1 AMLs and either Hoxa9+MMTV (dark blue) or Hoxa9+Meis1 (light blue). All 
fold changes are statistically significant (adj. P < 0.05). 
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3.10 FoxC1 and Hoxa9 AMLs feature specific upregulation of 
transcription factor and leukaemia-associated target genes 
Because we observed specific enrichment of TF binding motifs in DHSs upregulated in 
Hoxa9+FoxC1 AMLs (3.4), we analysed RNA-seq data to identify whether any TF genes 
encoding the TFs binding these motifs were differentially regulated. In keeping with an 
overrepresentation of C/EBP, MEIS and MYB motifs, we observed striking 
Hoxa9+FoxC1-dependent upregulation of Cebpe and Meis2 together with modest 
upregulation of Myb as compared to Hoxa9+Meis1 or Hoxa9+MMTV (Figure 3:20). 
These analyses also revealed substantial upregulation of the TF gene Sox5, and of 
L3mbtl2, which encodes a non-canonical Polycomb regulator344. 
 
Figure 3:20 Specific upregulation of mRNA expression in Hoxa9+FoxC1 AMLs  
mRNA expression fold changes for genes upregulated in Hoxa9+FoxC1 AMLs as compared to 
Hoxa9+Meis1 AMLs or Hoxa9+MMTV, calculated from average normalised RNA-seq expression 






Figure 3:21 Meis2 and Cebpe are the only substantially upregulated genes of their families in 
Hoxa9+FoxC1 AMLs. 
A: Analyses of normalised RNA-seq expression values for the three Meis family genes together with a 
constitutively expressed gene, Tbp. Values are presented as the average of three RNA-seq replicates 
for each of Hoxa9+MMTV, Hoxa9+Meis1 and Hoxa9+FoxC1 AMLs. Error bars were calculated from 
the standard error of the mean for replicate samples. 
B: Similar analysis to A, but for C/EBP family genes, again with Tbp as an internal control. 
 
136 
Meis2 and Cebpe were among the most highly upregulated genes in Hoxa9+FoxC1 
AMLs, both appearing in the top 15% of upregulated genes as compared to 
Hoxa9+MMTV (log2 FC ≥ 1.5, adj. p < 0.05). Because both of these genes belong to 
wider families of TFs, we manually inspected the RNA-seq expression levels for each 
family member (Figure 3:21). These analyses confirmed that both Cebpe and Meis2 
were the most substantially upregulated genes in their respective families in 
Hoxa9+FoxC1 AMLs as compared to either Hoxa9+MMTV or Hoxa9+Meis1 cells. Cebpd 
was the only other C/ebp family gene that showed a modest trend of upregulation in 
Hoxa9+FoxC1 AMLs, however this was not statistically significant (Hoxa9+FoxC1 vs 
Hoxa9+MMTV adj. p = 0.18). Conversely, the other C/EBP family genes Cebpb and 
Cebpg were significantly downregulated in Hoxa9+FoxC1 AMLs (Hoxa9+FoxC1 vs 
Hoxa9+MMTV adj. p = 0.008 and 0.007, respectively), possibly due to feedback 
regulation. Finally, Cebpa showed a trend of downregulation in Hoxa9+FoxC1 AMLs, 
although this was not statistically significant (Hoxa9+FoxC1 vs Hoxa9+MMTV adj. p = 
0.12). Similar RNA-seq analyses for the Meis family genes confirmed that only Meis2 
was upregulated in Hoxa9+FoxC1 AMLs as compared to the other samples. 
Finally, in addition to Hoxa9+FoxC1-specific upregulation of these TF and chromatin 
regulator genes, we observed an increase in mRNA expression levels of the LSC marker 
Prom1345,346, the tumour-specific antigen Rgs5347, the tumour-associated Olfm4348 and 




3.11 Integrative analyses of DNase-seq and RNA-seq data reveals cis-
regulatory elements potentially involved in the activation of 
Hoxa9+FoxC1 target genes  
To identify specific DHSs that may be involved in Hoxa9+FoxC1-specific patterns of 
gene expression, we integrated the overlap between commonly up-/downregulated 
mRNAs and DHSs that are annotated to the same gene (Figure 3:22).  
 
 
Figure 3:22 Commonly changing DHSs and gene expression in Hoxa9+FoxC1 AMLs are largely 
similar whether compared to Hoxa9+Meis1 or Hoxa9 alone. 
Venn diagram analyses showing the overlap of commonly upregulated (top) or downregulated 
(bottom) DHSs and mRNA expression in Hoxa9+FoxC1 AMLs as compared to either Hoxa9+Meis1 or 
Hoxa9 alone. 
A 4-fold difference in DNase-seq signal was used to define differential DHSs, while a 2-fold difference 




These analyses revealed 141 upregulated genes in Hoxa9+FoxC1 AMLs that also had 
local upregulated DHSs, compared to both Hoxa9+Meis1 and Hoxa9+MMTV. 
Conversely, we observed 360 downregulated genes with commonly downregulated local 
DHSs in Hoxa9+FoxC1 AMLs as compared to both Hoxa9+Meis1 and Hoxa9+MMTV. 
Furthermore, consistent with previous observations of either DNase-seq or RNA-seq 
data from these samples, there was substantial overlap in Hoxa9+FoxC1-specific genes, 
regardless of whether this was relative to Hoxa9+Meis1 AMLs or Hoxa9+MMTV. 
Filtering these results for genes only with substantially changing mRNA expression (2 
fold up-/downregulated in Hoxa9+FoxC1 vs Hoxa9+MMTV, adj. p <0.05) revealed 57 
upregulated genes and 187 downregulated genes in Hoxa9+FoxC1 AMLs (Appendix 
3:2).  
Manual inspection of several genes identified by these analyses revealed Hoxa9+FoxC1-
specific changes in chromatin accessibility that were associated with enhanced gene 
expression (Figure 3:23 and Figure 3:24). For example, Hoxa9+FoxC1-dependent 
upregulation of Myb expression was associated with enhanced hypersensitivity across 
the gene locus, as well as the presence of six footprints in Hoxa9+FoxC1 alone. Similar 
examples were observed at the Cebpe, Prom1, Sox5, L3mbtl2 loci and elsewhere, many 
of which featured evidence of Hoxa9+FoxC1-specific occupancy patterns in the form of 




Figure 3:23 Hoxa9+FoxC1-specific activation of target genes 
A-D: UCSC genome browser views of DNase-seq and RNA-seq data for four genes (Myb, Cebpe, Prom1 and Sox5) which are specifically upregulated in 
Hoxa9+FoxC1 AMLs. Specific footprinted sites in Hoxa9+FoxC1 cells (Fox-1 ∆FPs) are indicated above the DHS tracks with red asterixes. 







Figure 3:24 Hoxa9+FoxC1-specific activation of target genes (further examples) 
A-D: UCSC genome browser view of DNase-seq and RNA-seq data for four genes (L3mbtl2, Olfm4, Rgs5 and Piezo2) which are specifically upregulated in 
Hoxa9+FoxC1 AMLs. Specific footprinted sites in Hoxa9+FoxC1 cells (Fox-1 ∆FPs) are indicated above the DHS tracks with red asterixes. 







Figure 3:25 FoxC1 expression is associated with activation of the Polycomb group 
gene L3mtbl2. 
A: (Left) UCSC genome browser snapshot showing a Hoxa9+FoxC1-specific DHS close to the second 
exon of L3mbtl2.  
(Right) Detail of Hoxa9+FoxC1-specific patterns of genomic occupancy within the L3mbtl2 DHS, as 
revealed by very high read depth digital DNase-seq footprinting analyses. The upper strand (US) and 
lower strand (LS) DNase cut patterns are shown, revealing a Hoxa9+FoxC1-specific strand cutting 
imbalance indicative of specific occupancy. 
B: Analyses of RNA-seq expression data for L3mbtl2 together with other constitutively-expressed PRC 






Further inspection of the L3mtbl2 locus revealed a Hoxa9+FoxC1-specific DHS present 
at the second exon which featured two differentially-footprinted sites (Figure 3:25). The 
first footprint occupied a CTCF site, while the second footprint site spanned one ETS 
motif and at least one FOX motif. Because L3mbtl2 encodes a non-canonical PRC 
repressor protein which deposits repressive chromatin modifications as part of a larger 
multi-subunit complex350, we examined the mRNA expression levels of known interacting 
partners of L3mbtl2. In contrast to robust Hoxa9+FoxC1-dependent upregulation of 
L3mbtl2, the expression of various other subunits of the L3mbtl2 complex were largely 
invariant between the three different mouse models. 
3.12 Activation of the Meis2 locus in Hoxa9+FoxC1 AMLs 
Because upregulation of Meis2 mRNA was a particularly striking event in Hoxa9+FoxC1 
AMLs, we examined the DNase-seq data in more detail at the Meis2 locus to identify 
specific DHSs that may account for these changes. Indeed, we found 19 Hoxa9+FoxC1-
specific DHSs that were associated with the Meis2 locus, including a cluster of four 
promoter-proximal sites and at least 15 distal sites (Figure 3:26).   
To gain insight into the regulatory potential of DHSs activated at the Meis2 locus in a 
FoxC1-dependent manner, we inspected the underlying DNA sequences for TF binding 
motifs and evidence of evolutionary conservation. Furthermore, these findings were 
integrated with genomic occupancy data obtained both from our high-resolution DNase I 
digital footprinting analyses, publicly available ChIP-seq datasets for FoxC1351 and 





Figure 3:26 FoxC1 activates the Meis2 proto-oncogene. 
Top: UCSC genome browser view of DNase-seq data at the Meis2 locus. Differential DHSs 
specifically present in Hoxa9+FoxC1 AMLs are indicated in boxes. Footprinted sites within these 
DHSs that were occupied only in a Hoxa9+FoxC1 AML (Fox-1 ΔFPs) are indicated above the DNase-
seq tracks. 
Middle: ChIP-seq data from Amin et al. (2015) confirms Meis2 occupancy by FoxC1 in a different cell 
context. This includes binding at the Meis2 promoter and a distal regulatory element (red boxes) which 
are also activated in Hoxa9+FoxC1 AMLs. ENCODE CTCF ChIP-seq data identifies commonly 
occupied sites in normal bone marrow (BM) and spleen from isogenic mice. 




Table 3:2 Regulatory potential of Hoxa9+FoxC1-specific DHSs present at the Meis2 locus. 
Occurrence of TF binding motifs and genome occupancy events in Hoxa9+FoxC1-specific DHSs at 
the Meis2 locus are indicated. Distal DHSs were qualitatively scored for their gene regulatory potential 
according to the following criteria: 
   Digital DNase I Footprint +2 for each footprint 
   FOX, ETS, RUNX, CTCF motif: +1 for each motif occurrence [within the DHS window]. 
   All other motifs*:  +0.5 for each motif occurrence.  
   CTCF ChIP-seq:  +2 for high-confidence binding (> 20 mapped reads) in both BM and Spleen. 
   FoxC1 ChIP-seq:  +1 for weak binding (>12 uniquely mapped reads, presented as +);  
   +2 for strong binding (> 20 uniquely mapped reads, presented as ++); 
   (ofs. = ChIP peak summit occurred in proximity to but offset from DHS summit). 
   Active H3 Modifications: +0.25 for every enrichment (>  5 uniquely mapped reads) in either BM or Spleen. 
   Genomic Conservation: +1 for high evolutionary conservation (PhyloP placental mammals); 
   -1 for no conservation. 





These analyses confirmed enrichment of conserved TF binding motifs – in particular 
FOX, ETS and/or RUNX sites - at all of the Hoxa9+FoxC1-specific DHSs (Table 3:2). 
Many of these DHSs were also characterised by an enrichment of three histone marks 
associated with gene activation, including H3K4me1+3 and H3K27ac. Significantly, we 
detected the presence of least one differential TF footprint in six of these Hoxa9+FoxC1-
specific DHSs, suggesting that these sites may play a direct role in the regulation of 
Meis2 in Hoxa9+FoxC1 AMLs. 
3.13 Features of the Meis2 promoter-proximal DHS cluster, P:1-P:4 
TF binding motif enrichment, active histone modifications and evidence of TF occupancy 
were all observed at the promoter-proximal DHS cluster of sites P:1 to P:4 (Figure 3:27). 
Firstly, P:1 featured a highly conserved FOX binding motif close to the DHS summit, 
which overlapped with CTCF binding in ChIP-seq data from normal BM and spleen, 
where Meis2 is active. Furthermore, P:1 was also enriched for all three activating histone 
marks in normal BM and spleen. Next, P:2 was distinguished by a specific C/EBP 
footprint within the DHS and strong enrichment of the active enhancer-associated marks 
H3K4me1 and H3K27ac. Third, the P:3 DHS was found to be flanked by two conserved 
FOX binding motifs, one of which is bound by FoxC1 in ChIP-seq data from an 
embryonic tissue with high Meis2 expression. Furthermore, the P:3 DHS featured two 
Hoxa9+FoxC1-specific footprints, one spanning the part of a FOX site and a GC-box like 
motif, and the other occupying a Sp1 motif. Finally, P:4 exhibited the greatest 
evolutionary conservation of all the DHSs in this cluster and featured an upstream FOX 
motif which was also occupied in FoxC1 ChIP-seq data. The entire P:4 DHS was 
enriched for all three activating histone marks in normal BM and spleen.  
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Detailed DNA sequence analyses of the P:1-P:4 cluster (Figure 3:28) revealed the 
presence of other TF binding motifs in addition to FOX sites at these DHSs, including 
SOX, ETS and Sp1 motifs within these hypersensitive sites. 
 
 
Figure 3:27 A cluster of Meis2 promoter-proximal DHSs are specifically activated in 
Hoxa9+FoxC1 AMLs. 
(Left to right) UCSC genome browser views of four FoxC1-specific promoter-proximal DHSs (P:1 – 
P:4, in order of increasing genomic distance from the 5’ UTR of Meis2.  
DNase-seq data are shown together with 9 public ChIP-seq datasets (top to bottom = 1-9), 
Hoxa9+FoxC1-specific DNase I digital footprints, PhyloP evolutionary conservation data, FOX 
consensus binding motifs and the measured offset (in base pairs) between Hoxa9+FoxC1-specific 
DHS and FoxC1 ChIP-seq summits from another study. 
(1) FoxC1 ChIP-seq data from a study of mouse embyronic 2nd pharangeal arch (2nd P. arch), where Meis2 is 
highly active. 
(2-3) ENCODE CTCF ChIP-seq data from normal C57BL/6 mouse BM and spleen (Spl). 
(4-9) ENCODE ChIP-seq data also from BM and Spl for three histone modifications associated with gene 





Figure 3:28 Meis2 promoter-proximal DHSs are enriched for FOX and other TF binding motifs. 
P:1 – P:4: DNA binding motif content for each of the four FoxC1-specific promoter-proximal DHSs 
described in Table 3:3 and Figure 3:19.  
FOX binding motifs are highlighted in blue, and binding sites for other TFs also expressed in 
Hoxa9+FoxC1 AMLs are highlighted in orange. 
Occupied bases in Hoxa9+FoxC1-specific DNase I digital footprints are indicated with red asterixes. 
 
3.14 Features of distal DHSs in Hoxa9+FoxC1 AMLs at the Meis2 locus 
In addition to the promoter-proximal DHS cluster already described, we identified several 
distal DHSs which were present or substantially upregulated only in the Hoxa9+FoxC1 
AMLs that may be related to the expression of Meis2. These included two intragenic 
DHSs, I:1 and I:4, which both featured specific evidence of FOX motif occupancy in 




Figure 3:29 Hoxa9+FoxC1-specific intragenic DHSs at the Meis2 locus feature high confidence 
FOX occupancy patterns. 
A: (Left) UCSC genome browser view of the I:4 DHS (+20 kb from the Meis2 5’ UTR) showing 
Hoxa9+FoxC1-specific accessibility by DNase-seq, FoxC1 binding by ChIP-seq and FOX motif 
occupancy using high-resolution DNase-seq digital footprinting analyses. 
(Right) detail of occupied FOX sites as revealed by very high read depth digital DNase-seq footprinting 
analyses. The upper strand (US) and lower strand (LS) DNase cut patterns are shown, revealing a 
Hoxa9+FoxC1-specific strand cutting imbalance indicative of specific occupancy. The site indicated 
FOX* is a non-canonical FOX motif which can nevertheless be bound by FOX proteins. 
B: (Left) UCSC genome browser view of the I:1 DHS (+12.8 kb from the Meis2 5’ UTR) showing 
Hoxa9+FoxC1 specific accessibility and TF occupancy through analyses of high-resolution DNase-seq 
data. 
(Right) detail of occupied FOX site revealed by high read depth digital DNase-seq footprinting 
analyses as in (A). 
 
Either side of the Meis2 gene, we identified two Hoxa9+FoxC1-specific DHSs, D:1 and 
D:2, which both featured evidence of CTCF binding in normal BM and spleen151,335 as 
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revealed by analyses of ENCODE ChIP-seq data. Additionally, analyses of the DNA 
sequences in site D:1 revealed the presence of the sequence 5’-GTGCAGTACC-3’ 
immediately upstream of the main CTCF consensus, making a conserved CTCF-
composite site that is predicted to have insulator activity (Figure 3:30)352. Critically, our 
DNase I digital footprinting analyses revealed that the composite CTCF insulator site at 
D:1 was occupied in a Hoxa9+FoxC1-specific manner. Furthermore, both D:1 and D:2, 
together with several other distal DHSs, were found to be occupied by FoxC1 in ChIP-
seq data from another study as observed at the promoter-proximal cluster of DHSs 
(Table 3:2). 
 
Figure 3:30 The Meis2 D:1 DHS contains a conserved CTCF composite site with predicted 
insulator activity. 
A: UCSC genome browser view of the Meis2 D:1 DHS featuring evidence of CTCF occupancy in 
normal mouse BM and spleen as shown by ENCODE ChIP-seq data. A Hoxa9+FoxC1 AML-specific 
footprint overlapping a CTCF site is indicated below. 
B: (Top) genomic sequence detail of a putative CTCF composite site differentially occupied in a 
Hoxa9+FoxC1 AML, as evidenced by DNase I digital footprinting. (Bottom) conservation of the D:1 site 
(core sequences highlighted) with the consensus CTCF composite motif, with conserved bases 
connected by vertical dashes. 
 
Interestingly, we observed FoxC1 binding at the Meis2 locus often occurred close to 
Hoxa9+FoxC1-activated DHSs, but outside of the DNase I-hypersensitive region, 
consistent with nucleosomal binding (Figure 3:31). Offset binding of FoxC1 with respect 
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to nearby DHSs was an unexpected event, given that ChIP-seq signal for most TFs 
commonly overlap with hypersensitive regions, but this was a recurring event we also 
noticed in directly comparable DNase-seq and ChIP-seq datasets generated in FUJIOKA 
cells, which are discussed in Chapter 4. Finally, as our digital DNase I footprinting 
algorithm only detects TF occupancy patterns as they exist in accessible chromatin, 
putative offset binding of FoxC1 may also explain why we unexpectedly did not observe 
a significant enrichment of occupied FOX motifs in our global footprinting analyses 
(Figure 3:14). 
 
Figure 3:31 Offset binding of FoxC1 relative to Hoxa9+FoxC1 AML specific DHSs, and other 
features of elements activated at the Meis2 locus. 
UCSC genome browser views of two FoxC1-specific DHSs together with public ChIP-seq datasets, 
evolutionary conservation, FOX consensus binding motifs and offset FoxC1 binding in ChIP-seq from 
another study.  
A: The +208 kb intergenic DHS (D:2) features a Hoxa9+FoxC1 specific CTCF footprint, together with 
CTCF peaks in normal BM and spleen ChIP-seq data. This region is also distinguished by enrichment 
of activating histone marks H3K4me1+3 and H3K27ac. Three highly-conserved FOX binding motifs 
are present at this site and are occupied by FoxC1 in an unrelated tissue. FoxC1 ChIP-seq signal is 
enriched outside the DHS, with the FoxC1 ChIP-seq summit in this window offset from the D:2 DHS 
summit by ~125 bp. 
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B: The +17.5 kb intragenic DHS (I:3) features modest enrichment of all three histone marks, but 
particularly the H3K27ac modification associated with active enhancer regions. This window features 6 
FOX consensus binding sites, 5 of which are highly conserved. FoxC1 ChIP-seq data reveals this site 
to be occupied in an unrelated tissue, with maximal binding positioned ~600 bp downstream from the 
I:3 DHS summit. 
 
3.15 Genes deregulated by Hoxa9 and FoxC1 in mouse AML are 
commonly deregulated in FLT3-ITD human AMLs 
 
Given that FOXC1 was previously reported as a target gene of FLT3-ITD in human AML 
patients, where it was associated with specific changes in gene expression, chromatin 
accessibility and TF occupancy patterns271, we sought to investigate commonalities 
between the genes deregulated in FoxC1-dependent mouse AMLs and human FLT3-ITD 
AML patients. 
A comparison of differentially expressed mRNAs in the Hoxa9+FoxC1 AMLs (log2 FC ≥ 
1.0, p <0.05) revealed substantial overlap with the FLT3-ITD AML target genes identified 
in Cauchy et al. (2015) (Figure 3:32). Firstly, 11 of the 134 genes specifically upregulated 
in FLT3-ITD AML patients were also significantly upregulated in Hoxa9+FoxC1 mice, 
including Prickle1 (Table 3:3), previously connected with leukaemogenesis353. Further 
inspection of the chromatin landscape surrounding commonly upregulated genes 
revealed the presence of Hoxa9+FoxC1-specific DHSs and TF footprints, for example at 




Figure 3:32 FoxC1 activates a modest number of target genes in mouse AMLs that are common 
with human FLT3-ITD+ AML patient samples. 
Venn diagrams showing the overlap between Hoxa9+FoxC1 specific targets in mouse AMLs 
(compared to Hoxa9 alone) and FLT3-ITD-specific upregulated and downregulated genes (A and B 
respectively) in primary human AML samples from microarray analyses in Cauchy et al. (2015). 
Expression thresholds for significantly upregulated and downregulated genes in the mouse AML RNA-






Figure 3:33 Evidence of Hoxa9+FoxC1-specific regulation of commonly upregulated genes in human FLT3-ITD AMLs 
A-D: UCSC genome browser view of DNase-seq and RNA-seq data for four loci (Krt18, Prickle1, Spry2 and the Prtn3/Elane cluster) which are 
commonly upregulated both in Hoxa9+FoxC1 AMLs and the Cauchy et al. (2015) FLT3-ITD-specific gene list. DHSs which feature specific footprints in 
Hoxa9+FoxC1 cells are indicated with red asterixes. 
 genome browser view of DNase-seq and RNA-seq data for four loci (Krt18, Prickle1, Spry2 and the Prtn3/Elane cluster) which are commonly 
upregulated both in Hoxa9+FoxC1 AMLs and the Cauchy t al. (2015) FLT3-ITD-specific gene list. DHSs which feature specific footprints in Hoxa9+FoxC1 






Table 3:3 Hoxa9+FoxC1 AMLs share commonly activated and repressed genes with primary 
FLT3-ITD+ AML patient samples.  
Analysis of RNA-seq mRNA expression fold changes of Hoxa9+Foxc1 relative to Hoxa9+MMTV for 
significantly deregulated genes that are common to those of human FLT3-ITD AML patient samples 
from Cauchy et al. (2015). Genes coloured in grey are significantly deregulated, but fall below the 





Next, 28 of the 77 genes specifically downregulated in FLT3-ITD human AMLs were also 
downregulated in the Hoxa9+FoxC1 AML samples, including the pro-apoptotic factor 
Xaf1354 and murine orthologues of the human major histocompatibility (MHC) genes 
HLA-DMB and HLA-DQA1.  
Finally, as downregulation of MHC genes was a significant feature of human FLT3-ITD 
AMLs, and MHC genes diverge significantly between species355, we investigated the full 
complement of MHC genes in FoxC1-dependent mouse AMLs that were significantly 
deregulated. Three of the MHC genes downregulated in the human AMLs were also 
down-regulated in the mouse Hoxa9+Meis1 AML, plus we observed substantial 
downregulation of a further 12 MHC genes in Hoxa9+FoxC1 AMLs, 11 of which had 
conserved human orthologues (Table 3:4). 
Table 3:4 Widespread downregulation of major histocompatibility complex genes is a feature of 
the Hoxa9+FoxC1 leukaemia gene expression signature. 
RNA-seq data were analysed as in Table 3:2 and 3:3, with any human orthologues commonly 
downregulated in FLT3-ITD AML patient samples from Cauchy et al. (2015) excluded from this 
analysis to avoid duplication. 
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Chapter 3: Discussion 
3.16 DNase-seq analyses support existing gene expression data to 
indicate a functional relationship between FOXC1 and HOXA9 in primary 
human AML samples and cell lines 
Previous studies had ascertained a positive correlation between mRNA expression of 
FOXC1 and HOXA9 in human AMLs300, although it remained unclear whether there was 
a direct relationship between the way these two genes were regulated in AML. Through 
DNase-seq profiling of primary human AML samples and cell lines with varying levels of 
HOXA9 and FOXC1 mRNA expression (Figure 3:2 and Figure 3:3), we observed that the 
entire HOXA chromatin domain featured increased accessibility in samples with higher 
FOXC1 expression, strengthening the possibility of a functional relationship between the 
regulation of these two TF genes. 
3.17 Hoxa9+FoxC1 donor cells carry an abnormal myeloid phenotype 
consistent with the development of AML 
Our FACS immunophenotyping analyses indicated that all the mouse AML samples 
studied contained a sufficiently high proportion of CD45.1+ donor leukaemic cells to 
permit detailed downstream molecular analyses (Figure 3:5). These data confirmed that 
the Hoxa9+FoxC1-dependent AMLs infiltrated recipient spleens most extensively, closely 
followed by Hoxa9 with Meis1, a widely-documented oncogenic partner of Hoxa9330–332. 
Comparatively lower levels of engraftment for cells transduced with Hoxa9+MMTV is also 
consistent with findings elsewhere that the forced expression of Hoxa9 alone is not 
sufficient to induce frank leukaemia in mice in the absence of additional genetic factors, 
instead causing a myeloproliferative disorder356.  
We also observed that the CD45.1+ donor fractions of all samples studied were enriched 
for the CD11b and Gr1 myeloid surface markers, but that this was most striking in 
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Hoxa9+FoxC1 AMLs. Considering that a healthy mouse spleen is comprised of ~80% 
lymphoid cells357, these findings alone are indicative of a significant disruption to normal 
haematopoiesis. In another study of an MLL-AF9-driven mouse model of AML, 90% of 
LSCs detected in recipient spleens carried the Gr1+Cd11b+ phenotype, suggesting that 
the Hoxa9+FoxC1 samples were also enriched for LSCs and AML blast cells358. Finally, 
CD45.1+ donor cells also featured abnormally high levels of the primitive B cell marker 
CD43, which is normally lost from all but a minority population of peripheral B cells that 
reside in the spleen359. Critically, our FACS observations are consistent with previously 
published analyses of BM samples from the same mice300.  
Due to the substantial enrichment of abnormal CD45.1+ myeloid-like cells within these 
samples, we did not consider that the contaminating host cell populations - which were 
also much more heterogeneous in nature - were likely to impede subsequent genome-
wide analyses. These assumptions were corroborated by our RNA-seq analyses (Figure 
3:19), which demonstrated substantial Hoxa9+FoxC1-dependent downregulation of 
mature myeloid marker genes including Cd14 and three chemokine (C-C) motif ligand 
genes Ccl3, Ccl4 and Ccl6360–362. Furthermore, the striking concordance between 
DNase-seq and RNA-seq profiles of Hoxa9+MMTV and Hoxa9+Meis1 AMLs (Figure 3:7 
and Figure 3:17), despite varying levels of CD45.2+ cell composition between the two 
groups, are a strong indication that the CD45.2+ cells make a marginal contribution to our 
analyses. 
The Hoxa9+FoxC1-specific depletion of DHSs containing IRF binding motifs, in parallel 
with the downregulation of five Irf transcription factor genes, are strong indications that 
downregulation of normal myeloid-associated gene expression patterns is a defining 
feature of Hoxa9+FoxC1-dependent leukaemogenesis (Figure 3:11and Figure 
3:19)336,340,341,363. Trends observed by manual inspection of differentially-expressed gene 
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lists in the FoxC1-dependent AMLs were supported by KEGG pathway analyses (Table 
3:1), which revealed significant downregulation of numerous genes that are active in 
normal immune cells, including Toll-like receptor, TNF and NF-κB signalling364,365.  
3.18 FoxC1 promotes widespread reprogramming of accessible 
chromatin and gene expression in AML via the deregulation of proto-
oncogene TFs 
In this study, we sought to expand upon previous phenotypic analyses of FoxC1 in AML 
by identifying the target genes and cis-regulatory elements differentially regulated in 
FoxC1-dependent AMLs. We were successful in demonstrating a specific and robust 
chromatin signature activated in Hoxa9+FoxC1-dependent AMLs (Figure 3:7, Figure 3:8 
and Figure 3:9), which strongly correlated with changes in gene expression (Figure 3:16 
and Figure 3:17).  
We dissected the accessible chromatin signature of Hoxa9+FoxC1 AMLs further by 
investigating the TF motif composition of the most specific DHSs in these cells, and 
identified a FoxC1-dependent enrichment of C/EBP, MEIS and MYB binding motifs. 
These analyses were corroborated by motif co-localisation analyses, revealing that these 
DHSs were defined by an enrichment of HOX, FOX, C/EBP and MYB motifs (Figure 
3:12). Collectively, these global analyses implicated these factors as principal regulators 
of the Hoxa9+FoxC1-dependent transcription network. This was in contrast to an 
underlying motif binding signature of PU1:IRF, HOX, RUNX and AP-1 sites defining 
Hoxa9+MMTV-specific DHSs, which was lost from the Hoxa9+FoxC1 AML cells. 
The Hoxa9+FoxC1-specific enrichment of de novo C/EBP motifs (Figure 3:10 and Figure 
3:11), occupied C/EBP sites (Figure 3:13), and striking upregulation of Cebpe (Figure 
3:21), strongly suggests that deregulation of C/EBP proteins is a significant event in 
FoxC1-dependent transformation. Although upregulation of C/EBP family proteins, 
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including Cebpe in mice, is typically associated with myeloid progenitor expansion and 
eventual differentiation, the timing and level of C/EBP expression is critical. An essential 
role for C/EBPε in granulopoesis has been demonstrated in mouse knockout studies366, 
although there is currently no evidence in mice that overexpression of wild-type C/EBPε 
promotes leukaemogenesis. However, CEBPE is the target of chromosomal 
rearrangements of IGH in human lymphoid malignancies, where the wild-type CEBPE 
allele is translocated close to an enhancer site normally responsible for IGH activation, 
leading to upregulation of CEBPE with leukaemogeneic consequences367. Furthermore, 
there is evidence that overexpression of other C/EBP family members can have 
oncogenic consequences, including C/EBPδ in mouse AML and C/EBPβ in human solid 
tumours368–370. For example, in mouse AMLs, C/EBPδ deregulation is accompanied by 
the suppression of C/EBPα expression, promoting a myeloid differentiation block. In our 
own analyses, we observed only a modest downregulation of Cebpa expression in 
Hoxa9+FoxC1 AMLs as compared to Hoxa9+MMTV (log2 FC = 1.8, p = 0.04), but this 
did not survive correction for multiple testing (adj. p = 0.11). We speculate that 
overexpression of C/EBPε might have functional consequences relevant to the 
development of AML, although the downstream targets are not yet clear (see 3.20). We 
also consider the possibility that C/ebpε upregulation in the FoxC1-dependent AML 
mouse model is simply a negative feedback event to resist downregulation of the myeloid 
expression programme in these samples. However, given the striking overrepresentation 
of CEBP motifs present in FoxC1-specific DHSs, including those associated with both 
up- and downregulated genes, we consider this unlikely. 
Our observation that Hoxa9+FoxC1 AMLs featured upregulation of Myb and an 
enrichment of DHSs containing MYB binding sites (Figure 3:10 and Figure 3:23) may be 
a significant aspect of the gene regulatory network activated by Hoxa9 and FoxC1. 
 
160 
Firstly, in addition to essential roles in regulating the self-renewal of normal HSPCs371,371, 
MYB is a defined oncogene in both solid malignancies and leukaemias, where it is 
frequently amplified or overexpressed372,373. In mice, Myb is a validated target gene of 
Hoxa9 and Meis1 in AML, where Myb upregulation directly contributes to leukaemic 
transformation374. In Hoxa9+FoxC1 AMLs, the substantial FoxC1-dependent 
upregulation of Meis2 (Figure 3:26), which can exhibit functional redundancy with Meis1, 
may be important in this regard331,332. 
Critically, the considerable overlap between the accessible chromatin and gene 
expression profiles of Hoxa9+Meis1 AMLs and samples transduced with Hoxa9+MMTV 
is consistent with the previously defined role of Meis1 in stabilising Hoxa9 at target loci, 
rather than retargeting Hoxa9 binding to elsewhere375. Nevertheless, the Hoxa9+FoxC1-
specific chromatin and gene expression signature we defined remained remarkably 
similar whether compared to Hoxa9+Meis1 AMLs or Hoxa9+MMTV cells, strongly 
indicating that FoxC1 plays a significant role in the leukaemic transformation of these 
cells at both the epigenetic and transcriptional level. 
Finally, the above indications of Hoxa9+FoxC1-dependent deregulation of C/EBP and 
Myb proteins were supported further by motif co-localisation analyses (Figure 3:12). 
These revealed that the most specific DHSs in Hoxa9+FoxC1 AMLs were not only 
defined by an expected co-localisation of HOX and FOX motifs, but that these motifs 
were also co-associated with C/EBP and MYB sites. Collectively, these data provide a 
strong indication that the gene regulation network established in Hoxa9+FoxC1 AMLs is 
defined by aberrant co-option of C/EBP and Myb activity.  
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3.19 Activation of Meis2 is a significant event in Hoxa9+FoxC1 AMLs and 
is associated with widespread changes in chromatin accessibility across 
the entire Meis2 domain 
To our surprise, we observed a specific enrichment of MEIS motifs within DHSs 
specifically activated in Hoxa9+FoxC1 AMLs (Figure 3:11) that were not present even in 
the Hoxa9+Meis1 AMLs. This was likely related to the striking FoxC1-dependent 
upregulation of Meis2 (Figure 3:20), as other Meis genes were not expressed in 
Hoxa9+FoxC1 AMLs and Meis2 was not expressed in the samples lacking FoxC1 
expression (Figure 3:21).  
Through detailed analyses of DHSs associated with the Meis2 locus that were activated 
in Hoxa9+FoxC1 AMLs alone (Figure 3:26), we found compelling evidence of at least 19 
promoter-proximal and distal cis-regulatory elements present at the Meis2 locus in 
Hoxa9+FoxC1 AMLs but not the other samples. These included two distal DHSs (D:1 
and D:2) that bounded the 5’ and 3’ ends of Meis2 respectively, and were occupied by 
CTCF in normal mouse BM and spleen samples (Figure 3:26 and Table 3:2). The 
sequence and chromatin features of these two sites are likely of particular significance in 
Meis2 activation. Firstly, because site D:1 contained a highly conserved composite CTCF 
site demonstrated in other studies to have insulator activity352 (Figure 3:30), this DHS 
possibly acts as the 5’ boundary of a ~250 kb chromatin domain activated during Meis2 
upregulation. This prospect is strengthened further by the presence of a Hoxa9+FoxC1 
AML-specific CTCF footprint in our high-resolution DNase-seq digital footprinting 
analyses.  
Secondly, site D:2 features a canonical CTCF site occupied in a Hoxa9+FoxC1-specific 
manner by DNase I digital footprinting, as well as in normal mouse BM and spleen CTCF 
ChIP-seq, which also express Meis2335. Robust enrichment of the enhancer mark 
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H3K27ac376 and localised binding of FoxC1 in ChIP-seq data, strongly suggest that this 
DHS could function as a long-range enhancer which may interact with the Meis2 
promoter via looping during gene activation. Indeed, evidence for co-operativity between 
CTCF and another FOX protein, FoxA1, was previously described in ER-dependent 
breast cancer cells at cell-specific enhancer elements377. Distinct roles for CTCF as a 
mediator of longer-range enhancer-promoter interactions are emerging378, further 
increasing the possibility that site D:2 might play a role in the direct activation of Meis2 
expression.  
Analyses of a public FoxC1 ChIP-seq dataset from embyronic mesoderm, where Meis2 
is highly active351, revealed examples of offset FoxC1 binding in ChIP-seq data with 
respect to the D:2 DHS and other specific sites at the Meis2 locus. We speculate that 
this unusual mode of binding to nucleosomal sites may be evidence of FoxC1 pioneer 
activity. In addition to potential evidence of nucleosomal FoxC1 binding at the Meis2 
locus, we identified at least two examples of FOX motif occupancy at Hoxa9+FoxC1-
specific DHS summits (Figure 3:29), consistent with a more traditional model of TF 
binding at pre-existing open chromatin sites2. Although our mechanistic analyses of 
FoxC1 binding to chromatin are incomplete, studies of other FOX proteins show similar 
bimodal binding properties, supporting the possibility that FoxC1 may eventually be 
classified as a pioneer factor140,379. 
Many of the Meis2 DHSs described in this study existed in regions of high DNA 
sequence homology, suggesting that these cis-regulatory elements may be conserved 
and indeed involved in MEIS2 regulation in humans. This is of relevance to the biology of 
AML: in a study of human AMLs with RUNX1-ETO mutations, MEIS2 was demonstrated 
to have leukaemogenic properties by associating with the DNA-binding domain of the 
RUNX1-ETO oncoprotein, impairing the ability of RUNX1-ETO to repress target 
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oncogenes380. Future analyses could compare the activated sites at Meis2 in 
Hoxa9+FoxC1 AMLs with primary human AML samples to identify critical regulators of 
MEIS2 activation in this context. 
Collectively, these data strongly indicate that Meis2 may be a direct target gene of 
FoxC1 in Hoxa9+FoxC1 AMLs, a phenomenon that would be directly relevant to human 
disease. Additional experiments are required to validate mechanistic aspects of FoxC1-
dependent activation of Meis2, which are explored in 3:23. 
3.20 Widespread repression of differentiation-specific gene expression 
may be related to specific upregulation of the Polycomb regulator 
L3mbtl2 in Hoxa9+FoxC1 AMLs 
Given that previous biochemical analyses strongly suggested that FoxC1 is a 
transcriptional activator and not a repressor381,382, we searched for alternative 
mechanisms whereby FoxC1 could indirectly promote the widespread downregulation of 
mRNA expression we observed in Hoxa9+FoxC1 AMLs (Figure 3:16 - Figure 3:19).  
Through integrative analyses of RNA-seq and DNase-seq DHS and high-resolution 
digital footprinting data, we identified L3mtbl2 as a substantially upregulated target of 
Hoxa9 and FoxC1 (Figure 3:20 and Figure 3:24). In vitro studies have demonstrated that 
L3MBTL2 alone is sufficient to compact nucleosomal arrays, consistent with a role in 
transcriptional repression344. Furthermore, an essential role for L3mbtl2 in development 
was demonstrated using knockout studies: L3mbtl2-null mouse embryos are inviable, 
while L3mtbl2-/- ES cells are defective in both proliferation and differentiation350. 
In addition to intrinsic nucleosome compacting ability, L3mbtl2 functions as part of a 
larger PRC1-related complex (PRC1-like 4, or PRC1L4). In mouse ES cells, L3mbtl2 
targets PRC1L4 to differentiation-specific genes for repression, promoting proliferation 
and maintaining pluripotency350. Indications of a potential mechanism for this effect were 
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revealed in another study, which demonstrated that L3MBTL2 has intrinsic ubiquitin E3 
ligase activity344. Indeed, L3MBTL2 catalyses deposition of H2A lysine 119 
monoubiquitination (H2AK119ub) to target genes for repression via other members of 
this PRC1L4 complex. Significantly, we confirmed that several other genes encoding 
subunits of the PRC1L4 complex were expressed in Hoxa9+FoxC1 AMLs, including 
Ring1, Pcgf6, Cbx3 and E2f6 (Figure 3:25).  
Collectively, our analyses indicate that L3mbtl2, perhaps as part of the PRC1L4 complex, 
is co-opted in Hoxa9+FoxC1 AMLs, where its activity may contribute to the observed 
myeloid differentiation block by causing widespread repression of differentiation-specific 
genes. This potential mechanism is consistent with observations in other leukaemias 
including a mouse model of MLL-AF9 AML, where PRC-dependent activity was found to 
suppress the expression of similar differentiation-specific genes383.  
Although our observations raise the possibility that misregulation of Polycomb complexes 
might contribute to the repression of differentiation-specific genes in AMLs with high 
Hoxa9+FoxC1 expression, alternative mechanisms could equally account for these 
consequences. It is possible, for example, that FoxC1 could simply sequester or cause 
retargeting of other TFs away from differentiation-specific genes via one of its 
transactivation domains381. However, given that FoxC1 has only been characterised as a 
transcriptional activator to date, this possibility is perhaps less likely299,381,384. Future 




3.21 Commonalities and differences between the gene expression 
profiles of Hoxa9+FoxC1 mouse AMLs and primary human FLT3-ITD 
AMLs 
Because FOXC1 was previously reported to be upregulated in FLT3-ITD AMLs271, we 
sought to assess how the gene expression profiles of Hoxa9+FoxC1 AMLs were related 
to earlier observations made via analyses of primary FLT3-ITD AML samples (Figure 
3:32 and Table 3:3). Indeed, we found evidence of 39 genes that were commonly 
deregulated in both the Hoxa9+FoxC1 mouse AMLs and the Cauchy et al. (2015) FLT3-
ITD-specific gene list. 12 of these genes were upregulated in Hoxa9+FoxC1 AMLs, 
including Elane and the established AML-associated antigen Prtn3, which both exist as a 
cluster of upregulated genes in human FLT3-ITD AMLs271 as well as in this mouse model 
(Figure 3:33). Furthermore, Prickle1 and Spry2 were two additional commonly 
upregulated genes with evidence of FoxC1-dependent deregulation. PRICKLE1 has 
previously been associated with poorer clinical prognosis in lymphoid malignancies353, 
whereas a role for SPRY2 in leukaemia emerged in a recent study published earlier this 
year. However, we cannot yet conclude whether these effects are direct or indirect 
consequences of FoxC1 overexpression, given a current absence of functional 
validation. Ongoing work (3:23) aims to address these outstanding questions. 
In addition to the upregulated genes discussed, our analyses revealed 28 commonly 
downregulated genes between Hoxa9+FoxC1 mouse AMLs and the human FLT3-ITD 
AML-specific gene list. These included Xaf1, a pro-apoptotic protein which is often 
downregulated in malignancies including AML354,385, together with three murine 
orthologues of human HLA genes: H2-DMb1, H2-Aa and H2-DMb2. The latter trio of 
downregulated genes is particularly interesting, given the primary FLT3-ITD AML 
samples analysed in Cauchy et al. (2015) featured a broad reduction in the expression of 
MHC genes. Furthermore, we found substantial Hoxa9+FoxC1-dependent 
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downregulation of an additional 12 MHC genes (Table 3:4) that were not commonly 
downregulated in the human FLT3-ITD AML gene list. These findings indicate that Hoxa9 
and FoxC1 may potentially be involved in the repression of genes associated with 
immune recognition. This may be clinically significant, since immune evasion is a 
characterised hallmark of AML and is an area of active interest for the development of 
novel therapeutic agents386. 
3.22 Conclusions 
Through genome-wide interrogation of chromatin accessibility, TF footprinting and gene 
expression, we have successfully begun to identify a gene regulatory network activated 
by ectopic expression of FoxC1 in mouse AMLs (Figure 3:34). We have described a 
robust pattern of gene expression activated by Hoxa9+FoxC1, including upregulation of 
Cebpe and the proto-oncogenes Myb and Meis2, and note that the chromatin signature 
associated with these global changes in gene expression are defined by DHSs enriched 
for sites that could be bound by these factors. Furthermore, FoxC1 collaborates with 
Hoxa9 in this model to repress the myeloid gene expression programme, including eight 
IRF and KLF-family TF genes, together with the downregulation of DHSs containing 
motifs recognised by these factors. We speculate that the myeloid differentiation block in 
Hoxa9+FoxC1 AML cells may in part be driven by L3mbtl2-mediated repression of 






Figure 3:34 A working model of the transcriptional network activated in Hoxa9+FoxC1 AMLs. 
Collectively, our analyses suggest a model in which Hoxa9 and FoxC1 collaborate to activate a 
transcriptional network defined by downstream activation of C/EBPε, Meis2 and Myb. 
Hoxa9 and FoxC1 together with these upregulated TFs establish a specific program of gene 
expression promoting the survival and proliferation of Hoxa9+FoxC1 AML cells. We speculate that the 
widespread downregulation of the myeloid gene expression program is mediated in part by 
upregulation of the non-canonical Polycomb regulator L3mbtl2, which may directly repress 
differentiation-specific targets genes. 
 
We identify Meis2 as a putative target gene of FoxC1, and have thus far defined a 
collection of 19 cis-regulatory elements associated with Meis2 activation spanning a 
~250 kb chromatin domain. These sites include a probable 5’ insulator element, buffering 
neighbouring genes from Hoxa9+FoxC1-dependent activation of Meis2, and a potential 
long-range enhancer element involving CTCF that might act upon the Meis2 promoter by 
chromatin looping.  
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Prior to these studies, little was known about the cis-regulatory elements involved in the 
regulation of Meis2. As Meis2 is a homeotic factor involved both in normal embryonic 
development and tumorigenesis, our efforts represent a meaningful contribution to the 
study of Meis2 regulation that have implications beyond the study of this mouse model of 
AML. Significantly, despite upregulation of Meis2 in Hoxa9+FoxC1 AMLs and previous 
reports of functional redundancy between Meis proteins, the gene regulation network 
activated in Hoxa9+FoxC1 cells are clearly distinct from that of Hoxa9+Meis1 cells, and 
these differences may arise directly from FoxC1 itself, or indirectly from other TFs 
deregulated as a result of FoxC1 expression. 
Finally, integration of our analyses with those from primary FLT3-ITD human AML 
samples has demonstrated that the Hoxa9+FoxC1 AML gene expression signature 
shares some commonalities with these human primary AMLs, underlining the value of 
this mouse model as a relevant tool to gain insights into human disease. 
3.23 Current limitations and future prospects  
Despite the insights our analyses have generated thus far into the roles of Hoxa9 and 
FoxC1 in leukaemogenesis, we recognise that there are important limitations to the work 
as it currently stands.  
Firstly, a major shortcoming of these studies so far arises from our reliance on the only 
publicly available FoxC1 ChIP-seq dataset, which was generated from an unrelated 
embyronic tissue. The fact that Hoxa9+FoxC1 AMLs and the tissue used for FoxC1 
ChIP-seq are both distinguished by high Meis2 expression351 increases confidence in our 
analyses at this particular locus, but makes comparisons elsewhere challenging. To 
overcome this, we attempted to perform FoxC1 ChIP-seq analyses using chromatin 
prepared from a representative Hoxa9+FoxC1 AML sample, but were unsuccessful in 
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obtaining a meaningful signal enrichment (data not shown). Obtaining robust FoxC1 
ChIP-seq data results was an ongoing challenge throughout these studies, and is the 
subject of further discussion in Chapter 6: Overall Discussion. 
Secondly, despite a strong association between FoxC1 expression and the 
Hoxa9+FoxC1-specific upregulation of DHSs and proto-oncogenes including Myb, Meis2 
and others, the most reliable validation of target genes for a given TF such as FoxC1 is 
through further genetic perturbation experiments. To this end, in the latter months of this 
study we entered into a collaboration with Keith Humphries, who generously shared with 
us an immortalised murine leukaemia model generated from HSPCs transformed with 
the oncogene Mn1387,388. These cells not only feature robust expression of Hoxa9 and 
Foxc1, but also express high levels of Meis2, which was modified using CRISPR to 
include an epitope tag together with a fluorescent mCherry reporter gene which is 
expressed in parallel with Meis2 as a polycistronic transcript. These features allow 
reliable tracking of endogenous Meis2 expression in live cells using FACS, while the 
epitope tag will greatly facilitate downstream analyses of Meis2 in the absence of a 
reliable Meis2 antibody. Consequently, these cells may represent a viable immortalised 
cell model in which to test some outstanding questions generated from our findings so 
far, including the validation of FoxC1-dependent target genes and cis-regulatory 
elements.  
At the time of writing, we are generating lentiviral shRNA expression constructs targeting 
Foxc1 to transduce into MN1-dependent AML cells to validate candidate FoxC1 targets, 
including Meis2, Myb and the MHC class genes. These data will provide critical insights 
into which genes are directly regulated by FoxC1 in the context of mouse AMLs, as well 
as potentially identify novel sensitivities common to human AML patients that could be 
targeted therapeutically. We also plan to directly validate putative Hoxa9+FoxC1 targets 
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using similar shRNA knockdown approaches against downstream targets, coupled with 
phenotypic assays to examine changes in proliferation and differentiation. 
Thirdly, several key questions remain as to how Hoxa9 and FoxC1 promote the 
widespread repression of genes associated with myeloid differentiation. One possibility is 
that Cebpe expression leads to downregulation of the myeloid TFs C/EBPα and C/EBPβ 
by feedback inhibition, suppressing the activation of normal myeloid differentiation 
pathways. We also identified a key component of the PRC1L4 complex as being 
substantially upregulated in Hoxa9+FoxC1 AMLs, but so far our observations are purely 
correlative and provide only indications of a potential mechanism. However, there are 
several approaches that could be taken to test this model. We could perform L3mbtl2 
ChIP-seq in chromatin prepared from Hoxa9+FoxC1 AMLs to determine whether 
L3mtbl2 is localised to repressed loci and, if so, whether this is associated with an 
enrichment for the repressive H2AK119ub it deposits at target genes. By comparison of 
these data with those from Hoxa9+MMTV cells as a control, we could determine whether 
L3mtbl2 is a downstream mediator through which FoxC1 acts to promote the very 
striking repression of differentiation-specific genes we observed. These studies could be 
coupled with shRNA-mediated suppression of L3mtbl2 in the immortalised Mn1-
dependent AML cell model to directly assess the effect of L3mtbl2 depletion on 
H2AK119ub deposition, and/or the expression of these differentiation-specific genes. 
Critically, our observations to date are based on bulk population-based analyses of 
leukaemic cells. As a result, insights into potential subclonal diversity within these 
samples are impossible to detect. The concept of subclonal heterogeneity in mouse 
models of AML was previously a topic of contention, but more recent studies suggest 
that transgenic mouse models of AML and B-ALL do indeed establish a clonal hierarchy 
as observed in primary human AMLs389,390. We consider that this is even more likely to 
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occur in the transplantation models of AML we used in this study, where donor cells co-
transduced with Hoxa9 and FoxC1 or Meis1 are likely to be highly polyclonal, owing to 
variable viral transduction efficiencies, and are also probably subjected to clonal 
selection during engraftment in recipient mice. With the advent of reliable single-cell 
ATAC-seq and RNA-seq methods, a logical progression for this study would be to 
investigate the clonal composition of these cells, and the epigenetic and transcriptional 
signatures that underpin phenotypic differences between clones, if they exist.  
Finally, the accessible chromatin landscape of Mn1-dependent AML cells could be 
profiled to compare their global similarity to the Hoxa9+FoxC1 AML model. If DHSs at 
the Meis2 locus are identified that are common to the Hoxa9+FoxC1 model, the function 
of these cis-regulatory elements could be explored using classical enhancer reporter 
gene approaches, or by targeted perturbation of candidate enhancers/TF binding sites 





Appendix 3:1 Motif bootstrapping analyses performed on 2270 Hoxa9+MMTV-specific DHSs 
reveals that these sites are overwhelmingly enriched for PU.1:IRF binding motifs. 
Initial motif bootstrapping analyses revealed that Hoxa9+MMTV-specific DHSs were dominated by an 
enrichment of PU.1:IRF binding sites, masking any other significant motif co-association patterns also 



















Chapter 4: Molecular characterisation of FUJIOKA cells, an 
acute myeloid leukaemia cell line featuring high expression of 
FOXC1. 
 
One of the aims of this study was to identify more appropriate cell models to study 
FoxC1 in the context of human AMLs. We determined that FUJIOKA human AML cells 
expressed comparatively high levels of FOXC1 mRNA (Figure 3:1), therefore we sought 
to characterise epigenetic and transcriptional changes occurring as compared to other 
cells with low FOXC1 expression. In this chapter I will investigate the chromatin, TF 
binding and gene expression profiles in FUJIOKA cells, and how these features may be 
related to the presence of FoxC1. 
4.1 FUJIOKA cells feature a specific accessible chromatin signature 
enriched for RUNX, C/EBP and ETS binding motifs 
To identify the complement of accessible chromatin regions present in FUJIOKA cells, 
we performed DNase-seq and compared these data to those generated from K562 
cells151, which feature comparatively modest levels of FOXC1 expression. These 
analyses revealed the existence of 14,592 DHSs specific to FUJIOKA cells, 36,379 
DHSs common to both FUJIOKA and K562 cells, and 27791 DHSs specific to K562 cells 
(Figure 4:1A).  
Focusing on the 14,592 FUJIOKA-specific DHSs, HOMER de novo motif discovery 
analyses revealed a robust enrichment of ETS, C/EBP and RUNX binding motifs that 
were either less strongly-enriched or absent altogether in the 27,791 K562-specific sites 
(Figure 4:1C). FUJIOKA-specific DHSs also featured an enrichment of AP-1, E-box and 
FOX binding motifs, albeit at more modest levels. A search carried out within these DHS 
using the known FOX binding motif suggests that the FOX motif is present in FUJIOKA-




Figure 4:1 FUJIOKA cells feature a specific chromatin signature differentially enriched for TF 
binding motifs. 
A: Profiles of DNase-seq signal for FUJIOKA cells and K562 cells, presented as the union of all peaks 
in both cell lines ranked in order of increasing FUJIOKA / K562 DNase-seq signal fold-difference. 
Profiles are displayed as 2 kb windows, centred on the summits of all DHSs. DHSs exhibiting greater 
than a +/- 4 fold change were classified as differential DHSs.  
B: HOMER motif density plots for various TF binding sites enriched in FUJIOKA-specific DHSs. At far 
right is the FOX binding motif, which is not significantly enriched, but abundantly distributed in 
FUJIOKA-specific DHSs. 





Figure 4:2 K562-specific DHSs are enriched for distinct TF binding sites to FUJIOKA DHSs. 
A: Profiles of DNase-seq signal for FUJIOKA cells and K562 cells, with HOMER motif density plots for 
various TF binding sites enriched in K562-specific DHSs plotted against the same co-ordinates. 
B: HOMER de novo discovery results for TF motifs significantly enriched in K562-specific DHSs. 
C: Detail of NFE2 and GATA motif enrichment in K562-specific DHSs, centred on the DHS summits as 






4.2 DHSs absent in FUJIOKA cells but activated in K562 cells are 
enriched for distinct classes of binding motifs 
Next, we sought to identify specific features of the K562 cistrome that were absent in 
FUJIOKA cells by performing similar motif analyses on the group of 27,791 K562-specific 
DHSs (Figure 4:2B). At these DHSs we identified a specific enrichment of GATA, KLF, 
NFE2 and STAT binding motifs. NFE2 motif enrichment was not revealed by de novo 
motif discovery, but an AP-1 motif which could be recognised by NFE2 was enriched in 
the de novo analyses. These DHSs were also enriched for CTCF binding motifs together 
with the group of DHSs common to both K562 and FUJIOKA cells. Finally, a search 
within these DHSs using the known NFE2 binding motif (Appendix 4:1) revealed a 
preferential enrichment of NFE2 sites closer to the summits of K562-specific DHSs, while 
GATA sites were most strongly enriched either side of the summits of these DHSs 
(Figure 4:2C). 
4.3 DHSs activated in FUJIOKA cells are distinguished by occupancy of 
RUNX1, C/EBPα and FoxC1 
To investigate which TFs might play important roles in the control of the cis-regulatory 
elements specifically present in FUJIOKA cells, we performed ChIP-seq to profile the 
occupancy patterns of FoxC1, RUNX1 and C/EBPα, which all had enriched binding 
motifs in FUJIOKA-specific DHSs (Figure 4:1). 
These analyses revealed robust occupancy of both RUNX1 and C/EBPα at FUJIOKA-
specific DHSs, with the strongest binding occurring at DHS summits, in concordance with 
motif enrichment patterns (Figure 4:3B). RUNX1 and C/EBPα binding was also observed 
at more modest levels in the common group of DHSs shared by FUJIOKA and K562 
cells. Similar to RUNX1 and C/EBPα, the binding of FoxC1 at FUJIOKA-specific DHSs 
occurred most strongly towards the summits of these DHSs. However, FoxC1 binding in 
the shared group of DHSs occurred predominantly at regions flanking the hypersensitive 
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sites, in stark contrast to RUNX1 and C/EBPα. These FoxC1-bound sites were not 
enriched for any motifs, although the hypersensitive sites they flanked did feature an 
overrepresentation of an unknown 5’-CGCCC(T/C)(T/C)T-3’ motif. 
 
Figure 4:3 FUJIOKA-specific DHSs are occupied by RUNX1, C/EBPα and FoxC1. 
A: Profiles of DNase-seq signal for FUJIOKA cells and K562 cells, presented as in Figures 4:1 and 
4:2. 
B: HOMER known motif density and TF ChIP-seq signal intensity, plotted on the same axis as A. 
C: Venn diagram analyses showing pairwise comparisons of the highest-confidence peaks* in each of 
the three TF ChIP-seq datasets to identify common and discretely occupied loci for each pair of TFs. 
*for this analysis, each ChIP-seq dataset was filtered to remove repeat elements and artefactual sequences from 
the ENCODE hg19 blacklist. A peak was considered high confidence if the number of uniquely-mapped reads 
exceeded the following thresholds: C/EBPα = 44; RUNX1 = 7; FoxC1 = 8.  
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To investigate whether binding for the above TFs occurred within close proximity of each 
other, we performed an overlap of the highest-confidence ChIP-seq peaks for each 
dataset (Figure 4:3C). Indeed, 57% of RUNX1 binding events overlapped with C/EBPα 
binding, and 26% of sites bound by FoxC1 also overlapped with C/EBPα binding. The 
overlap between RUNX1 and FoxC1 binding was more modest, with around 16% of 
FoxC1-bound regions also being occupied by RUNX1 in these datasets. 
 
Figure 4:4 A subset of DHSs activated in FUJIOKAs are occupied by C/EBPα and FoxC1. 
(Continued on next page) 
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UCSC genome browser views of loci activated in FUJIOKA cells that also feature binding of FoxC1 
and C/EBPα, as shown by DNAse-seq, RNA-seq and ChIP-seq analyses. Views are shown of two 
DHSs at the RUNX1 locus (A and B), as well as others at the CST7 (C) and FLI1 (D) loci. 
Samples are shown alongside a representative FLT3-ITD/NPM1c+ AML patient (ITD AML) and t(8;21) 
AML patient with wild type FLT3 (WT AML). These samples are named ITD/NPM1-2 and t(8;21)-4 in a 
manuscript currently being prepared by this laboratory. 
 
Manual inspection of individual loci enriched for FoxC1 binding in FUJIOKA cells 
confirmed co-association with C/EBPα binding for a subset of sites which were also 
DHSs specific to primary FLT3-ITD AMLs (Figure 4:4). These included two DHSs 
activated at the RUNX1 locus as well as two DHSs associated with the genes CST7 and 
FLI1, all of which were found to be upregulated in FUJIOKA cells relative to K562 cells 
(Figure 4:7). Another FoxC1 binding peak at the intragenic RUNX1 DHS occurred at a 
site previously determined to be specifically occupied in primary FLT3-ITD AML cells 
using high-resolution DNase I digital footprinting analyses271. Finally, as found elsewhere 
in FUJIOKA cells (Figure 4:3) and our in vivo experiments (Figure 3:31), we observed 
evidence of offset FoxC1 binding with respect to DHSs at the RUNX1 and CST7 loci. In 
these examples, the offset distance between maximal FoxC1 ChIP-seq signal and the 
DHS summit was ~200 and ~300 bp, respectively. 
4.4 Regions bound by FoxC1 in FUJIOKA cells correlate with specific 
DHSs and TF occupancy patterns in primary FLT3-ITD AML samples 
FOXC1 is upregulated in a high proportion of primary FLT3-ITD AML samples271,300, 
which prompted us to investigate whether regions bound by FoxC1 in FUJIOKA cells 
correlated with FLT3-ITD-specific chromatin accessibility patterns from a representative 
primary sample, sample ITD-1 from Cauchy et al. (2015), as compared to normal CD34+ 
PBSC cells (Figure 4:5). Indeed, we found that FoxC1 binding in FUJIOKA cells was 
preferentially enriched at regions corresponding to upregulated DHSs in primary FLT3-
ITD AML samples. Furthermore, these regions were also distinguished by an enrichment 
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of FOX:E footprints from high-resolution DNase I digital footprinting analyses of the same 
primary FLT3-ITD AML sample. 
 
Figure 4:5 FoxC1 binding events in FUJIOKA cells correlate with DHSs and FOX:E footprints in 
a representative FLT3-ITD AML patient. 
(Left) Analyses of DNase-seq data from normal human CD34+ PBSCs and a representative primary 
FLT3-ITD AML sample (ITD-1) from Cauchy et al. (2015). DNase-seq profiles are plotted in order of 
increasing fold difference in DNase-seq signal between ITD-1 and CD34+ PBSCs. 
(Right centre) FOX:E and FOX DNase-seq digital footprints identified in ITD-1, plotted against the 
same DHS coordinates as the DNase-seq data. For clearer visualisation of footprint positions within 
DHSs, these are plotted on a smaller window of +/- 200 bp relative to the same DHS summits as the 
DNase-seq data. 
(Far right) FoxC1 ChIP-seq from FUJIOKA cells presented on the same genomic co-ordinates as the 
DNase-seq and FOX:E footprinting data. 
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4.5 Patterns of chromatin accessibility are associated with changes in 
gene expression between FUJIOKA and K562 cells 
We sought to assess whether the differences in chromatin features identified between 
FUJIOKA and K562 cells were associated with specific changes in the expression of 
mRNAs by performing transcriptomic analyses of RNA-seq data.  
 
Figure 4:6 Figure 4:6: DHSs specific to FUJIOKA and K562 cells correlate with changes with 
gene expression. 
A: (Right) Gene expression changes between FUJIOKA and K562 RNA-seq data, presented as the 
nearest genes to DHSs ranked by FUJIOKA / K562 DNase-seq fold difference (left). 
(continued on next page) 
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B: XY scatter plot of differentially expressed genes between FUJIOKA and K562 RNA-seq data. 
Significantly and substantially* upregulated genes in FUJIOKA cells are coloured in red, while similarly 
downregulated genes are coloured in green. 
C: Venn diagram analyses showing pairwise comparisons of differentially-expressed genes in 
FUJIOKA cells with FLT3-ITD-specific genes identified in Cauchy et al. (2015). 
*Genes were considered significantly and substantially changing if the expression values exceeded the following 
threshold: log(2) FC > 1.0, adJ p < 0.05. 
 
Indeed, we found that changes in chromatin accessibility between the two cell lines 
correlated with broad shifts in gene expression (Figure 4:6A). The FUJIOKA-specific 
DHSs were associated with an upregulation of mRNAs relative to K562 cells. By 
contrast, DHSs specific to K562 cells were associated with genes downregulated in 
FUJIOKA cells. Furthermore, a pairwise comparison of duplicate RNA-seq datasets for 
both cell lines (Figure 4:6B) revealed the significant upregulation of 2300 genes and 
downregulation of 2655 genes in FUJIOKA cells as compared to K562 cells.  
Strongly upregulated genes in FUJIOKA cells included FOXC1 together with HOXA9, 
similar to observations made in primary AML samples (Figure 4:7). In concordance with 
an enrichment of ETS sites in FUJIOKA-specific DHSs, we observed an upregulation of 
the ETS family genes FLI1 and SPI1. Furthermore, we identified FUJIOKA-specific 
upregulation of CEBPA and RUNX1, consistent with an enrichment of binding motif and 
TF occupancy patterns within FUJIOKA-upregulated DHSs (Figure 4:3). Conversely, 
FUJIOKA RNA-seq analyses revealed broad downregulation of a number of transcription 
factors recognising motifs enriched in K562-specific DHSs, including GATA, KLF, AP-1 
and STAT family TF genes. NFE2 was also downregulated in FUJIOKA cells, but less 






Figure 4:7 FUJIOKA cells feature upregulation of HOXA9 and FOXC1, together with several TF 
genes that recognise enriched motifs in FUJIOKA-specific DHSs. 
mRNA expression fold changes for differentially-expressed genes in FUJIOKA cells as compared to 
K562 cells, calculated from average normalised RNA-seq expression values across two replicates for 
each cell line. 
A: Upregulation of TF genes that may recognise motifs enriched in FUJIOKA-specific DHSs. 
B: Downregulation of TF genes that may recognise motifs enriched in K562-specific DHSs. 
* = adj. P <0.05; ** = adj. P <0.01; *** = adj. P <0.001 
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Because another aim of this study was to identify alternative cell models to study FOXC1 
in the context of FLT3-ITD, we inspected the extent to which differentially regulated 
genes in FUJIOKA cells overlapped with the FLT3-ITD-specific gene expression 
signature previously identified in Cauchy et al. (2015) (Figure 4:6C). These analyses 
revealed a modest overlap between the two datasets, with 25 upregulated genes and 
seven downregulated genes present in both FUJIOKA cells and the FLT3-ITD gene list 
(Table 4:1).  
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Table 4:1 Genes differentially regulated in FUJIOKA cells (vs K562 cells) are also deregulated in 











4.6 Preliminary data suggest that shRNA-mediated knockdown of FoxC1 
disrupts proliferation of FUJIOKA cells 
Previous studies for several leukaemia cell lines demonstrated that knockdown of 
endogenous levels of FOXC1 expression disrupted proliferation and induced 
morphological differentiation300, consistent with overexpression studies in normal human 
HSPCs and the Hoxa9+FoxC1 mouse model of AML, which led to enhanced cell 
proliferation and a block to normal differentiation. However, these studies did not yet 
extend to the FUJIOKA cell line, which also express comparatively high levels of FOXC1 
mRNA for a leukaemia cell line (Figure 3:1). Critically, these analyses did not explore 
how FOXC1 suppression impacted the chromatin landscape and gene expression profile 
in any leukaemia cell line to date. To address this, we cloned lentiviral FOXC1 shRNA 
vectors to introduce into FUJIOKA cells for FOXC1 knockdown. 
 
Figure 4:8 Preliminary data suggests that transduction of FUJIOKA cells with an shRNA 
targeting FOXC1 impairs cell growth. 
Cell growth curves for FUJIOKA cells transduced with lentiviral expression vectors for shRNAs 
targeting FOXC1 (shFOX B), together with a scrambled non-targeting control (shMM). Cell numbers 
are expressed as the ‘true’ concentration, i.e. based on retention of all cells at each passage. The 
preliminary data presented here is from a single replicate for each shRNA transduction. 
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At the time of writing, owing to unforeseen delays in generating shRNA expression 
vectors, we were unable to complete these experiments in time for inclusion here. 
However, an initial pilot experiment (of just one replicate thus far) suggests that 
introduction of one FOXC1-targeting shRNA (shFOX B) into FUJIOKA cells caused a 
delay in cell growth as compared to a mismatch shRNA control. (Figure 4:8). We are now 
profiling the mRNA and protein expression of FOXC1 in these samples and have begun 
replicate experiments both with the constructs described, as well as with vectors 
expressing two further shRNA sequences targeting FOXC1 mRNA, to account for 
potential off-target effects. 
4.7 CRISPR deletion of the FOXC1 gene coding region 
To investigate the epigenetic and transcriptional consequences arising from complete 
ablation of FOXC1 expression in AML cells, we used a CRISPR/Cas9 genome-editing 
strategy to introduce a targeted deletion of the FOXC1 locus in FUJIOKA cells (Figure 
4:9). A pair of single guide RNAs (sgRNAs) targeting a region immediately downstream 
of the FOXC1 start codon and another pair targeting the stop codon were designed, with 
the aim of deleting almost all of the coding region of FOXC1. Two independent pairs of 
sgRNA sequences were used for each site targeted to mitigate against potential off-
target effects (full experimental details can be found in Materials & Methods 2.11.1). 
From these experiments, 2 viable clones of ~750 transfected single cells were found to 
carry heterozygous deletion for FOXC1, as determined by PCR analyses (Figure 4:9B). 
qPCR analyses of FOXC1 mRNA expression revealed an increase in FOXC1 mRNA in 
CRISPRΔ1 clone 4 relative to wild-type, whereas the other clone (CRISPRΔ2 clone 1) 
featured a modest but significant (p < 0.001) decrease in FOXC1 mRNA as compared to 
wild-type FUJIOKA cells. Finally, we note that thus far, we were unable to obtain viable 




Figure 4:9 CRISPR deletion of the FOXC1 gene in FUJIOKA cells. 
A: CRISPR deletion strategy for the coding region of FOXC1. Indicated underneath the FOXC1 gene 
map are the regions targeted by pairs of sgRNAs (black) and by sets PCR primers (red) to validate 
deletions. 
B: Agarose gel electrophoresis of PCR products (using screening primers 1 and 4) reveals 
heterozygous FOXC1 deletions (ΔFOXC1) in one clone for each independent pair of sgRNAs tested. 
Positive clones of FUJIOKA cells are indicated with red arrows.  
C: qRT-PCR analyses of FOXC1 mRNA expression in normal FUJIOKA cells as compared to the two 
heterozygous FOXC1wt/Δ clones which grew. Error bars plotted show the standard error of technical 
qRT-PCR replicates. ** = p <0.001, as measured by paired student t-test. 
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Chapter 4: Discussion 
4.8 Transcription factor motif enrichment patterns in FUJIOKA and K562-
specific DHSs broadly reflect differences in lineage bias 
Through DNase-seq analyses, we have identified a specific accessible chromatin 
signature present in FUJIOKA cells but not K562 cells (Figure 4:1). DHSs present in 
FUJIOKA cells but not K562 cells were distinguished predominantly by an enrichment of 
ETS, RUNX and C/EBP binding sites, but also a modest enrichment of FOX motifs. An 
overrepresentation of ETS and C/EBP motifs, which are recognised by the myeloid-
associated TFs PU.1 and C/EBPα, is consistent with the monocytoid phenotype of 
FUJIOKA cells, which were established from a primary acute monoblastic leukaemia 
sample391. Indeed, analyses of RNA-seq data from FUJIOKA cells confirmed that SPI1 
(PU.1) and CEBPA, both of which encode myeloid lineage regulators, were upregulated 
as compared to K562 cells (Figure 4:7), together with the granulopoietic TF gene 
CEBPE366. However, we also noted substantial upregulation of the proto-oncogene FLI1, 
which may bind ETS motifs preferentially enriched in FUJIOKA-specific DHSs392,393.  
By contrast, the global DNase-seq profile of K562 cells was distinguished from FUJIOKA 
cells by an enrichment of binding sites for GATA, KLF and NFE2 factors (Figure 4:2). 
K562 cells are a myelogenous leukaemia cell line derived from a primary blast crisis 
CML sample, and have the potential to differentiate into monocytes/macrophages and 
granulocytes394, but they also bear substantial erythroid characteristics, including 
expression of the erythrocyte marker glycophorin395. Thus, it is not surprising that the 
DHSs specific to K562 cells were enriched for binding sites which are recognised by TFs 
involved in erythroid lineage commitment, including GATA1 and KLF1 (EKLF), both of 
which were upregulated in K562 cells as compared to FUJIOKA cells (Figure 4:7).  
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Our observations that NFE2 binding sites were enriched at the summits of K562-specific 
DHSs (Figure 4:2) in contrast to GATA sites, which tended to flank DHS summits, 
recapitulates earlier locus-specific analyses on a genome-wide scale. For example, 
previous studies of the human beta-globin LCR demonstrated that activation of DHS ‘2’, 
the only site in the LCR to act as a transcriptional enhancer, was dependent upon prior 
binding of NFE2 which, via recruitment of ATP-dependent chromatin remodelling 
enzymes, caused localised opening of chromatin for GATA1 and EKLF to subsequently 
gain access to target motifs flanking this pre-bound NFE2 site396.  
4.9 The FUJIOKA-specific accessible chromatin signature is 
distinguished by co-localised binding of C/EBPα and FoxC1 
Because we observed an enrichment of RUNX, C/EBP and FOX binding sites in DHSs 
specific to FUJIOKA cells (Figure 4:1), we performed ChIP-seq analyses for three 
abundantly-expressed TFs recognising these sites, including FoxC1. Firstly, these 
analyses confirmed that DHSs specific to FUJIOKA cells and shared with K562 cells 
were occupied by RUNX1. Occupancy of sites present in these phenotypically dissimilar 
haematopoietic cell types is consistent with extensively documented roles of RUNX1 as 
a master regulator of haematopoiesis, where its expression is essential not only for the 
emergence of primitive blood precusors during embryogenesis, but also throughout adult 
haematopoiesis including differentiation into erythroid, myeloid and lymphoid 
lineages210,397,398.  
Secondly, an enrichment of C/EBPα binding in FUJIOKA-specific DHSs is – at a 
superficial level – reflective of the myeloid lineage bias and higher relative expression 
levels of CEBPA mRNA in FUJIOKA cells as compared to K562 cells230,236. Similarly, 
robust FoxC1 binding within FUJIOKA-specific DHSs is concordant with substantially 
higher levels of FOXC1 expression in these cells as compared to K562 cells. Critically, 
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we also observed that FOXC1 upregulation in FUJIOKA cells was paralleled by a robust 
increase in HOXA9 mRNA expression, which is strongly downregulated in differentiating 
haematopoietic cells329. These two observations reflect other studies – including those 
discussed in Chapter 3 – that highlight a phenotypically evident but mechanistically 
unclear co-operativity between HOXA9 and FoxC1 in AML300.  
Because other FOX proteins are known to interact with a myriad of other TFs to establish 
highly context-specific patterns of gene regulation399,400, we explored the possibility that 
FoxC1 binding might overlap with that of RUNX1 and C/EBPα in FUJIOKA-specific DHSs 
(Figure 4:3). Our observations that a large proportion of FoxC1 binding events occurred 
within FUJIOKA-specific DHSs, in the vicinity of C/EBPα or RUNX1, builds upon previous 
genome co-occupancy patterns determined from DNase I digital footprint bootstrapping 
analyses in primary FLT3-ITD AMLs, where RUNX, C/EBP, FOX (and FOX:E) footprints 
formed a tight cluster as compared to other TFs, which did not tend to occupy sites in 
primary FLT3-ITD AML-specific DHSs271. Manual inspection of FUJIOKA-specific DHSs 
revealed frequent co-occurrence of FoxC1 and C/EBPα binding in ChIP-seq analyses, 
further corroborating previous DNase-seq digital footprinting analyses.  
Collectively, these data indicate that FoxC1 might functionally co-operate with C/EBPα 
and perhaps also RUNX1 in AML cells to promote the ectopic activation of leukaemia-
associated genes. This is consistent with a model proposed by Cauchy et al. (2015), 
where they observed in primary FLT3-ITD AML samples that the normal myeloid RUNX1 
and C/EBP binding signature was co-opted in parallel with upregulation of FOXC1, 
leading to the activation of an oncogenic gene signature. Similar roles for other FOX 
proteins in the retargeting of endogenously expressed TFs have been described 
elsewhere in oncogenesis, perhaps most convincingly between FoxA1 and the estrogen 
receptor in breast cancer and FoxA1/FoxO1 with the androgen receptor in prostate 
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cancer139,401–403. However, co-association of binding for more than one TF in independent 
ChIP-seq experiments is insufficient to confirm a mechanism of co-operative regulation. 
For this, further experiments are required, as detailed in 4.13. 
4.10 The bimodal pattern of FoxC1 binding may be indicative of pioneer 
activity 
 
The observation that a subset of FoxC1 binding events occurred at regions flanking 
DHSs – particularly those common to both FUJIOKA and K562 cells – suggests that 
FoxC1 may instead act as a pioneer factor in this context by binding nucleosomes at 
target cis-regulatory elements to open up nearby chromatin, allowing other factors 
access to target binding sites. This would be consistent with known activities of other 
FOX proteins including FoxA1, which was the first documented TF to have true pioneer 
activity. A distinguishing feature of FOX proteins defined as pioneer factors are their 
highly context-specific chromatin-binding properties. Binding may occur in a DNA 
sequence-specific manner, correlating more closely with defined FOX motifs that may 
exist within DHSs, or they may bind non-specifically to nucleosomes lacking a canonical 
FOX motif140,379. Furthermore, the DNA-binding domain of FOX proteins is the primary 
structural determinant of these context-specific activities, and this is the most highly-
conserved region of FoxC1 as compared to the pioneer factor FoxA1122,382. Indeed, the 
observation that FoxC1 binding within DHSs correlated with the presence of FOX motifs 
suggests that our ChIP-seq dataset is not simply artefactual.  
Finally, it should also be considered that a limitation of the DNase-seq methodology is 
that it is not well-suited to determining specific nucleosomal positioning patterns, but just 
detects nucleosome-free regions404. Indeed, another high-profile study investigating 
binding of the pioneer factor FoxA1 with the glucocorticoid receptor found that FoxA1 
occupancy was not associated with detectable footprints, further suggesting that DNase I 
 
195 
digital footprinting analyses alone may be an inefficient way to capture FoxC1 binding 
events that occur in a nucleosomal context. At the time of writing, we have plans for 
further studies to address current methodological shortcomings, as detailed in 4.13.  
4.11 An evaluation of FUJIOKA cells as an alternative cell model for 
study of FoxC1 function and other targets in primary FLT3-ITD AMLs 
Our RNA-seq analyses revealed a modest overlap between differentially regulated genes 
in FUJIOKA cells as compared to K562 cells and the Cauchy et al. (2015) FLT3-ITD-
specific gene signature (Figure 4:6 and Table 4:1), including CST7, which we 
demonstrated featured evidence of promoter occupancy by FoxC1 in ChIP-seq analyses 
(Figure 4:4). Furthermore, comparison of our FoxC1 ChIP-seq data with primary FLT3-
ITD AML DNase-seq data revealed that FoxC1 binding was enriched in regions 
corresponding FLT3-ITD-specific DHSs that were also enriched for FOX:E composite 
footprints (Figure 4:5).  
Collectively, these data suggest that FUJIOKA cells may represent an alternative AML 
cell line in which to explore mechanisms of gene deregulation which may commonly 
apply to FLT3-ITD AMLs. In support of this, a  very recently published study has 
identified strong correlations between (a) high GFI1 expression and the presence of 
FLT3-ITD, and (b) genes upregulated in the presence of either FLT3-ITD or high GFI 
expression, even in the absence of FLT3-ITD405. High GFI1 expression was associated 
with high FLT3 expression. Furthermore, siRNA-mediated depletion of GFI1 in FUJIOKA 
cells led to the downregulation in surface expression of FLT3 in parallel with several 
genes upregulated in the Cauchy et al. (2015) FLT3-ITD AML gene signature. However, 
this study did not detect a notable reduction in the growth or viability of FUJIOKA cells 
following GFI1 suppression, suggesting that this marker was not a survival factor in these 
cells even though it was associated with the FLT3-ITD gene signature. Moreover, the 
 
196 
phenotypic impact of downregulated FLT3-ITD target genes on the phenotype of 
FUJIOKA cells is difficult to assess, given the longest time point following GFI1 depletion 
was 96 hours. At this time point, depending on factors including protein stability and the 
efficiency of siRNA knockdown, there may not be a meaningful reduction in protein 
expression of downstream target genes for a growth or morphological phenotype to 
become apparent.  
Critically, our preliminary shRNA knockdown analyses (Figure 4:8) indicate that 
FUJIOKA cells may be sensitive to depletion of FoxC1, consistent with FoxC1 
knockdown experiments performed in other leukaemia cell lines lacking notable 
expression levels of FLT3-ITD-specific genes300,405. At the time of writing, our analyses 
so far are encouraging evidence that FUJIOKA cells may be an ideal model in which to 
explore some outstanding questions which remained from previous studies of FLT3-ITD 
AMLs conducted in this laboratory271. This is significant, because it emerged during the 
course of this study that two of the most frequently used immortalised FLT3-ITD AML cell 
lines, MV4-11 and MOLM-14 cells, are poor models for primary FLT3-ITD AMLs, as the 
chromatin, gene expression and phenotypic signatures of these cell lines are dominated 
by MLL fusion oncoproteins406. The clinical incidence of FLT3-ITD AMLs with MLL 
rearrangements – or indeed any chromosomal translocation - is surprisingly rare260,407. 
The only FLT3-ITD cell line lacking an MLL rearrangement, PL-21, instead has a more 
mature phenotype which is likely due to these cells being derived from an Acute 
Promyelocytic Leukaemia sample408. Indeed, our own chromatin profiling analyses 
revealed even less overlap between these cells and primary FLT3-ITD AML cells than 
MV4-11 cells (data not shown). 
Finally, we were unsuccessful in obtaining homozygous FOXC1-/- clones using a double 
sgRNA-based CRISPR gene editing approach, which might suggest that this is an 
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inviable phenotype in FUJIOKA cells. Whilst this is a potentially interesting result in itself, 
we intend to repeat this experiment to resolve whether apparent inviability is a true 
biological effect or simply a consequence of the single-cell outgrowth conditions required 
to generate monoclonal cell lines or low CRISPR efficiency in these cells. 
4.12 Conclusions  
Through genome-wide chromatin and gene expression profiling, we have identified a 
specific epigenetic signature present in FUJIOKA cells but not K562 cells. These studies 
identify a group of almost 15,000 FUJIOKA-upregulated DHSs which were also 
associated with nearby upregulated genes as compared to K562 cells, a subset of which 
included commonly activated targets upregulated in primary FLT3-ITD AML patients. 
Furthermore, these DHSs were defined by an enrichment of motifs and binding for the 
TFs RUNX1, C/EBPα and FoxC1, in concordance with previous genome-wide 
occupancy analyses of primary FLT3-ITD AML cells.  
Collectively, these findings suggest that FUJIOKA cells indeed share common features 
of gene deregulation with primary FLT3-ITD AMLs. Crucially, given the absence of stable 
FLT3-ITD cell lines relevant to the overwhelming majority of primary human FLT3-ITD 
AMLs, FUJIOKA cells may represent a suitable alternative model in which to advance 
our understanding of the impact some FLT3-ITD-activated genes, including FOXC1, 
have on the development of leukaemia in primary AML patients. 
Furthermore, analyses of FoxC1 binding patterns in FUJIOKA cells revealed an 
unexpected bimodal binding signature that may be indicative of pioneer activity, as well 
as potential co-operativity with C/EBPα in the activation of cis-regulatory elements 
associated with oncogene activation. 
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Our analyses represent a starting point for further mechanistic interrogation of FoxC1 
function in the context of AML. An aim of future work in this laboratory is to eventually 
extend these studies to a patient-derived xenograft mouse model of primary FLT3-ITD 
AML, which was only recently developed in collaboration with the Heidenreich laboratory.  
4.13 Current limitations and future prospects 
Our studies of FUJIOKA cells are so far almost entirely descriptive, and need to be 
followed up with functional experiments to validate our hypotheses. At the time of writing, 
we are repeating FOXC1 CRISPR deletion experiments in an attempt to delete the 
second FOXC1 allele. If the FOXC1-/- cells are viable, these loss of function experiments 
should help to reveal FoxC1-dependent changes in gene regulation by comparison with 
our existing datasets. These analyses will be complemented further by shRNA-mediated 
knockdown experiments, firstly for FOXC1 and subsequently for putative target genes. 
Significantly, we plan to use these knockdown experiments as a platform from which to 
extend the FoxC1 studies into primary human AML cells expanded using a patient-
derived xenograft mouse model. Using this model, we will finally be able to confidently 
link FoxC1-dependent changes in chromatin features and gene expression to 
phenotypes in a more directly relevant model of human AMLs. 
Our ChIP-seq analyses gave preliminary indications of a functional co-operativity 
between FoxC1 and other haematopoietic TFs in the context of AML, but require further 
experiments to increase confidence that this is a true biological effect. To explore this, 
we could perform FoxC1 co-immunoprecipitation experiments followed by mass 
spectrometry to identify interacting partners of FoxC1 in an unbiased manner. Next, the 
contribution of candidate interactors identified could be assessed using RNAi-based 
knockdown approaches paired with further ChIP-seq studies and/or chromosome 
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interaction assays, to evaluate changes in cis-element occupancy and potential 
promoter-distal element looping.  
Next, questions remain as to the mechanism by which FoxC1 binds to target sites in 
FUJIOKA cells. The observed bimodal pattern of binding, either close to DHS summits 
enriched for FOX motifs or in nucleosomal regions that flanked DHSs, was indicative of 
possible pioneer activity. However, several experiments are required to test this 
possibility further. Firstly, these ChIP-seq analyses should be repeated, ideally with an 
independent antibody, to eliminate the possibility that this is an artefact of our analyses. 
However, given that we independently observed a similar trend in a ChIP-seq dataset 
prepared by another lab in mice (Chapter 3), we consider this possibility to be unlikely. 
Furthermore, as a defining feature of some FOX proteins are their ability to bind to 
chromatin independently of DNA sequence140,379, it would be crucial to assess binding of 
FoxC1 directly to nucleosomes.  To this end, we are now preparing His-tagged FoxC1 
expression constructs to generate recombinant protein in E. coli for purification and use 
in nucleosome binding assays.  
Finally, a limitation of our current analyses stems from the DNase-seq methodology, 
which efficiently detects nucleosome-free regions but does not precisely map alterations 
in nucleosome positioning. Using this method in isolation, we are unable to identify 
regions where FoxC1 might bind nucleosomal sites. To resolve this outstanding 
question, we could perform titrated MNase-seq, which has successfully been used to 
discriminate between FoxA binding at both accessible and nucleosomal sites379. 
Integrating our ChIP-seq data with the MNase-seq data would allow us to understand 
how FoxC1 binding relates to underlying nucleosome structure, and would complement 
in vitro nucleosome binding data. Furthermore, MNase-seq analyses could be performed 
following FoxC1 knockdown and compared to untreated FUJIOKA cells, to investigate 
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FoxC1-dependent shifts in nucleosome positioning. Collectively, these in vitro and 
genome-wide analyses would provide robust indicators of whether FoxC1 is indeed a 















Appendix 4:1 Known TF binding motif logos from the HOMER database used in these analyses. 
As described in this chapter, some motif analyses involved known motif searches, specifically the 
FoxO1 motif, a validated canonical FOX binding site, and the NFE2 motif. 
The known AP-1 motif in the HOMER database is shown for comparison to the NFE2 motif.
 
202 
Chapter 5: Ectopic expression of FOXC1 is associated with the 
activation of FOX:E composite cis-regulatory elements in 
primary FLT3-ITD AML patients. 
Immediately prior to beginning these studies, ongoing work in this laboratory determined 
that primary FLT3-ITD AML samples were distinguished from other primary AML 
samples by a chromatin signature featuring the specific activation of FOX:E (FOX:E) 
composite elements. These data were consistent with the binding of FOX family proteins 
co-ordinately with basic helix-loop-helix (bHLH) family E-box-binding proteins, in parallel 
with the FLT3-ITD-specific upregulation of FOXC1 mRNA expression271. In this chapter, I 
will introduce FLT3-ITD-specific FOX:E cis-regulatory elements, then explore their 
function in order to understand their activity in the context of  FLT3-ITD-dependent gene 
activation.  
5.1 FLT3-ITD AML samples feature the specific activation of FOXC1 and 
DHSs enriched for FOX or FOX:E composite binding motifs   
It was previously introduced in 1.5.6 that FOXC1 is frequently upregulated in AML patient 
samples with FLT3-ITD (Figure 5:1A). Furthermore, activation of the FOXC1 locus was 
associated with a recurrent FLT3-ITD-specific DHS 56 kb upstream of the promoter that 
was enriched for RUNX motifs and demonstrated by ChIP-seq analyses to be occupied 
by RUNX1 (Figure 5:1B and C). As these patients also featured elevated RUNX1 
expression as compared to FLT3 wild-type (FLT3-WT) patients, it was postulated that 




Figure 5:1 FLT3-ITD-dependent activation of FOXC1 is associated with a differential DHS 
enriched for RUNX motifs and RUNX1 occupancy 
A: Analyses of normalised microarray mRNA data of AML patient samples and normal cells from 
Cauchy et al. (2015) for FOXC1. Primary FLT3-ITD AML samples are coloured in red, whereas wild-
type FLT3 samples are coloured in blue. Normal CD34+ PBSCs (CD34+ SC) and CD14+ BM 
monocytes (CD14+ BM) are coloured in black. AML samples carrying RUNX1 mutations are indicated 
with an R above their mRNA expression values. 
B: UCSC genome browser view of DNase-seq data (upper tracks) for the human FOXC1 locus. The -
56 kb FLT3-ITD-specific DHS is circled in red and also features RUNX1 binding in the anchor sample 
for this study, ITD1, as shown by RUNX1 ChIP-seq data (at bottom). 
C: Genomic sequence detail of the -56 kb FOXC1 upstream DHS circled in B, with RUNX binding 
motifs highlighted. 
 
Further inspection of microarray analyses published in this study revealed that FOXC1 
was the only substantially upregulated FOX gene in FLT3-ITD AML patients as 
compared to all FOX genes expressed in primary AMLs with/without FLT3-ITD, and 
normal CD34+ PBSCs (Figure 5:2A). However, this pattern was not consistent for AML 
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cell lines, which were found by similar analyses to feature only modest levels of FOXC1 
expression (Figure 5:2B). 
 
Figure 5:2 FOXC1 upregulation in FLT3-ITD AMLs is specific compared to other genes in the 
FOX family. 
A: Analyses of primary AML and CD34+ PBSC mRNA expression data from Cauchy et al. (2015) 
reveal FLT3-ITD-specific upregulation of gene expression of FOXC1. 
B: Microarray analyses reveal the specific complement of FOX gene mRNAs expressed in three 
FLT3-ITD AML cell lines (PL-21, MOLM-14 and MV4-11), together with the FLT3-WT cell line, THP-1. 





Figure 5:3 SCARA3 and FAM92A1 are two examples of FLT3-ITD-specific DHSs distinguished 
by FOX:E composite sites 
A: Analyses of normalised microarray mRNA expression values for SCARA3 and FAM92A1 from 
primary AML samples, presented as in Figure 5:1.  
B: UCSC genome browser views of FLT3-ITD-specific DHSs associated with the SCARA3 and 
FAM92A1 loci (circled in red). 
C: Genomic sequence detail for SCARA3 and FAM92A1 DHSs, with FOX:E composite site highlighted 
together with other TF binding motifs. 
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In addition to FLT3-ITD-specific upregulation of FOXC1, this study also identified several 
differentially-activated DHSs enriched for FOX and FOX:E composite binding motifs in 
FLT3-ITD AML samples. Furthermore, many of these DHSs were associated with the 
upregulation of nearby FLT3-ITD-specific target genes, including SCARA3 and 
FAM92A1 (Figure 5:3). Finally, the observation that many of these FOX:E sites were 
predicted to be occupied in vivo by high-resolution DNase-seq digital footprinting 
analyses (Figure 5:4A) strongly suggested that DHSs containing FOX:E elements might 
play a critical role in the FLT3-ITD-dependent activation of target genes promoting 
leukaemogenesis. Thus, the aims of these studies were to delineate mechanisms of 
FOX:E element activation by TFs and whether these sites functioned as a novel class of 
enhancer elements to drive expression of FLT3-ITD target genes. 
 
Figure 5:4 The SCARA3 FLT3-ITD AML-specific DHS features FOX:E footprints in vivo. 
A: (Top) DNA sequence of the human SCARA3 FLT3-ITD AML-specific DHS. Underneath are the 
strand-specific DNase I cutting patterns in a representative FLT3-ITD AML patient sample, as revealed 
by very high depth sequencing. Both the FOX:E composite element and a RUNX site are preferentially 
protected from nuclease digestion. At the bottom of this panel are the predicted occupancy (footprint) 
probabilities as determined by from the DNase cutting patterns, with higher confidence footprints 
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presented  as taller peaks (e.g. the FOX:E footprinted site) as compared to lower confidence 
footprints. 
B: View of the wild-type SCARA3 FOX:E composite site and flanking sequences used for the design 
of probes in EMSA assays. The ‘intact’ SCARA3 sequence used in EMSAs features three point 
mutations to ablate a low-affinity GC-box and GATA site to improve specificity of binding reactions 
(changed residues in red), as well as an additional 5’ overhang sequence used for end-filling probes 
with radiolabelled cytosine (32P-dCTP). Mutant sequences lacking FOX or E-box sites were also 
tested. 
 
5.2 Observation of E-box binding to FOX:E composite elements in vitro 
To examine whether FOX:E elements were occupied by TFs recognising the FOX and E-
box sequences in vitro, we performed EMSA assays using probes containing FOX:E 
composite elements specifically activated in primary FLT3-ITD AML samples (Figure 
5:4B). For these analyses, the prototype FOX:E sites associated with SCARA3 and 
FAM92A1 loci were tested the most extensively. 
Firstly, evidence of potential E-box-binding was observed in the form of three discrete 
bands with both the SCARA3 and FAM92A1 probes when using nuclear extracts 
prepared from MV4-11 cells, which express FLT3-ITD in addition to the MLL-AF4 fusion 
oncoprotein (Figure 5:5). The specificity of this binding to both probes was confirmed 
using competition EMSA assays, where a 100-fold molar excess of various unlabelled 
competitor E-box or FOX:E sequences were all sufficient to disrupt E-box binding. 
However, no evidence of specific binding to the FOX site in these probes was observed 
with MV4-11 nuclear extracts. A similar pattern of binding was observed in EMSAs 
performed with MOLM-14 cells, which also feature FLT3-ITD in addition to the MLL-AF9 




Figure 5:5 Formation of specific E-box complexes at FOX:E composite elements using MV4-11 
nuclear extracts. 
EMSAs of SCARA3 and FAM92A1 FOX:E composite elements identified in Cauchy et al. (2015) as 
activated in FLT3-ITD AML patients. Binding reactions contained nuclear extract from MV4-11 cells, 
which carry FLT3-ITD in addition to an MLL translocation. 
Specificity of E protein complexes (E) were tested using a 100-fold molar excess of homologous or 
heterologous unlabelled DNA competitor sequences (indicated at top). (* =  non-specific band) 
 
5.3 Evidence of specific FOX and E-box motif occupancy in vitro 
Because no evidence of specific FOX motif binding was observed in EMSAs with either 
MV4-11 or MOLM-14 cells, we next performed EMSAs with PL-21 cells. Like MV4-11 
and MOLM-14, PL-21 cells carry FLT3-ITD and express modest levels of FOXC1 mRNA 
(Figure 5:2), but importantly do not feature an MLL translocation.  
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In contrast to observations made with other FLT3-ITD cell lines, EMSAs performed using 
nuclear extracts from PL-21 cells did exhibit signs of specific FOX motif binding in 
addition to E-box binding (Figure 5:6). FOX motif binding was distinguished by the 
presence of an additional band with a particularly slow electrophoretic mobility, 
appearing in the upper region of gel images. In contrast to the E-box binding complexes, 
which varied in mobility when bound either to the SCARA3 and FAM92A1 probes, FOX 
motif binding caused a band shift to the same position on the gel, regardless of which 
probe was used. Furthermore, competition assays using a range of unlabelled FOX and 
FOX:E DNA competitors suggested putative FOX binding to both probes was specific.  
 
Figure 5:6 Evidence of putative FOX complexes at SCARA3 and FAM92A1 FOX:E composite 
elements using PL-21 nuclear extracts. 
Evidence of E protein (E), and FOX protein (FOX) protein complexes are indicated to the left of gel 
images. Specificity of complexes was tested using a 100-fold excess of unlabelled DNA competitor as 




To further verify specificity of FOX protein binding, we tested the SCARA3 probe in 
EMSAs with nuclear extracts prepared from THP-1 cells. Although THP-1 cells do not 
carry FLT3-ITD, they are known to express moderate levels of FoxC1 protein, in contrast 
to most other available AML cell lines300. Indeed, we found evidence of specific binding 
of both FOX-like proteins and E-box–binding bHLH-like protein binding between THP-1 
nuclear extracts and the SCARA3 probe (Figure 5:7). The binding of FOX-like proteins to 
the SCARA3 probe was efficiently disrupted using homologous FOX competitor 
sequences and a range of other previously published sequences that are known to 





Figure 5:7 Further competition experiments support FOX protein binding to the SCARA3 probe, 
but supershift assays fail to identify the specific FOX family member involved. 
EMSAs performed on stimulated THP-1 cell nuclear extracts with the SCARA3 probe and further 
heterologous FOX  competitor sequences or α-FOX protein antibodies. 
In contrast to FAM92A1-based FOX competitors, several other heterologous competitors efficiently 
disrupted FOX protein binding with the SCARA3 probe, including those from three published studies of 
the FOX proteins FoxO1 (eNOS), FoxA1 (ALB) and FoxA2 (CLPS). 
However, further α-FOX protein antibodies tested did not alter the formation or migration of putative 
FOX:SCARA3 complexes. (* =  non-specific band) 
 
Finally, we sought to further validate specificity of E-box and FOX-like protein binding in 
EMSAs by using antibodies raised against various bHLH and FOX proteins, including 
FoxC1, but were unsuccessful in disrupting or altering the mobility of FOX-like 
complexes using this approach (Figures 5:7 and 5:8). In parallel with one of these 
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experiments (Figure 5:8), we tested the competitive activity of a third putative FOX:E 
composite element present at the VANGL1 locus. These assays revealed that this 
sequence was a poor competitor of both E-box or FOX motif binding at the SCARA3 
probe. 
 
Figure 5:8 Supershift EMSA assays fail to identify specific E-box binding proteins in various 
nuclear extracts. 
EMSAs performed on nuclear extracts prepared from three FLT3-ITD AML cell lines in combination 
with antibody raised against two known E-box binding proteins, E2A and E2-2, or a third putative 




5.4 FOX and bHLH protein binding to the SCARA3 FOX:E element is not 
enhanced following cell stimulation 
Because many TFs including FOX proteins exhibit signalling-dependent changes in 
DNA-binding activity, we sought to test whether observed TF binding in EMSAs was 
affected by stimulation of signalling pathways which might target FOX and bHLH family 
proteins for post-translational modification. For these experiments we used THP-1 cells, 
which already exhibited specific FOX and E-box motif binding in previous EMSAs, but 
are also known to feature inducible cell signalling following treatment with PMA and 
Calcium Ionophore411,412.  
At the SCARA3 probe, we detected no appreciable difference in the extent of FOX or E-
box binding using unstimulated or stimulated THP-1 nuclear extracts (Figure 5:9). 
However, previous evidence of FOX and E-box disruption using competitor sequences 
was reproducible regardless of whether the nuclear extract used was prepared from 




Figure 5:9 FOX and E protein binding is not enhanced following stimulation of mitogenic and 
inflammatory cell signalling in THP-1 cells. 
EMSAs performed on nuclear extracts from THP-1 leukaemia cells, with/without stimulation of 
mitogenic and inflammatory signalling using PMA and Calcium Ionophore. 
Specific FOX and E protein complexes formed with the SCARA3 probe, which was supported by 
competition assays as in figures 5:1 and 5:2. Critically, FAM92A1-based competitor sequences did not 
efficiently outcompete putative FOX binding to the SCARA3 probe. 
However, there were no observable differences in the intensity or composition of specific complexes 
forming with/without stimulation, except at the upper non-specific band (*) migrating between FOX and 




5.5 FLT3-ITD-specific DHSs containing FOX or FOX:E composite sites do 
not function as classical enhancer elements as tested in luciferase 
reporter assays 
Given that we observed evidence of specific FOX and E-box occupancy at FOX:E 
sequences in vitro, we sought to test whether DHSs containing FOX or FOX:E composite 
sites acted as enhancer elements when tested in a Firefly luciferase reporter construct 
containing a minimal promoter fragment326. For these studies we used FUJIOKA cells, 
which feature robust FoxC1 expression and are amenable to plasmid co-transfection as 
required by this assay. Because primary FLT3-ITD AML samples are distinguished by 
chronic MAP kinase signalling activation, we also tested the enhancer output of these 
reporter constructs in Fujioka cells stimulated with PMA and Calcium ionophore for 8 
hours. 
Of the 7 constructs tested containing DHS fragments with FOX or FOX:E sites, none 
enhanced the ability of a minimal promoter to drive expression of a Firefly luciferase 
reporter gene as compared to a promoter-only control or positive enhancer control 
(Figure 5:10). The same trend was observed for an additional pair of reporter constructs, 
featuring either 3 copies of the FAM92A1 FOX:E composite site or a fragment of the 
FOXC1 -56 kb upstream regulatory element specifically activated in primary FLT3-ITD 
AML samples (FOXC1). Furthermore, none of the constructs tested featured significantly 
increased luciferase reporter activity in cells stimulated with PMA and Calcium 
ionophore. Notably, the IL2RA(2) DHS fragment  was substantially induced following 
FUJIOKA cell stimulation but not to a point that was statistically significant (p > 0.05) 
when compared to the uninduced conditions via a paired t-test. This was in stark contrast 





Figure 5:10 DHSs containing FOX:E composite elements do not operate as classical enhancers 
in FUJIOKA cells as tested in luciferase reporter assays. 
Luciferase reporter assays for various Firefly luciferase reporter constructs containing either 3 copies 
of the FAM92A1 FOX:E site (FOX:Ex3), fragments of DHSs containing FOX:E motifs, or a FLT3-ITD 
AML-specific DHS associated with activation of the FOXC1 locus itself (FOXC1) as tested in FUJIOKA 
cells under non-induced (-) or stimulated (+ PMA/CaI) conditions.  
Assays are presented as the average of several biological replicates normalised against in internal 
Renilla luciferase reporter control construct, and compared to a promoter-only (TK229) and positive 
enhancer (SV40e) control contructs. 
* = p <0.05; ** = p <0.00; n.s. = not significant (p ≥0.05) 
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Chapter 5: Discussion 
5.6 Despite evidence of specific FOX and E-box motif binding in vitro, the 
specific factors occupying FOX:E elements remains unclear 
In this chapter, we explored the potential roles of FOX:E DNA elements in the regulation 
of AML cells. We were able to observe the presence of potential FOX-like and bHLH 
protein-like complexes forming specifically with FOX and E-box DNA motifs respectively 
in some of the nuclear extracts tested, particularly those prepared from PL-21 cells and 
THP-1 cells. Using a range of homologous and heterologous unlabelled competitor 
sequences, including those with specific FOX or E-box sites ablated by mutations, we 
were able to determine with reasonable certainty that these sites were specifically 
occupied in vitro.  
Our observation of two E-box protein-like complexes is consistent a known mechanism 
of DNA binding by bHLH proteins, which involves each monomer of a homo- or hetero-
dimeric HLH protein complex binding to each half site of the palindromic CANNTG E-box 
sequence415. Thus, it is possible that one complex represents a homodimer of a protein 
such as E2A, while the other complex may involve a heterodimer such as E2A/TAL1. We 
were unable, however, to confirm the identities of any of the HLH protein-like complexes 
using any of the HLH antibodies that we employed. FOX DNA motif binding complexes 
appeared as a single specific band, which agrees with other EMSA data with confirmed 
FOX protein binding to free DNA141,147. We were, however, also unable to confirm the 
identities of the FOX protein-like protein complexes. There are several possibilities that 
might explain this. Firstly, we illustrated in Figure 5:2B that of the ~43 human FOX genes 
classified to date, over 30 of these were abundantly expressed at the mRNA level in the 
AML cell lines used to prepare nuclear extracts for testing in EMSAs. We therefore 
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tested available antibodies raised against four candidate FOX genes, FoxC1, FoxM1, 
FoxO3 and FoxP1, identified as expressed in analyses of microarray data or by Western 
blot (Figure 5:2 and Appendix 5:1), together with antibodies against the E-box binding 
proteins, E2-2 and E2A. These included two antibodies raised against FoxC1, the 
candidate FOX protein binding to FOX:E motifs in vivo in FLT3-ITD AMLs.   
We considered the possibility that these antibodies were inefficient at binding target 
epitopes, and tried various alternative protocols to our standard EMSA protocol to 
overcome this. Firstly, we employed an extended binding reaction time of 1 h at 4°C prior 
to gel electrophoresis, to allow greater opportunity for antibody to conjugate with target 
proteins. Next, we tried varying quantities of antibody and non-radioactive polydI-dC to 
shift binding kinetics in favour of antibody-protein binding. Finally, we changed the order 
in which components of the binding reaction were added, incubating nuclear extract with 
the antibody prior to addition of the EMSA probe. Ultimately, all of these modifications 
still failed to cause any detectable disruption or electrophoretic mobility shift to FOX motif 
binding (data not shown), leading us to surmise that despite reasonable evidence 
correlating FOXC1 expression with the activation of FOX:E elements in vivo, the 
reagents and tools available at the time of this analysis were not appropriate to confirm 
this in vitro. Having invested over 18 months in these optimisation experiments, and 
considering that there were dozens of both FOX and bHLH proteins expressed in AML 
cells, we decided that it would be impractical and financially inviable to test every 
available antibody. Consequently, the overall focus of this study shifted to 
characterisation of other molecular changes related to FoxC1 upregulation, as discussed 
in the previous two results and discussion chapters.  
Ultimately, these redirected efforts proved to be a more productive use of limited 
research time, despite these outstanding questions. We obtained more robust evidence 
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of FOX protein activity using these alternative approaches, particularly high-resolution 
DNase-seq analyses in the Hoxa9+FoxC1 mouse AML model, and ChIP-seq analyses of 
FoxC1 binding in FUJIOKA cells (Chapters 3 and 4). We are now in a position to revisit 
the above in vitro DNA binding studies using alternative approaches, detailed in section 
5.9.  
5.7 FOX:E composite elements may act as priming DHS elements in 
FLT3-ITD AMLs 
In an effort to obtain direct evidence of the function of DHSs containing FOX:E motifs in 
the activation of transcription, we tested fragments of FOX:E DHSs in luciferase reporter 
gene assays. Although we succeeded in establishing a reliable reporter assay in 
FUJIOKA cells, none of the FOX:E motif-containing DHS fragments we tested enhanced 
transcription as compared to the SV40 enhancer control, which caused a substantial, 
reproducible increase in luciferase signal. 
One possibility that may account for these observations is that FOX proteins targeting 
FOX:E elements may not efficiently recognise target sites as they exist on supercoiled 
plasmids in reporter gene assays. Although it has previously been demonstrated that 
transfected plasmids acquire some degree of chromatinisation in mammalian cells416, 
there is still dispute over whether the chromatin topology of these sequences reliably 
reflects the native sequence as it would exist in native chromatin417. This may be relevant 
in relation to occupancy of FOX:E sites, since in other studies binding of FOX proteins to 
target loci appears to be at least partly dependent upon the chromatin context. For 
example, FoxA1 has been demonstrated to “scan” chromatin prior to recognition of target 
sites and stable binding140,150. Thus, it is possible that FOX proteins may not recognise 
binding sites as they exist on plasmids with an atypical chromatin structure. To test this 
hypothesis, an alternative enhancer reporter assay interrogating sequences of interest as 
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they exist in native chromatin is required. One appropriate strategy to test FOX:E sites is 
using site-specific integration FACS followed by sequencing (SIF-seq), which allows 
medium throughput screening of cis-regulatory elements in an unbiased manner418. 
However, a more compelling possibility that may explain our observations is that DHSs 
containing FOX:E composite elements may instead act as priming DHSs (pDHSs) rather 
than as classical enhancers. Previous studies published by our group defined pDHSs in 
T cells as regions of accessible chromatin that stably maintain an active chromatin 
structure at inducible genes without directly activating transcription themselves184. We 
determined in these studies that pDHSs lack classical enhancer activity as tested in 
reporter gene assays, similar to the results obtained here with DHSs containing FOX:E 
sites.  
An additional defining feature of pDHSs defined in T cells was their close proximity to 
highly inducible DHSs strongly enriched for motifs recognised by the inducible factors 
NFAT and  AP-1, whereas pDHS are most highly enriched for ETS and RUNX motifs. 
This is of relevance to our observations, given that the FLT3-ITD-specific DHSs identified 
in Cauchy et al. (2015) were also most strongly enriched for ETS and RUNX binding 
sites, including those DHSs containing FOX:E motifs. Furthermore, our observations that 
binding to FOX and E-box motifs in EMSAs was not dependent upon induction of MAPK 
suggested that these factors might stably occupy such elements in vivo, in contrast to 
inducible factors which have shorter residency times. These observations suggest that 
FOX:E motifs may function to maintain an accessible chromatin structure in a natural 
chromatin context which enables the subsequent binding of inducible factors activated by 
constitutive FLT3-ITD signalling via MAPK. We also considered the possibility that these 
inducible factors might bind within the same DHS, but the observation that FOX:E-
containing DHS fragments did not feature inducible enhancer activity as tested in 
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reporter gene assays suggests otherwise. Nevertheless, these data are consistent with a 
model whereby FOX:E DHSs act as a novel class of non-inducible priming element that 
somehow cooperate with nearby DHSs to promote gene activation. 
In our previous study of T cells, we used CRISPR genome editing to delete a specific 
pDHS associated with IL3 expression, directly linking loss of this element to a reduction 
in target gene expression and validating the priming activity suggested by reporter gene 
assays. Thus, a logical extension of our current work would be to delete candidate 
FOX:E motif-containing DHSs and inspect the changes on putative target gene 
expression. However, our studies in the context of these FOX:E DHSs are still limited by 
a lack of known cell lines with DHSs containing FOX:E motifs, limiting these functional 
approaches. 
5.8 Conclusions  
Using DNA binding assays, we have successfully confirmed that candidate FOX:E 
composite sites are occupied by nuclear factors in vitro in EMSAs. Furthermore, 
competition assays allowed us to determine that patterns of E-box and FOX motif binding 
to these composite sites were indeed specific.  
Secondly, our luciferase reporter gene assays suggest that DHSs containing FOX:E 
motifs do not operate as classical enhancers, and did not directly respond to induction of 
MAPK or calcium signalling following cell stimulation with PMA and CaI. The significance 
of these findings are not yet clear, but are perhaps consistent with DHSs containing 
FOX:E elements operating as priming enhancers, as previously described in studies of T 
cell activation.  
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5.9 Current limitations and future prospects 
A major limitation of the in vitro DNA binding studies to date was that we were unable to 
confirm the identity of specific factors binding to FOX and E-box motifs in EMSAs. As all 
of the nuclear extracts we tested in EMSAs featured expression of over 30 FOX proteins 
and at least as many (if not more) bHLH proteins, to systematically test various 
antibodies against all of these factors in ‘supershift’ EMSAs would not be cost-effective.  
However, we consider FoxC1 to be the most likely candidate FOX protein binding to 
these elements in vivo, given the highly FLT3-ITD-specific activation of FOX:E elements 
in parallel with FOXC1 upregulation. In future experiments, we plan to express 
recombinant FoxC1 as His-tagged protein in E. coli and/or using in vitro 
transcription/translation protocol for use in EMSAs. These studies will allow us to 
determine the mobility patterns of FoxC1:DNA complexes in EMSAs and greatly increase 
our confidence that previous results obtained with nuclear extracts are indeed 
attributable to FOX motif binding by a FOX protein. However, the question of which 
bHLH factors bind to FOX:E motifs in AML cells still remains.  
To address this outstanding question, we could perform double-stranded biotinylated 
oligonucleotide pulldown assays with AML cell nuclear extracts, and then use mass 
spectrometry to identify proteins binding to FOX:E motifs in an unbiased manner. These 
experiments could be used in conjunction with nuclear extract EMSAs and co-
immunoprecipitation experiments to shed light on potential in vivo protein complexes 
binding to FOX:E elements, as well as allowing identification of the specific factors 
binding to probes in EMSAs. These approaches may also identify other potential TFs 
and/or chromatin regulators that are involved in the activity of FOX:E elements, and 
would serve as a platform from which to embark on detailed mechanistic studies. 
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Finally, the question of what the function of FOX:E elements are in vivo remains 
unanswered. To fully address this question, we would need to develop new model 
systems in which to perform functional analyses, as immortalised AML cell lines 
investigated thus far, including FUJIOKA cells, lack the DHSs containing FOX:E 
elements we described in primary AML samples. These could include, for example, the 
generation of a novel cell line from normal CD34+ PBSCs with overexpression of FLT3-
ITD and both HoxA9 with FoxC1. Another alternative would be to perform shRNA 
knockdown of FOXC1 in primary AML cells that feature activation of these DHSs. We are 
already pursuing the latter experiments for other reasons, as described in 4.13, but from 
the perspective of studying FOX:E motifs, extension of these experiments to include 
genome-wide profiling of chromatin accessibility and gene expression would allow direct 
assessment of the effects FOXC1 depletion has on these DHSs and the potential target 
genes they are thought to regulate. 
Collectively, these additional studies should provide a more detailed analysis of DHSs 
containing FOX:E sites and their function in AML, and would represent significant 










Appendix 5:1 FoxO3 is expressed in the nuclei of PL-21 cells 
Western blot showing expression of FoxO3 in various subcellular fractions of PL-21 AML cells. A 
titration of NaCl and Urea buffer conditions were tested to extract histone-associated proteins. GAPDH 




















Chapter 6: Overall Discussion 
 
6.1 Indications that FoxC1 may be a pioneer factor  
A recurring observation throughout this study was that many DHSs associated with 
increased FOXC1 expression lacked an enrichment of canonical FOX binding motifs. 
These findings were documented both in the context of the Hoxa9+FoxC1-dependent 
mouse AML model (Chapter 3), as well as in primary human AML samples and cell lines 
distinguished by high expression of FOXC1 (Chapter 4). Furthermore, our analyses of 
FoxC1 binding from two independent ChIP-seq datasets from human and murine tissues 
suggested that a considerable proportion of FoxC1 binding events occur at nucleosomal 
sites in the absence of a defined binding motif. 
As DHSs are often enriched for TF binding motifs involved in their regulation and 
function, an absence of a specific TF motif might superficially suggest that this particular 
factor does not participate directly in the regulation of the DHS31,419. This argument is 
certainly valid for the overwhelming majority of TFs, which generally only recognise 
target binding sequences as they exist in nucleosome-free chromatin demarcated by 
DNase I hypersensitivity137. However, members of the FOX protein family are 
distinguished from most other TFs by a common winged-helix DNA-binding domain that 
mediates sequence-independent binding to compacted chromatin144,147,148,379. Indeed, 
there is compelling evidence indicating that FOX proteins do not just bind to sites in 
compacted chromatin via a canonical 5’-RYMAAYA-3’ FOX motif140,145.  
These observations of both sequence-specific DNA binding and ‘non-specific’ 
nucleosome binding by FoxC1 raise questions regarding the functionality of this TF in 
vivo, chiefly that these findings may be consistent with pioneer factor activity. Indeed, an 
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elegant study from the Zaret laboratory compared binding dynamics of the pioneer factor 
FoxA1 between asynchronous and mitotic Huh7 liver cells, linking a previously observed 
bimodal FoxA1 binding pattern to distinct in vivo functionality140,  Using fluorescence 
recovery after photobleaching (FRAP), they demonstrated that FoxA1 was highly mobile 
in mitotic cells, moving in the nuclei ~2.5 fold more rapidly than in asynchronous cells. 
Furthermore, by studying FoxA1 mutant proteins lacking the amino acid residues 
involved in either specific or non-specific modes of binding, they confirmed that this 
greatly increased nuclear mobility was due to the non-specific binding mode. This effect 
was observed in FoxA1 ChIP-seq analyses as an increase in non-specific binding 
enrichment in mitotic cells. Finally, it was determined that the non-specific binding mode 
enables FoxA1 to act as a mitotic bookmark, priming essential target genes for rapid re-
activation following cell division. As the structural determinants conferring bimodal 
properties of FoxA1 binding occur in the most highly-conserved region of the FoxC1 
primary amino acid sequence (Figure 6:6:1), we postulate that FoxC1 may act in a 
similar manner to this more extensively characterised pioneer factor. A similar series of 
experiments to those just described by the Zaret laboratory for FoxA1, instead 
investigating FoxC1, would shed light on the significance of this potential mechanism.  
Focusing on the specific mode of binding, recent studies using MNase-seq demonstrated 
that FoxA proteins often bind nucleosomal FOX motifs at liver-specific enhancers without 
eviction of the underlying nucleosome379. Critically, these nucleosomal sites are not 
efficiently digested by DNase I enzyme, which preferentially cleaves naked DNA in 
nucleosome-free regions2. Furthermore, another study of FoxA1 binding co-operatively 
with GR also noted a conspicuous lack of occupied FOX sites at nucleosome-free 
regions using similar high-resolution DNase I footprinting approaches to our own at high-
confidence FoxA1 binding sites identified from ChIP-seq analyses420. These 
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observations raise the possibility that our DNase I footprinting method may simply not 
detect many FoxC1 binding events, which may not have a sufficiently long residency 
time on nucleosome-free DNA to leave conspicuous genomic footprints.  
 
Figure 6:6:1: Specific residues involved in bimodal binding activity of FoxA1 are conserved in 
FoxC1. 
Multiple protein sequence alignment of FoxA1 and FoxC1 generated using ClustalW2 (EMBL-EBI) of a 
portion of the Forkhead DNA-binding domain sequences in FoxC1 and FoxA1. Conserved residues 
revealed as critical to different binding properties of FoxA1145 are highlighted.  
    Blue - Asp and His residues that are essential to normal non-specific binding activity of FoxA1. 
    Pink - Ser and Trp residues involved in sequence-specific recognition of the canonical FOX motif. 
    Green - Arg residues essential to both modes of binding. 
 
Alternatively, it is possible that FoxC1 may instead promote the binding of another TF to 
target DHSs without directly interacting with the DNA itself. Indeed, in studies of estrogen 
receptor (ER)-positive breast cancer cells, almost all detectable ER binding events were 
found to depend upon the ectopic overexpression of FoxA1, yet only ~50% of ER binding 
events overlap directly with FoxA1 binding401. These observations raised two 
possibilities. Firstly, FoxA1 could act as a ‘hit and run’ factor, using its pioneer activity to 
open up chromatin for the co-operative binding of further TFs and then dissociating from 
DNA. However, a more compelling scenario is that FoxA1 instead promoted activation of 
DHSs by modulating the local chromatin structure. Indeed, a more recent study of ER-
positive breast cancer cells demonstrated an association between FoxA1 binding and 
that of the BRD4, a chromatin factor involved in the nucleation of protein complexes 
responsible for maintaining active chromatin domains by engaging with acetylated 
histones, and previously implicated in carcinogenesis421,422. Given the considerable 
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homology between FoxA1 and FoxC1 in key functional domains, we speculate that 
similar mechanisms may account for our own analyses of FoxC1 binding in AML cells. 
6.2 Overcoming the technical limitations of FoxC1 ChIP-seq 
Although other methods can offer informative insights into potential regions bound by 
FoxC1, alone it is insufficient to formally confirm FoxC1 as the TF binding to loci of 
interest. For this, optimal ChIP conditions need to be established, or alternative methods 
pursued. We discussed these problems at length with several other groups studying 
FoxC1, including the laboratories of Tim Somervaille (CRUK Manchester Institute), 
Elaine Fuchs (Rockefeller University), Rui Yi (University of Colorado, Boulder), Emily 
Bernstein (Mount Sinai, New York) and Nicoletta Bobola (University of Manchester, 
whose group generated the embryonic dataset used in our mouse AML analyses in 
Chapter 3). These discussions revealed that FoxC1 seems to be an especially 
challenging target to study in conventional ChIP-PCR assays, let alone ChIP-seq. In 
future experiments, we plan to test a recently released FoxC1 antibody that is being 
marketed as ChIP-grade, and we have entered discussions with Proteintech who have 
agreed to send us pre-bleeds of their latest FoxC1 antibody to test in ChIP assays. In 
parallel, our collaborators at the CRUK Manchester Institute are generating a custom 
antibody which we will be given access to if they have success. An alternative would be 
to perform experiments using an epitope-tagged FoxC1 expression construct. Although 
this would preclude study of primary AML samples, it may at least permit more robust 
interrogation of FoxC1 activity in appropriate model systems. 
Beyond the limitations of ChIP-seq, emerging alternative approaches may permit more 
detailed interrogation of FoxC1 activity. Firstly, the Henikoff laboratory recently generated 
a novel approach to interrogate specific TF binding, called ‘Cleavage Under Targets and 
Release Using Nuclease’ (CUT&RUN)423. Although this method is still reliant on an 
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antibody, which is used to target a nuclease to sites occupied by the TF of interest, it is a 
cross-linking free approach performed on intact cell nuclei. The lack of a cross-linking 
step reduces the potential for the antibody not to recognise TFs of interest by epitope 
masking, which may also be a limitation of ChIP assays in the study of FoxC1 binding.  
Another technique that could be used is the ‘CRISPR affinity purification in situ of 
regulatory elements’ (CAPTURE) method424. Briefly, this approach uses sgRNAs and an 
inactivated variant of Cas9 to target loci of interest and promote biotinylation of 
molecules associated with that loci, including TFs, by a separate biotin ligase recruited to 
loci by the sgRNA/Cas9 complex. Biotinylated macromolecules can then be purified by 
high-affinity streptavidin pulldown and interrogated in an unbiased approach using mass 
spectrometry (MS)-based proteomics. This is an appealing alternative to ChIP assays, 
especially given the high sensitivity of current proteomic approaches to interrogate 
complex macromolecular complexes, and would permit formal identification of FoxC1 at 
loci of interest, together with potential interacting partners which could inform future work. 
An additional benefit of this method is the capability to identify long-range chromatin 
interactions using 3C-based methods, which would allow the study of FoxC1 in 
promoting long range 3D chromosomal interactions in AML cells. 
6.3 FoxC1: co-opter or co-opted? 
Previous studies by Somerville et al. (2015) elegantly demonstrated that the 
overexpression of Hoxa9 and FoxC1 was sufficient to induce an aggressive, 
transplantable AML in mice, suggesting a functional synergy between these two TFs. 
Indeed, our analyses performed on Hoxa9+FoxC1 cells reinforced the notion that FoxC1 
functionally co-operates with HOX family proteins to reprogram haematopoietic cells 
during leukaemogenesis, although the specific mechanism by which this occurs remains 
as yet unclear. We described experiments to address this question in 3.23.  
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Beyond the evidence favouring a co-operation between HOX proteins and FoxC1 in 
AML, our analyses throughout these studies also implicated FoxC1 in the re-targeting or 
disruption of normal haematopoietic TFs. For example, in Hoxa9+FoxC1 AML cells, our 
integrative accessible chromatin, DNase I footprinting and gene expression analyses all 
implicated FoxC1 in the redirection of normal Myb and C/EBP activity (Chapter 3). 
Independently, we observed in ChIP-seq analyses that FoxC1 binding frequently co-
associated with C/EBPα and RUNX1 binding in FUJIOKA-specific DHSs (Chapter 4). 
These data corroborated earlier analyses of primary human AML samples which 
demonstrated a FLT3-ITD-dependent upregulation of FOXC1 in parallel with disruption of 
the normal RUNX1 and C/EBP transcriptional network271. Finally, we cannot overlook a 
stated aim of this project, which was to further understand the role that FOX:E composite 
sites, highly specific to FLT3-ITD AMLs in primary human samples, but also since found 
to be a part of the Hoxa9+FoxC1 mouse AML chromatin signature (Chapter 5). 
The prospect of FoxC1 co-opting normal haematopoietic TF function is perhaps not 
surprising, given previously documented roles for other FOX proteins in the oncogenic 
retargeting of tissue-specific factors. Indeed, this concept was elegantly illustrated in 
work by the Brown laboratory, which demonstrated cell-type specific collaboration of the 
pioneer factor FoxA1 with the ER and androgen receptor (AR) in breast and prostate 
cancers, respectively78. Indeed, further studies of ER-positive breast cancer cells 
revealed that ER binding was almost exclusively dependent upon FoxA1, where FoxA1 
promoted ER-mediated transcription of oncogenic target genes401. Furthermore, ectopic 
expression of FoxA1 in either ovarian cancer cells or osteosarcoma cells, which express 
inactive ER, was sufficient to promote ER binding to known target genes, upregulating 
the ER-dependent gene expression programme. Finally, of direct relevance to our own 
studies of FoxC1 in AML, FoxA1-dependent recruitment of ER to target loci occurred 
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both at nucleosome-free regions and within condensed chromatin, as revealed by 
accessible chromatin analyses.  
In the context of prostate cancer, it was recently demonstrated that forced expression of 
FoxA1 with HoxB13 in an immortalised prostate cell line caused extensive redistribution 
of AR binding, causing cells to acquire an epigenetic and gene expression signature 
consistent with those of primary prostate tumour samples402. Independent studies 
confirmed that AR-target loci in prostate cancer cells were occupied by a complex 
containing the AR, FoxA1 and HOXB13. Interestingly, in castration-resistant prostate 
cancer (CRPC), FoxA1 seemed to re-target binding of AR instead to non-canonical AR 
binding sites, where it may contribute to relapse by the activation of genes involved in 
invasion and metastasis. 
In summary, common roles for FoxA1 overexpression have emerged in distinct cancer 
types, whereby FoxA1 co-operates with pre-existing tissue-specific TFs to drive 
epigenetic changes promoting transformation. Similar roles implicating other FOX 
proteins as oncogenic partners of tissue-specific TFs have been postulated for the FoxO 
and FoxM1 family members425,426, increasing confidence that FoxC1 may behave in a 
similar manner. It is compelling to consider that in the context of developing blood cells, 
ectopic upregulation of FoxC1 may similarly act to corrupt the activity of existing 
haematopoietic TFs, contributing to the epigenetic and transcriptional reprogramming 
that occurs during leukaemogenesis. 
6.4 Final conclusions 
To our knowledge, we have performed the first integrative genome-wide analysis of 
chromatin elements and gene expression as related to ectopic expression of FoxC1, not 
just in AML, but indeed in any cancer. Although our analyses are not yet conclusive, we 
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have postulated from several independent lines of investigation that FoxC1 may 
represent a novel pioneer factor which may cause the mistargeting of tissue-specific TFs. 
This is of potential relevance to several other cancers where roles for FoxC1 have 
emerged. These include basal-like breast cancer (BLBC), where a phenotypic co-
operativity between FoxC1 and the inflammatory TF NFκB has emerged427. Here, FoxC1 
seems to promote ectopic proliferation, self-renewal and the epithelial-to-mesenchymal 
transition, although the genome-wide events accompanying these changes have yet to 
be described306. Furthermore, FoxC1 overexpression is a poor prognostic marker in 
tumours of the liver, stomach, pancreas and endometrium, and in melanoma302–304,428,429. 
The ground has now been laid for a more detailed mechanistic dissection of FoxC1 
function, not just in the study of leukaemogenesis, but also for other solid malignancies, 
where genome-wide characterisation of FoxC1 function is now needed. Critically, the 
study of TFs and the mechanisms through which they act to drive oncogenic chromatin 
and gene expression patterns are essential for an improved understanding of the 
molecular basis of disease, by identifying novel sensitivities that may be targeted in the 
clinic. Furthermore, despite the longstanding dogma that TFs themselves are 
‘undruggable’ targets in the context of disease therapy, pioneering work led by the 
Bushweller group and others strongly suggests otherwise430. Given that FoxC1 
expression is not a feature of normal haematopoietic cells, we propose that FoxC1 may 
itself be an attractive target for therapy in AML431. Finally, given that FOXC1 expression 
is associated with subtypes of AML that are refractory to current therapeutic approaches, 
including FLT3-ITD AMLs271, identifying novel treatments to improve outcomes in the 
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